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Abstract 
This thesis investigates active TB case finding and antiretroviral therapy for 
tuberculosis control in a setting with high HIV prevalence in Cape Town, South 
Africa. Many countries in sub-Saharan Africa have seen a worsening tuberculosis 
epidemic since the 1990s. Rising tuberculosis incidence rates have largely been 
attributed to high HIV prevalence in this region. Conventional tuberculosis control 
efforts focus on passive case finding and high cure rates in smear-positive patients, 
achieved through short course chemotherapy. These control strategies are 
insufficient in controlling the tuberculosis epidemic where HIV prevalence is high. 
Additional control strategies have been proposed, including active tuberculosis 
case finding, isoniazid preventive therapy for HIV infected individuals, infection 
control and antiretroviral therapy. 
The feasibility, uptake, yield, treatment outcomes and costs of population-based 
active tuberculosis case finding are investigated in the first part of the thesis. The 
second part determines losses along the HIV care pathway, community 
antiretroviral coverage and the association between coverage and tuberculosis 
risk. 
The main finding is that population-based active tuberculosis case finding linked to 
a mobile HIV testing service had a high uptake and yield. Treatment outcomes in 
patients diagnosed through active case finding were as good as outcomes in 
patients diagnosed through passive case finding in primary care clinics in Cape 
Town. Costs were USD 1,177 per TB case diagnosed and USD 2,458 per 
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successfully treated TB case, in an incremental costing analysis adopting a health 
service provider perspective. 
Analysis of the HIV care pathway in a peri-urban impoverished settlement in the 
greater area of Cape Town highlighted substantial losses along the pathway 
between HIV diagnosis and antiretroviral therapy. These results illustrate the 
operational challenges in achieving high treatment coverage. Antiretroviral 
coverage in this community increased from 18% in 2004 to 84% in 2009. 
Increasing antiretroviral coverage was associated with decreasing tuberculosis 
risk among patients receiving antiretroviral therapy, even controlled for time- 
updated CD4 count, suggesting an effect on transmission, not just on individual 
risk reduction. 
The impact of active tuberculosis case finding and antiretroviral therapy on 
tuberculosis incidence on a population level was beyond the scope of this thesis. 
Large scale cluster randomized controlled trials are needed to investigate the 
effect of these strategies on tuberculosis control. In the meantime researchers 
conducting active tuberculosis case finding studies should be encouraged to collect 
data on treatment outcomes and costs. In addition further interventions are 
needed to increase retention and linkage to care in individuals prior to initiating 
antiretroviral therapy. 
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1 Introduction 
1.2 Background 
Estimated tuberculosis (TB) incidence in countries in sub-Saharan Africa increased 
from 171 per 100,000 population in 1990 to 345 per 100,000 population in 2009. 
Increases in TB incidence have been most pronounced in countries with high HIV 
prevalence where TB notification rates have increased 2- to 5-fold since 1990 
(Figure 1.1) [1,2]. HIV is thought to be the key driver of the TB epidemic in those 
countries. While TB notification rates are still increasing in some African countries 
with high HIV prevalence such as South Africa and Swaziland, they have started to 
decline in other countries like Malawi, Zambia and Uganda. 
Figure 1.1: TB notification rates in sub-Saharan African countries with high 
HIV prevalence (>5%) from 1990-2009 
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Data source: Global Tuberculosis Control (2010) Geneva, Switzerland: World Health Organization. 
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South Africa ranks 4th among the 22 highest TB burden countries in the world and 
has the worst HIV and TB epidemics in the world with a national HIV prevalence of 
18.1% and a TB incidence of 970 per 100,000 population in 2009 [1,2]. TB 
notification rates have risen 3-fold over the last 30 years and yearly TB mortality 
rates have increased by 2.8 times from 1996 to 2006 [1,2]. Historically the 
Western Cape Province always had the highest TB notification rates in South Africa 
and has only recently been overtaken by KwaZulu Natal Province [1,3]. TB 
notification rates in Cape Town varied between 399 per 100,000 population in 
Mitchell's Plain and 1122 per 100,000 population in Khaylitsha in 2003 [4]. Sub- 
district variations are mainly due to variations in HIV prevalence and levels of 
deprivations [5-8]. TB notification rates as high as 2,000 per 100,000 population 
have been reported in one of Cape Town's peri-urban townships where adult HIV 
prevalence was 23% in 2010 [9-11]. 
The World Health Organization (WHO) directly observed short-course (DOTS) 
strategy, which relies on a process of passive TB case finding, has been the key TB 
control strategy globally over the past 15 years. DOTS has been a remarkable 
success story and resulted in improved TB control in many settings. However, it 
has failed to do so in countries with HIV-associated epidemics in sub-Saharan 
Africa [2]. In recognition of this challenge, the WHO and the Stop TB Partnership 
recommend additional interventions to reduce the burden of TB in people living 
with HIV: scale-up of antiretroviral therapy (ART) and the WHO'three I's strategy' 
(intensified case finding, isoniazid preventive therapy and infection control) [12, 
13]. The Global Plan to STOP TB 2011-2015 recognizes these four interventions in 
14 
addition to the DOTS strategy as key interventions to prevent HIV-associated TB 
[14]. 
The implementation of the three I's has seen limited success. The estimated 
percentage of HIV positive people who were screened for TB increased from 0.6% 
in 2005 to only 5.2% in 2009 [15]. A total of 60,509 HIV positive individuals in 
Africa received 6 months of isoniazid preventive therapy in 2009, which was less 
than 1% of the population living with HIV on the African continent at that time 
[15]. A meta-analysis of placebo-controlled trials showed that isoniazid preventive 
therapy in HIV-infected patients conferred an overall risk reduction of 33% [16]. 
However, benefit was only observed among patients who tested tuberculin skin test 
(TST) positive. A major programmatic obstacle to implementation has been the 
necessity to rule out active TB and to assess TST status before initiating isoniazid 
preventive therapy [17-19]. Thus even though policy recommendations for the use 
of isoniazid preventive therapy have been made years ago, national rollout has 
only been attempted in Botswana [18]. Isoniazid preventive therapy for HIV- 
infected individuals is not the standard of care in governmental health care clinics 
and therefore few HIV infected individuals benefit from this intervention. In 
contrast roll-out of ART has been much more successful, with almost 4 million 
people having initiated ART by the end of 2009 [15]. However, due to low HIV test 
uptake and losses along the pathway between HIV testing and ART treatment [20], 
ART coverage was estimated to be only 40% in sub-Saharan Africa in 2009 [15,21, 
22]. 
15 
ART and isoniazid preventive therapy have been shown to reduce TB risk 
substantially in HIV infected individuals [16,23,24]. Studies from South Africa, 
Brazil and Botswana suggest a synergistic effect of the sequential or concurrent 
use of ART and isoniazid preventive therapy [24-27]. The benefit of intensified TB 
case finding and infection control seems intuitive, but so far no study has shown an 
effect on morbidity, mortality or transmission of Mycobacterium tuberculosis in 
HIV infected individuals. 
Ideally one would hope that these additional control measures have an effect 
beyond the individual effect. While reduction of TB associated morbidity and 
mortality in HIV infected individuals is a worthwhile endeavour, TB control 
ultimately aims to reduce Mycobacterium tuberculosis transmission in the 
population. As such the three I's strategy targeting HIV infected individuals only, 
with ART accessible only to HIV infected individuals with advanced stage HIV 
disease might have limited impact even when implemented at scale [18,28]. 
Therefore, community-based strategies including HIV negative individuals, higher 
ART coverage and ART initiation at earlier stage of HIV disease need to be explored 
to tackle the HIV/TB epidemic. 
1.2 Active (intensified) tuberculosis case finding 
Population-based surveys in sub-Saharan Africa have found a prevalence of 0.7- 
1.6% of previously undiagnosed culture-positive TB and 0.2-0.8% of previously 
undiagnosed smear-positive TB [22,29-37]. Delays in TB diagnosis are multi- 
factorial and due to (i) patients not seeking health care, (ii) health care staff failing 
to identify the patient as a TB suspect and (iii) delays in receiving results of 
16 
diagnostic tests [38]. Community-based active TB case finding tries to address 
these delays by providing easily accessible services. A recent community-based TB 
case finding trial from Zimbabwe provided valuable evidence that active TB case 
finding can have a positive impact on TB control in a community with high HIV 
prevalence [39]. 
The first part of this thesis concentrates on active TB case finding in high HIV 
prevalence settings. This includes a literature review and the results of a study 
investigating the feasibility, acceptability, yield and cost of community-based 
active TB case finding linked to a mobile HIV testing service in communities with 
high HIV prevalence. 
1.3 Antiretroviral therapy for tuberculosis control 
Mathematical modelling suggests that ART, as currently implemented, may have 
limited impact on TB control on a population level [40]. However observational 
data from South Africa and Malawi showed decreasing TB notification rates 
following the scale-up of ART [9,41]. These studies have several limitations. 
Uncontrolled before-and-after comparisons are vulnerable to coincidental time 
trends such as increased migration and changes in reporting systems. The South 
African study chose 2005 as the baseline comparison year - the year with the 
highest TB notification rates. ART was rolled-out in 2004 in the study community. 
If 2004 was used as the baseline comparison year, the study might not have found 
any effect of ART on TB notifications. None of the studies controlled for 
confounders. In addition precise population denominators are difficult to 
determine especially in settings with high migration rates. 
17 
More recently a strategy known as "test and treat" has been proposed to reduce 
HIV transmission. This strategy is characterized by very high coverage of HIV 
testing and immediate initiation of ART regardless of the stage of HIV progression 
[42]. Mathematical models predict a major reduction in TB if this strategy was to 
be successfully implemented [43]. Losses along the HIV care pathway are 
recognised as a substantial operational hurdle in achieving high ART coverage 
under the current guidelines [20] and are likely to remain a challenge if "test and 
treat" strategies are implemented. 
The second part of this thesis investigates the losses along the different steps in the 
HIV care pathway, describes ART coverage in a community and investigates the 
association between ART coverage and TB risk in an ART cohort. 
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2 Study question part I 
This thesis aimed to examine strategies of active TB case finding as outlined in the WHO 
31s policy by conducting a systematic review. The key outcomes of the systematic 
review were yield of screening in specific target groups, screening strategies, treatment 
outcomes and cost-effectiveness. 
The thesis further aimed to investigate population based mobile TB case finding in Cape 
Town South African. This was addressed in three studies. The first study was a pilote 
study of active TB case finding in lay health care workers using a mobile team. The 
second study compared sputum quality using a human powered nebuliser to an 
electronic nebuliser. The third study investigated the feasibility, uptake, yield, treatment 
outcomes and cost-effectiveness of a community-based active TB case finding program 
linked to a mobile HIV testing service in Cape Town, South Africa. All studies were 
conducted in under-serviced communities in the greater area of Cape Town (Figure 
2.1). 
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Figure 2.1: Map of Cape Town indicating the main areas in which the mobile 
services operated. 
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3 Literature review: active TB case finding 
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Yield of HIV-associated tuberculosis during intensified case 
finding in resource-limited settings: a systematic review and 
meta-analysis 
Katharina Kranzer, Rein M G] Houben, Judith R Glynn, Linda-Gail Bekker, Robin Wood, Stephen D Lawn 
Intensified case finding is the regular screening for evidence of tuberculosis in people infected with HIV, at high risk 
of HIV, or living in congregate settings. We systematically reviewed studies of intensified case finding published 
between January, 1994, and April, 2009. In 78 eligible studies, the number of people with tuberculosis detected during 
intensified case finding varied substantially between countries and target groups of patients. Median prevalence of 
newly diagnosed tuberculosis was 0.7% in population-based surveys, 2.2% in contact-tracing studies, 2.3% in mines, 
2.3% in programmes preventing mother-to-child transmission of HIV, 2.5% in prisons, 8.2% in medical and 
antiretroviral treatment clinics, and 8.5% in voluntary counselling and testing services. Metaregression analysis of 
studies that included only people with HIV showed that for each increment in national prevalence of tuberculosis of 
100 cases per 100 000 population, intensified case finding identified an additional one case per 100 screened individuals 
(p.. 0.03). Microbiological sputum examination of all individuals without prior selection by symptom screening 
yielded an additional four cases per 100 individuals screened (p-0.05). Data on the use of serial screening, treatment 
outcomes in actively identified cases of tuberculosis, and cost-effectiveness, however, were lacking. Concerted action 
is needed to develop intensified case finding as an important method for control of tuberculosis. 
Introduction 
The sixth Millennium Development Goal target of 
halving the 1990 prevalence of tuberculosis and death 
rates by 2015 will not be achieved if present trends 
continue. ' Any shortfall from this target worldwide will 
be associated with a failure to achieve these targets in 
sub-Saharan Africa where HIV has seriously undermined 
the control of tuberculosis. Worldwide there are more 
than 1.3 million cases of HIV associated tuberculosis 
each year, resulting in almost half a million deaths; 
sub-Saharan Africa is estimated to account for 79% of 
this disease burden? Although the incidence of 
HIV associated tuberculosis worldwide is estimated to 
have peaked in 2006,2 more progress is needed in 
reducing prevalence and mortality. 
The WHO directly observed short-course strategy, 
which relies on a process of passive tuberculosis case 
finding, has helped to control tuberculosis in many parts 
of the world but not in countries with generalised 
epidemics of HIV (prevalence of HIV greater than 1% in 
the general population). ', ' In recognition of this failure, 
WHO and the Stop TB Partnership developed an interim 
policy on collaborative tuberculosis and HIV activities' 
that included additional interventions to reduce the 
burden of tuberculosis in people living with HIV. Within 
this policy the four core prevention strategies for 
tuberculosis were intensified case finding, isoniazid 
preventive therapy, tuberculosis infection control, and 
scale-up of antiretroviral therapy. " 
Despite dear policy guidelines, antiretroviral therapy is 
the only one of the four core strategies that has been used 
at a large scale. ' Use of 
isoniazid preventive therapy is 
still limited and provided 
for only 0.1% of individuals 
infected with HIV. 2 Data on the use of tuberculosis 
infection control are scarce. Intensified case finding 
among patients attending HIV care services reached just 
2.2% of the 33 million people estimated to be living with 
HIV in 20072 To address the substantial gap in the 
scale-up of these interventions, WHO launched the 31s 
policy initiative in 2008, which is a three-pronged strategy 
of intensified case finding, isoniazid preventive therapy, 
and tuberculosis infection control to be used with the 
scale-up of antiretroviral therapy. ' 
Several terms have been used for the screening of 
patients for active tuberculosis. The terms intensive case 
finding, active case finding, and enhanced case finding 
are often used interchangeably and all refer to strategies 
to identify and treat people with tuberculosis who have 
not sought diagnostic services on their own initiative. 
However, whereas intensified case finding and active 
case finding require face-to-face contact and on-site 
screening, enhanced case finding works primarily 
through making populations aware of the symptoms of 
tuberculosis and encouraging self-presentation to 
medical services. ' In the 31s policy, intensified case 
finding is defined as the regular screening of all people 
with HIV or at high risk of HIV or in congregate settings 
(such as mines, prisons, military barracks) for symptoms 
and signs of TB followed promptly with diagnosis and 
treatment", and this is the definition we have used in this 
Review. ' The policy also recommends screening of 
household contacts of people with tuberculosis' 
Intensified case finding is the central intervention of 
the 31s strategy, because its aim is to identify patients as 
either having active tuberculosis (and in need of 
treatment) or free of the disease (and warranting 
preventive therapy), although in practice the status of 
some patients will be unclear and these patients need 
prospective evaluation. Intensified case finding is also 
the key means by which the prevalence of untreated 
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disease can be reduced within clinical services, congregate 
See Online forwebappendix settings, and in the community, thereby reducing the 
transmission of tuberculosis. In view of this new policy 
initiative, there is a great need for data that inform 
development of strategies of intensified case finding. 
Whereas the specific investigations (eg, sputum 
microscopy, sputum culture, chest radiography) used in 
screening for tuberculosis might have an important 
affect on the yield of new cases of tuberculosis identified; 
overall investigational strategy and target group are also 
very important. For example, establishing that a patient 
has the symptoms of tuberculosis has traditionally been 
central to screening strategies, and yet recent studies91' 
have shown that a proportion of patients with 
HIV associated tuberculosis have asymptomatic disease 
or very minor symptoms. As a result, the yield of 
intensified case finding in some groups might be higher 
if all individuals are investigated without preselection. 
The identification of groups for which intensified case 
finding should be prioritised is a further issue. The yield 
of cases of tuberculosis is likely to be highly variable, 
depending on a range of factors that include the local 
prevalence of tuberculosis, the function of local 
tuberculosis control services, the prevalence of HIV in 
the target group, and the degree of associated 
immunodeficiency. In turn, the prevalence oftuberculosis 
detected established the number needed to screen (NNS) 
to identify one new case of undiagnosed active 
tuberculosis. Other important factors affecting decisions 
on implementing intensified case finding include the 
feasibility and cost of the screening, the laboratory 
capacity, and treatment outcomes in newly detected 
cases. Treatment outcomes are particularly important 
because adherence might be lower in patients identified 
in active screening without preselection than in those 
detected passively, potentially limiting the effect of 
intensified case finding on the control of tuberculosis. 
The purpose of this systematic review is to examine 
strategies of intensified case finding as outlined in the 
WHO 31s policy. ' Key outcomes of interest in reviewed 
published work include the prevalence of tuberculosis in 
specifically targeted groups, the associated NNS, the 
screening strategy used, cost-effectiveness, and treatment 
outcomes of newly detected cases. 
Methods 
Search strategy and selection criteria 
The searches and review process were done according to 
a prespecified protocol. We aimed to identify studies 
using intensified case finding in resource-limited settings. 
Both cross-sectional and cohort studies published in all 
languages were eligible for inclusion. We searched 
available systematic and narrative reviews for active case 
finding and household-contact investigations. Two 
systematic reviews were identified a" Additionally, we 
searched Medlin, EmBase, and Global Health for reports 
published through April, 2009, and African Health Line 
up to March, 2009. Search strategies are presented in the 
webappendix. The search strategy for African Health Line 
included "tuberculosis", "active or intensified or enhanced 
case finding", "prisons or prisoners", "mines or miners", 
"homosexuals", "voluntary counselling", and "testing or 
VCT". Abstract books covering the years 1998-2008 of the 
World Conference on Lung Health published by the 
International Union Against Tuberculosis and Lung 
Disease were hand searched. Reference lists of primary 
studies, reviews, and editorials identified by the above 
methods were hand searched. Experts in the specialty 
were contacted for additional publications. 
According to the WHO 31s policy, regular screening for 
tuberculosis is recommended in groups at high risk of 
infection with HIV, individuals infected with HIV, groups 
living in congregate settings, and in contacts of people 
with tuberculosis. The strategy to be used in contact 
tracing is not explicitly described in the policy, and so for 
the purposes of this Review we focused on contact tracing 
studies in populations where the prevalence of HIV was 
at least 5% among notified cases of tuberculosis. We also 
defined groups at high risk for infection with HIV as 
prisoners, commercial sex workers, injecting drug users, 
men who have sex with men, and individuals attending 
voluntary counselling and testing centres and sexually 
transmitted disease clinics. Even though the 31s policy 
does not recommend mass screening on a population 
level, it is arguable that general populations in 
sub-Saharan Africa constitute groups at high risk for 
HIV. Thus, surveys of the prevalence of tuberculosis in 
populations with a prevalence of HIV of greater than 5% 
were included in this Review. 
Our Review was limited to studies published from 1993 
(when WHO declared tuberculosis to be a worldwide 
emergency) to 200915 We only included studies in 
low-income and middle-income countries, as defined by 
the World Bank in 2008, " and studies that screened a 
minimum of 100 people. We excluded editorials, case 
studies, case reports, studies screening only children 
younger than 15 years, and studies with unclear screening 
strategies or denominators. However, we included 
contact-tracing studies that screened both adults and 
children. 
The initial database created from the electronic searches 
was compiled, duplicate citations were eliminated, and 
citations were screened by title and abstract to capture 
potentially relevant studies. The full text of these studies 
was obtained and reviewed according to inclusion and 
exclusion criteria. Screening of full text from citations 
found to be potentially relevant was done by two reviewers 
(KK and SDL). Queries on study design and study quality 
were discussed with another reviewer (JRG), and studies 
were only included if there was consensus. 
Data extraction and analysis 
Where data from a single study were present in multiple 
publications, these data were compiled. The data 
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extraction form was adapted from the STROBE statement 
checklist. " Variables recorded included title, objective, 
year of study, year of publication, study design, setting, 
eligibility criteria of participants, sources and methods of 
selection of participants, screening strategy, diagnostic 
criteria for tuberculosis, internal and external quality 
checks, efforts to reduce bias, numbers of individuals at 
each stage of the study, number of cases of tuberculosis, 
prevalence of tuberculosis, and funding source. One 
reviewer (KK) extracted data from all eligible studies. A 
second reviewer (SDL) independently extracted data from 
20 of the included studies. The ratings given by the two 
reviewers were in complete agreement. 
Primary outcome of interest was the yield of intensified 
case finding as defined by the prevalence of newly 
microbiologically confirmed or clinically or radiologically 
diagnosed cases of tuberculosis in the target population 
and the NNS to find one new case of tuberculosis. The 
NNS was calculated as the reciprocal of the prevalence of 
newly diagnosed tuberculosis. Secondary outcomes of 
interest were the screening strategy used, treatment 
outcomes, and cost per case found. 
All analyses were done in Stata 10. We report medians 
and ranges; weighted medians were used to compare 
yield of screening for tuberculosis in individuals infected 
with HIV by use of different screening strategies. We 
used inverse-variance-weighted metaregression to 
investigate the association between yield of intensified 
case finding and country prevalence of tuberculosis, 
prevalence of HIV in the general population, screening 
strategies, availability of culture, and HIV status of the 
study population. ", " Country prevalence estimates for 
tuberculosis and HIV were obtained from the WHO 
Global Health Atlas 2° We analysed residuals to check 
model assumptions. 
Results 
83 publications (69 published papers and 14 abstracts) 
published between January, 1994, and April, 2009, were 
eligible for inclusion (figure 1). After compiling multiple 
publications of the same study a total of 78 studies were 
included. Most studies (55) were published in the past 
6 years, with the largest numbers of publications being 
in 2008 (12) and 2007 (13). 
Of those studies included, 30 were from congregate 
settings, ten from voluntary counselling and testing 
settings, three from programmes preventing mother-to- 
child transmission (PMTCT), 16 from antiretroviral 
therapy and medical clinics, ten contact tracing studies, 
eight population-based surveys of the prevalence of 
tuberculosis, and one study among men who have sex 
with men and injecting drug users. Most studies were 
from sub-Saharan Africa (41); others were from the 
Americas (22) and Asia (19). 
The proportion of eligible individuals who agreed to 
participate in these studies was variable, ranging from 
40-100% in prisons, 44-100% in voluntary counselling 
and testing and PMTCT settings, 35-100% in clinic- 
based settings, 83-100% in contact tracing studies, and 
66-100% in population-based surveys (webappendix). 
Clear external and internal quality-control procedures for 
microbiological and radiological investigations were only 
recorded in three studies in congregate settings, two 
studies in clinic-based settings, one study in household 
contacts, and four population-based surveys. 
The prevalence of newly diagnosed tuberculosis varied 
greatly between different countries and specific target 
populations (table 1). The minimum was 0.01% in a 
contact-tracing study from Peru and the maximum was 
24.7% in an antiretroviral therapy clinic in South Africa. 
Median NNS varied greatly, ranging from 148 in 
population-based prevalence surveys to just 12 in 
voluntary counselling and testing services and in 
antiretroviral therapy and medical clinics (table 1). 
Results of studies of intensified case finding in prisons, 
psychiatric hospitals, mines, and refugee camps are 
presented in the webappendix. HIV status was established 
in three of 30 studies and screening strategies varied 
substantially, with most using an initial questionnaire on 
the symptoms of tuberculosis followed by diagnostic 
testing of people suspected to have tuberculosis. Three of 
six studies in miners combined the screening of symptoms 
with chest radiology to define those people suspected of 
having tuberculosis, whereas the other three studies used 
sputum microbiology irrespective of symptoms. 
The median NNS in all prisons was 40 (range 14-833), 
but was lower in studies in prisons in sub-Saharan Africa 
8353 potentially relevant citations identified from electronic databases 
73 potentially relevant citations identified from reference lists 
35 potentially relevant citations identified from conference abstract books 
8214 excluded after first screen 
2664 duplicates 
5550 on basis of title or abstract 
1 247 articles selected for full test review 
164 excluded after first screen 
32 population-based surveys of prevalence of tuberculosis with 
HIV prevalence less than 5% 
5 contact screening studies with prevalence of HIV in incident 
cases of tuberculosis less than 5% 
9 studies in subpopulations with prevalence of HIV less than 5% 
27 retrospective studies 
2 studies limited to individuals not infected with HIV 
29 reviews, commentaries, editorials 
8 studies in high-income countries 
11 studies in children 
2 tuberculin skin test surveys 
3 sample size less than 100 
29 unclear study design 
7 already published 
1 69 publications and 14 abstracts included I 
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Figure 2: Prevalence of tuberculosis among individuals screened in different settings in countries with 
generalised epidemics of HIV 
VCf=voluntary counselling and testing. PMTCT-prevention of mother-to-child transmission. 
(median 28, range 14-55; table 1). The prevalence of HIV 
was established in only one study in a Brazilian prison 
(25%). " 
Studies in miners and ex-miners found a median NNS 
of 43 (range 20-86; table 1). In one study enrolling only 
miners infected with HIV, the prevalence of newly 
diagnosed tuberculosis was 4.9%. *, Of the remaining five 
studies only one study tested miners for HIV, and 
reported a prevalence of 27%. " 
Most studies in voluntary counselling and testing 
clinics, PMTCT programmes, and in groups at high risk 
of infection with H IV (men who have sex with men and 
injecting drug users)"" identified people suspected of 
having tuberculosis by screening their symptoms before 
using diagnostic tests (webappendix). Sputum microscopy 
was the only microbiological test available in half of the 
studies. The median NNS was 12 (range 4-123) in 
voluntary counselling and testing settings and 44 (range 
29-47) in PMTCT settings (table 1). 
Intensified case finding was done as part of isoniazid 
preventive therapy programmes or before antiretroviral 
therapy was started, in individuals infected with HIV 
accessing health care or enrolled in home-based care 
services. Half of the studies used questionnaires on the 
symptoms of tuberculosis as the first step before 
microbiological investigations for symptomatic individuals 
(webappendix). Median NNS was 12 (range 4-71; table 1). 
Results from contact-tracing studies (webappendix) are 
not directly comparable with results from other settings 
since most studies included children. Microbiological 
examinations were only done in individuals that were 
symptomatic or in individuals with positive tuberculin 
skin tests. Median NNS was 48 (range 7-10 000; table 1). 
Five of eight population-based surveys of the prevalence 
of tuberculosis in settings with high prevalence of HIV 
used a step-wise screening approach with screening for 
the symptom of tuberculosis preceding microbiological 
examination. The remaining three studies examined the 
sputum in all individuals irrespective of symptoms 
(webappendix). Median NNS was 148 (range 29-5000; 
table 1). 
Figure 2 summarises data from 47 studies in countries 
with generalised epidemics of HIV. More than half the 
studies (27) reported a prevalence of newly diagnosed 
tuberculosis in the screened population of greater than 
3% (NNS less than 33). Excluding population surveys, 
two-thirds (26 of 39) of the studies reported prevalence of 
newly diagnosed tuberculosis of greater than 3%. 
The screening strategies varied widely across the 
studies. Symptom screening was used in all but one of 
the prison studies, screening of mine workers invariably 
included chest radiography, and all contact-screening 
studies used symptom screening and assessment of 
responses to the tuberculin skin test. Symptom 
questionnaires were diverse, ranging from any kind of 
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respiratory symptoms to various durations of productive 
cough plus or minus weight loss, night sweats, fatigue, 
fever, and haemoptysis. Similarly, the number and timing 
of sputum samples varied substantially. 
In 12 studies that included only individuals infected 
with HIV, sputum examination was done irrespective of 
symptoms. Nine of these studies were done in 
antiretroviral therapy services, medical clinics, or 
home-based HIV care programmes and the remaining 
three were done in voluntary counselling and testing 
centres. All but one of these studies did both smears and 
cultures. 17 studies screened individuals infected with 
HIV with symptom-based questionnaires preceding 
sputum examination of people suspected to have 
tuberculosis. These studies were done in antiretroviral 
therapy and medical clinics (seven studies), voluntary 
counselling and testing centres (seven), and PMTCT 
programmes (three). Of these 17 studies, seven only did 
sputum smears whereas ten did both smears and 
cultures. In the subset of studies in which both smears 
and cultures were done, the prevalence of newly 
diagnosed tuberculosis in individuals infected with HIV 
was slightly lower (weighted median 9.8%) in studies 
only investigating preselected people suspected to have 
tuberculosis on the basis of symptom screening 
compared with studies doing sputum smears and 
cultures on everyone irrespective of symptoms (weighted 
median 11.6%). 
Because the strategies and yield of intensified case 
finding were very heterogeneous between studies done 
in different countries and patient groups, we sought to 
identify variables independently associated with the yield 
of tuberculosis by use of metaregression analysis (tables 2 
and 3). 
Of the 78 studies included in the analysis, some target 
populations included only individuals infected with HIV 
(30 studies), whereas the remainder included individuals 
with and without HIV (congregate settings, contact 
screening, and population-based prevalence studies). 
Metaregression analysis was therefore stratified with 
regards to HIV status of the screened population. 
In the univariate analysis of studies with patients with 
mixed or unknown HIV-status (48 studies), national 
prevalence of tuberculosis and HIV, screening strategy of 
microbiological investigations in all individuals, and 
availability of culture were not associated with yield of 
screening (table 2). 
By contrast, univariate analysis of studies that only 
included individuals infected with HIV (30 studies) 
found that both the use of symptom prescreening and 
the country prevalence of tuberculosis were associated 
with the detected yield of tuberculosis (table 3). However, 
the availability of culture and the national prevalence of 
HIV were not associated with the detected yield of 
tuberculosis. Multivariate analysis showed that 
microbiological sputum examination (smear or culture) 
on all individuals without prior selection on the basis of 
screening for symptoms detected an additional four cases 
per 100 individuals screened (p=0.05). Furthermore, an 
increment in country prevalence of tuberculosis of 
100 cases of tuberculosis per 100000 population was 
associated with an additional yield of one case per 
100 individuals screened (p=0.03). 
Restricting the analysis to studies in individuals 
infected with HIV routinely doing both sputum smears 
and cultures as part of the microbiological investigations 
(22 studies) showed similar results with regards to effect 
estimate for symptom screening (slope 3.6,95% Cl 
-0 .9 to8.0). 
Estimates of national prevalence of tuberculosis are 
infrequently on the basis of prevalence survey data, they 
are instead derived from estimates of the incidence of 
tuberculosis. In view of this and that national estimates 
of incidence of tuberculosis are more readily available, 
we repeated the metaregression analysis with the 
inclusion of estimated incidence of tuberculosis rather 
than estimated prevalence. In this model, an increment 
in country incidence of tuberculosis of 100 cases of 
tuberculosis per 100000 people was associated with an 
additional yield of 0.7 case per 100 individuals screened 
(p=0.04). 
Only three studies reported treatment outcomes of 
individuals diagnosed with tuberculosis during 
intensified case finding. In a population-based study in 
South Africa, only 13 (56%) of 23 people actively detected 
Country prevalence of tuberculosis' 
Country prevalence of HIVt 
Availability of culture# 
Symptom screenings 
Slope(95%Cl) pvalue 
-02(-0.5 to 0-1) 0.21 
-48(-128 to 3-3) 024 
-0-3 (-1.6 to 1-1) a65 
-03(-2.4to 18) 077 
*One unit increase-100 cases of tuberculosis per 100 000 people. tOne unit 
increase"10% increase in prevalence. tCoded as 0 if no culture available or 1 if 
culture available. SCoded as 0 if symptom screening used to identify people 
suspected to have tuberculosis or 1 if all individuals screened with sputum smears 
or culture. 
Table 2: Univariate analysis of factors potentially affecting yield of 
intensified case screening in populations with mixed or unknown HIV 
status 
Slope (95%CI) p value in Slope (95% Cl) p value in 
in univariate univariate in multivariate multivariate 
analysis analysis analysis analysis 
Country prevalence of tuberculosis* 11(0.2 to 2.0) 0.02 1(01 to 1.9) 0.03 
Country prevalence of HIV l 13 (-17 5 to 431) 0.4 
Availability of culturet 2.0 (-2.7 to 6.7) 0.39 
Symptom screeningS 43 (034 to 8 2) 0 03 3.7 (0 05 to 7 4) 0 05 
*One unit increase-100 cases of tuberculosis per 100 000 people. tOne unit increase-10% increase in prevalence. 
tCoded as 0 if no culture available or 1 if culture available. SCoded as 0 if symptom screening used to identify people 
suspected to have tuberculosis or 1 if all individuals screened with sputum smears or culture. 
Table 3: Factors potentially affecting yield of intensified case screening in populations with individuals 
infected with HIV 
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with tuberculosis completed treatment" Among 
24 women infected with HIV in India diagnosed with 
tuberculosis after giving birth, 21 started treatment for 
tuberculosis and 17 (70%) were either cured or still 
receiving treatment at time of analysis °= In the 
Cöte d'Ivoire, of 134 prisoners diagnosed with 
tuberculosis, 99 (74%) were cured, 32 (24%) died, and in 
three (2%) treatment failed. ' None of these studies had 
data for treatment outcome available for those diagnosed 
passively. 
None of the studies included in this systematic review 
did costing or cost-effectiveness analyses. 
Discussion 
Intensified case finding is a key component of the WHO 
Ms policy that aims to strengthen the public health 
response to the epidemic ofHIV ofHIV-associated tubercul 
major stumbling block to attainment of the sixth 
Millennium Development Goal targets for worldwide 
control of tuberculosis. In this systematic review, we 
included 78 studies from 27 different countries, most 
from sub-Saharan Africa. The yield of screening for 
tuberculosis varied greatly between countries and target 
populations, with the highest yields in antiretroviral 
therapy and voluntary counselling and testing clinics, 
and the lowest yields in population-based surveys of the 
prevalence of tuberculosis. Our analysis showed that the 
yield of intensified case finding depends strongly on the 
prevalence of HIV of the target population, the national 
prevalence of tuberculosis, and the screening strategy. In 
studies only screening individuals infected with HIV, 
each increment in national prevalence of tuberculosis of 
100 cases per 100000 people resulted in an additional 
yield of one case per 100 individuals screened. 
Furthermore, substantially higher yields can be achieved 
if all individuals have sputum examination irrespective 
of symptoms. These data will help inform implementation 
of intensified case finding policies. 
Using a process of passive case finding, the directly 
observed short-course strategy has failed to control rising 
incidence rates of HIV associated tuberculosis in 
resource-limited settings, "' and many patients dying with 
HIV/AIDS have tuberculosis thathas not beendiagnosed. '°' 
Intensified case finding aims to increase case-detection 
rates and shorten the time to diagnosis of tuberculosis, 
thereby reducing morbidity and mortality and shortening 
the period of infectiousness, and it should, in turn, reduce 
the risk of transmitting tuberculosis in community and 
health-care settings'" However, intensified case finding 
is more resource-intensive than passive case finding and a 
number of key issues must be considered. These issues 
include the populations to be targeted, the NNS to identify 
each new case, the screening strategy, laboratory capacity, 
operational feasibility, outcomes of newly identified cases 
of tuberculosis, and costs. 
Prevalence of newly diagnosed tuberculosis and 
subsequently the NNS varied widely between different 
target populations with a median of 148 (range 29-5000) 
in population-based surveys, 45 (7-10000) in contact 
tracing studies, 43 (20-86) in mines, 40 (14-833) in 
prisons, 12 (4-123) in voluntary counselling and testing, 
44 (29-47) in PMTCT settings, and 12 (4-71) in 
antiretroviral therapy or medical clinics. 
The upper limit for the NNS at which intensified case 
finding is deemed useful might differ between target 
populations. For example, the importance of identification 
of tuberculosis among prisoners is high because of the 
high probability of transmission to other prisoners, and 
among pregnant women it is high in view of the 
probability of transmission to unborn children. ", " 
Intensified case finding might also be prioritised in 
settings with known high prevalence of drug-resistant 
tuberculosis, such as prisons. 
Guidelines originating from the era before HIV assume 
that state programmes for tuberculosis in resource-limited 
settings should screen an average of ten people suspected 
to be infected to identify one smear-positive case to 
prevent laboratory overload. 109 Laboratory equipment and 
consumables for tuberculosis are allocated on this basis. 
More recent experience has shown that in practice an 
average of seven people newly suspected of having 
tuberculosis are screened to identify one sputum 
smear-positive case of tuberculosis, although this number 
varies widely (3.3-20). 10 Irrespective of the specific target 
populations, we found that intensified case finding will 
need more resources. Scale-up will only be possible if 
laboratory capacity increases in parallel and quality 
assurance procedures are adequate. 
The effectiveness of intensified case finding depends 
on the screening strategy used. In studies of groups of 
patients infected with HIV, intensified case finding with 
microbiological (sputum smear or culture) investigation 
in all patients irrespective of symptoms detected an 
additional four cases per 100 individuals screened. This 
finding is consistent with the observation that a substantial 
proportion of individuals infected with HIV have 
subclinical tuberculosis when screened actively. 'o-'u. % 
The WHO 31s strategy recommends repeated intensified 
case finding in individuals infected with HIV. However, 
no empirical data exist on the use of this type of serial 
screening, especially in a population of people infected 
with HIV. Serial screening with mass radiography in 
Czechoslovakia in 196172 showed a decrease in 
prevalence of newly diagnosed tuberculosis from 36 cases 
per 100000 people to 18 cases per 100000 people. " Thus, 
a similar effect might happen with serial intensified case 
finding in individuals infected with HIV, although the 
yield in groups of patients infected with HIV is also likely 
to vary in parallel with changes to the degree of 
immunodeficiency. Studies establishing the yield obtained 
during serial screening, the optimum screening interval, 
and the implications for laboratory capacity are needed. 
The diagnosis of tuberculosis by active screening is 
typically less advanced than the diagnosis of disease 
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during passive case finding. """"" Patients with less 
advanced disease might, in turn, have lower numbers of 
adherence to treatment, potentially resulting in poorer 
treatment outcomes among those whose disease is 
detected by intensified case finding. However, data on 
treatment outcomes are scarce. A study from South Africa 
found that the rates of treatment for tuberculosis were 
low (73%) among actively detected cases. "' Similar results 
were reported from population-based prevalence surveys 
from India and Nepal showing higher treatment refusal 
and default rates in actively compared with passively 
detected cases of tuberculosis. "` 15 Therefore, intensified 
case finding must be accompanied with effective means 
of ensuring that newly identified cases of tuberculosis 
are effectively treated. 
Our metaregression analysis found that each increment 
in national prevalence of tuberculosis of 100 cases per 
100000 people was associated with an additional yield of 
about one case per 100 screened individuals infected with 
HIV. These data provide some basis for estimating the 
potential benefits of intensified case finding in different 
countries. Although none of the studies presented in 
this Review investigated cost-effectiveness, modelling 
suggests that population-based intensified case finding 
symptom screening every 7 years would be highly 
cost-effective in sub-Saharan Africa, averting 29 million 
cases of tuberculosis and 13 million deaths by 2050.111 
One study from South Africa estimated a cost of US$12 
for each person screened for tuberculosis in the 
community health centre and $7 per person in the 
primary health-care clinic. The cost per case of 
tuberculosis prevented was estimated to be $323-366, 
assuming that 25 cases of tuberculosis would be 
prevented for every 100 cases of tuberculosis detected by 
intensified case finding. "' However, more country-specific 
and setting-specific data on costs are needed to inform 
policy makers. 
Our systematic review has several strengths. Publication 
bias was limited by the use of a prespecified comprehensive 
search strategy and review process that included published 
and unpublished studies without language restrictions. 
Reproducibility of data extraction was verified for a subset 
of studies. Heterogeneity of study results was investigated 
using metaregression analysis. This Review, which is 
primarily descriptive, also has limitations. Assessment of 
ascertainment bias at study level was limited because of 
the lack of reporting of internal and external quality-control 
procedures. Furthermore, variable uptake in the 
proportions of eligible individuals who agreed to 
participate in these studies might have influenced 
reported prevalence of tuberculosis. Regression analyses 
could be subject to residual confounding. 
Conclusion 
In countries with high prevalence of tuberculosis, 
intensified case finding among individuals infected with 
HIV identifies a high yield of people with tuberculosis 
and the yield is significantly increased if all such 
individuals are screened microbiologically without 
preselection on the basis of the screening of symptoms. 
The data presented might help the prioritisation of 
specific groups for intensified case finding. Scaling-up of 
intensified case finding will need development of 
standardised screening algorithms, substantial increases 
in the capacities of quality-assured laboratories, and 
efficient systems to ensure that people newly diagnosed 
with tuberculosis receive adequate treatment. Concerted 
action in tandem with further research might help 
develop this policy as an important method to accelerate 
progress towards the tuberculosis targets within the sixth 
Millennium Development Goal. 
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Community health care workers in South Africa are at 
increased risk for tuberculosis 
K Kranzer, L-G Bekker, N van Schaik, L Thebus, M Dawson, J Caldwell, H Hausler, R Grant, R Wood 
To the Editor. High rates of tuberculosis (TB) and human 
immunodeficiency virus (HIV) in sub-Saharan Africa pose a 
serious threat to health care systems and health care workers 
(HCWs). Studies in South Africa' and Ethiopia' have indicated 
that HCWs have an increased risk of TB disease compared 
with the general population. The risk for TB disease is even 
higher among HCWs co-infected with HIV. Studies from South 
Africa found an HIV prevalence among HCWs of 15.7% in 4 
provinces in 20023 and of 11.5% in 2 hospitals in Gauteng in 
2005. ' 
Many sub-Saharan African countries face a severe shortage 
of qualified HCWs as a result of the dual HIV/TB epidemic, 
which has triggered task shifting to a range of lay community 
health care workers (CHWs) - for example, home-based care 
workers, lay counsellors and adherence supporters, for both 
TB and highly active antiretroviral therapy (HAART). CHWs 
may experience a considerable occupational TB risk; however, 
their risk of TB disease and HIV prevalence has never been 
documented. 
The TB/HIV Care Association is a non-governmental 
organisation that employs CHWs to provide adherence 
support to both TB patients and patients taking HAART. The 
Desmond Tutu HIV Foundation partnered with the TB/HIV 
Care Association to provide HIV and TB testing to their CHWs, 
and subsequently determined the prevalence of diagnosed and 
undiagnosed TB and HIV among them. 
Methods 
Between October 2008 and February 2009, our mobile HIV 
testing unit (the TUTU tester) provided HIV testing, CD4 
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counts and TB screening to TB and antiretroviral adherence 
supporters employed by the TB/HIV Care Association in Cape 
Town on 8 days in 8 venues. All CHWs were asked about any 
previous HIV testing, history of TB treatment, hypertension, 
diabetes, and their most recent Pap smear. Verbal consent 
for HIV testing was obtained. HIV testing was performed 
according to the Western Cape guidelines. All CHWs were 
offered post-test counselling. Individuals who tested HIV- 
positive were offered a CD4 count test. Individuals who 
needed treatment or follow-up were referred to clinics. 
Individuals who were HIV positive and those with 
symptoms of TB were offered to undergo sputum induction. 
Smears and cultures were performed on 47 out of 62 sputum 
samples, and the remaining 15 sputum samples were 
only examined for acid-fast bacteria (AFBs) with light and 
fluorescence microscopy. 
Results 
A total of 215 female CHWs were offered HIV and TB testing; 
the most common age group was 40 - 49 years old (N=72,33%); 
58 (27%) had never had a previous HIV test, and only 57 (27%) 
had had an HIV test within the last 12 months (Table I). Older 
CHWs were significantly more likely to have never tested 
before (p<0.01). 
A total of 42 CHWs (20%) were HIV-positive, 11 were newly 
diagnosed, and 31 already knew their status. Among the 31 
known HIV-positive CHWs, 17 were on HAART, and 11 were 
not yet eligible for HAART. Of 26 CHWs who knew their most 
recent CD4 count, 6 had a CD4 count <350 cells/µl. Eight of 
those who were newly diagnosed as HIV positive had had a 
CD4 count at the time of diagnosis, and 5 (63%) had a CD4 
count <350 cells/}il. HIV prevalence (23%) and prevalence of 
newly diagnosed HIV (9%) was highest among the 30 - 39- 
year-old age group. 
Sputum induction was offered to 80 CHWs; 38 were MV- 
positive, and 42 reported TB symptoms. A total of 62 sputum 
samples were obtained - 29 from HIV-positive individuals 
and 33 from HIV-negative symptomatic individuals. Twelve 
CHWs were unable to produce sputum, and 6 refused sputum 
induction. 
The overall TB prevalence was 5% (10/215); 6 (3%) were 
on TB treatment at the time of the study; 4 (2%) were newly 
diagnosed with TB, one was smear- and culture-positive, and 
3 were smear-negative and culture-positive. Two of the newly 
diagnosed TB cases were HIV negative and symptomatic, 1 
was known HIV positive and not yet on HAART, and 1 was on 
HAART. 
Discussion 
Corresponding author. K Kranzer (katharina. kranzer®lahtm. ac. uk) 
This is the first report of HIV and TB prevalence among CHWs 
in South Africa. The observed HIV prevalence of 20% is higher 
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Table I. HIV testing experience, HIV prevalence and TB prevalence in lay community health care workers stratified by age 
Age in years 
<30 
N(%) 
30 - 39 
N (%) 
40 - 49 
N(%) 
250 
N(%) 
Total 
N (%) 
Previous HIV testing experience 
Never tested 6 (18) 5 (9) 16 (23) 31(58) 58 (27) 
Last test <3 months ago 5 (15) 5 (9) 4 (6) 4(8) 18 (9) 
Last test 3-6 months ago 2 (6) 1(2) 3 (4) 0 (0) 6 (3) 
Last test 6- 12 months ago 6 (18) 12 (22) 12 (17) 3(6) 33 (16) 
Last test >12 months ago 6 (18) 19 (35) 28 (40) 12 (23) 65 (31) 
Previously tested positive 8 (24) 13 (24) 7 (10) 3 (6) 31(15) 
HIV result 
Negative 23 (68) 36 (65) 61 (85) 48 (89) 168 (78) 
Newly diagnosed positive 2 (6) 5 (9) 2 (3) 2(4) 11(5) 
Known positive 8 (24) 13 (24) 7 (10) 3 (6) 31(14) 
Refused 1(3) 1 (2) 2 (3) 1(2) 5 (2) 
On TB treatment 
yes 1(3) 4(7) 1 (1) 0(0) 6(3) 
No 33 (97) 51(93) 71 (99) 54 (100) 209 (97) 
TB diagnosed on screening 
yes 0(0) 2(4) 1 (1) 1(2) 4(2) 
No 33 (100) 49 (96) 70 (99) 53 (98) 205 (98) 
than the HIV prevalence of 17.9% among antenatal women in 
the Western Cape Metropolitan area in 2008.5 
Only 27% of CHWs had an HIV test within the last 12 
months; more importantly, 27% had never had an HIV test. A 
total of 11 new HIV diagnoses were established. At least half 
of the newly diagnosed HIV-infected CHWs would be eligible 
for HAART according to the WHO ART guidelines and the 
proposed new South African guidelines for implementation in 
the near future. 
Only 5 CHWs did not consent to HIV testing, suggesting that 
HIV testing uptake is improved when access is facilitated. An 
obstacle to access may be concerns with confidentiality, and 
CHWs may not feel comfortable about testing in the health care 
facilities where they work. 
TB prevalence among CHWs was 5%, with 4 out of 10 TB 
cases (40%) only identified through active case finding. A 
recent population-based prevalence survey in a township 
near Cape Town found a TB prevalence of 3% with a 
similar proportion of undiagnosed TB (48%). ' However, the 
population-based survey included men and women, with men 
having a higher risk of TB disease, whereas the CHWs screened 
in this study were all women; this finding suggests that CHWs 
are at higher risk of TB disease than the communities they live 
in. 
Limitations of this report include relatively small sample 
size and that the sample was not representative of all CHWs 
working in Cape Town. TB screening included only one 
induced sputum sample per person, and some of the sputum 
samples were not cultured. 
We conclude that CHWs are at high risk for HIV and TB. 
HIV testing should be actively facilitated, CHWs should be 
screened regularly for TB, and more emphasis should be placed 
on effective infection control measures. 
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Quality of induced sputum using a human-powered nebuliser 
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SUMMARY 
OBJECTIVES: To investigate the quality of induced spu- 
tum samples using a human-powered (HPN) and an 
electric-powered nebuliser (EPN). 
METHODS: For each participant two sputum samples 
were induced using the HPN and the EPN. 
The sequence 
of the two nebulisers was allocated at random. 
The 
proportion of good quality sputum according to 
differ- 
ent assessment criteria was compared using an exact 
McNemar test. The difference in time to expectoration 
was compared using the Wilcoxon matched-pairs signed- 
rank test. 
RESULTS: A total of 123 individuals were eligible for 
the study. Nine individuals refused to participate and 
five were unable to produce a sputum sample. The pro- 
portion of good quality sputum was higher among spu- 
tum samples induced by the HPN compared to those 
obtained using the EPN. The median time to produce a 
sputum sample was 2.2 min (IQR 1.13-4.1) for the 
HPN and 2.5 min (IQR 1.4-4.1) for the EPN. 
CONCLUSION: The HPN induced good quality sputum 
within 3 min. The device operates without electricity and 
is suitable not only for remote clinics with unreliable 
electricity, but also for mobile services and community- 
based intensified tuberculosis (TB) case finding. Further 
research needs to investigate the yield of TB in sputum 
samples induced by the HPN. 
KEY WORDS: tuberculosis; induced sputum; diagnosis; 
South Africa; resource-limited 
POOR DIAGNOSIS remains a major obstacle to 
global tuberculosis (TB) control. An estimated 9.4 mil- 
lion new cases of TB were reported in 2008, and 
1.8 million estimated deaths occur every year. ' TB 
diagnosis is often based on microscopy of stained 
sputum smears? Current World Health Organization 
(WHO) guidelines recommend a two-specimen case- 
finding strategy and same-day diagnosis by micros- 
copy. 3,4 However, a substantial number of these cases 
occur among human immunodeficiency virus (HIV) 
positive individuals, including children, 
in resource- 
limited settings. Confirming TB infection in this 
population is particularly challenging 
due to pauci- 
bacillary presentations and difficulties in obtaining ap- 
propriate specimens. s-7 HIV infected individuals of- 
ten present with few symptoms7-9 and 
have difficulty 
expectorating spontaneously. Spontaneous sputum ex- 
pectoration is difficult to achieve in children, and cul- 
ture confirmation thus relies on sequential gastric 
lavages. s 
For adults and children who are unable to expec- 
torate sputum spontaneously, sputum induction is one 
way to obtain good quality sputum, and it has been 
shown to be as sensitive as bronchoalveolar lavage 
and gastric washing for detection of pulmonary TB 
in both adults and children. 10-13 A hypertonic saline 
solution is administered via a mouthpiece or mask 
using an ultrasonic nebuliser. The procedure is non- 
invasive and requires little staff training. 14 
However, sputum induction remains largely under- 
utilised as a means of obtaining sputum samples for 
TB diagnosis, especially in highly under-resourced set- 
tings where access to consistent supplies of electrical 
power can be a challenge. Battery operated nebulisers 
exist, but recharging batteries typically requires elec- 
tric power, and the costs of obtaining new batteries 
are considerable. Human-powered or solar-powered 
devices might be more suitable for under-resourced 
settings. 
This study aimed to compare the quality of in- 
duced sputum samples using a human-powered (HPN) 
and an electric-powered nebuliser (EPN). 
Correspondence to: Katharina Kramer, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medi- 
cine, Faculty of Health 
Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa. Tel: 
(+27) 828 781 226. Fax: (+27) 216 506 963. e-mail: katharina. kranzer@lshtm. ac. uk 
Article submitted 26 October 2010. Final version accepted 9 February 2011. 
1078 The International Journal of Tuberculosis and Lung Disease 
METHODS 
Study setting 
This study was conducted as part of an evaluation of 
an intensified TB case-finding strategy linked to a 
mobile voluntary counselling and testing (VCT) ser- 
vice. The mobile VCT service is nurse-run, counsellor 
supported and operates in underserviced peri-urban 
areas in greater Cape Town. 1 I All adults testing HIV- 
positive or with symptoms suggestive of TB were re- 
ferred for sputum induction. 
Study design 
All clients referred for sputum induction as part of 
the intensified TB case-finding study between June 
and July 2010 were asked for their consent to partici- 
pate in the study. Two induced sputum samples using 
the HPN and EPN were performed. The sequence of 
the two nebulisers was allocated using Stata version 11 
(StataCorp, College Station, TX, USA) to randomly 
sample one of the two nebulisers as the first device to 
be used. The procedure was repeated 130 times, and 
patients started with either the HPN or the EPN per 
their allocation. Sputum induction was performed in 
an open-roofed tent using 15-20 ml sterile 3% hyper- 
tonic saline solution. The patient breathed through the 
nebuliser mouthpiece until a satisfactory sample was 
produced or he/she wished to abandon the procedure. 
The procedure was performed without nose clips. 
Human-powered nebuliser 
The HPN is a pneumatic piston pump system con- 
nected to a modified stationary bicycle frame (Fig- 
ure 1). The output of the piston (Bimba, University 
Park, IL, USA) goes through one-way valves (US Plas- 
Figure 1 The HPN. One end of the piston is affixed to the 
frame and the other is connected to a rotating disk affixed to 
the rear gear system. There are two outputs of the piston and 
the tubing is set up with one-way valves so that air flows out of 
the HPN on both the upstroke and downstroke of the piston. 
The flow regulator is marked by an arrow. HPN = human pow- 
ered nebuliser. 
tics, Lima, OH, USA) and a flow regulator (Gates LLC, 
Houston, TX, USA) to achieve the necessary air flow 
rate of 8 I/min to make a jet nebuliser and mouth- 
piece (Hudson Micro Mist, Hudson RCI, Research 
Triangle Park, NC, USA; mass mean aerodynamic di- 
ameter 3.6 µm, nebulisation rate 0.25-0.3 ml/min) 
work properly. The one-way valves and flow regula- 
tor ensure that the HPN operates at 8 l/min or not at 
all. The HPN takes about 60 pedal cycles/min to op- 
erate; the effort of pedalling the HPN is equivalent to 
riding a bicycle at approximately 13 km/h. In bench 
top experiments, the output of the HPN was com- 
pared to the Pulmo-aide compressor (DeVilbiss, Som- 
erset, PA, USA), which has a flow rate of >8 I/min us- 
ing the same nebuliser. The time of nebulisation of 
5 ml liquid was not different between the two (P = 
0.41). In this study, assistants to the nurse in charge 
of TB testing pedalled the HPN. Tubing was long 
enough so that the assistants could either be in a sep- 
arate tent or in the open away from the tent where 
the subject was seated. 
Electric powered nebuliser 
An ultrasonic Flo-Eolo nebuliser (CA-MI, Pilastro, 
Italy) was used for electric sputum induction as 
a comparison. 
Microscopy and culture of mycobacteria 
Sputum samples were analysed within accredited lab- 
oratories using standardised protocols and quality 
control procedures. Following decontamination with 
N-acetyl-L-cysteine sodium hydroxide, centrifuged 
sputum deposits were examined for acid-fast bacilli 
(AFB) using auramine 0 fluorescent stain and cultured 
using mycobacterial growth indicator tubes (MGIT, 
BD, Sparks, MD, USA). Cultures positive for AFB 
were identified as Mycobacterium tuberculosis com- 
plex by inhibition of growth by p-nitrobenzoic acid 
or by the polymerase chain reaction. 
Microscopic sputum quality assessment 
Gram stains were performed on each sputum speci- 
men and examined by laboratory technicians. The 
slides were evaluated for quality under low power 
(310). Salivary contamination was detected by not- 
ing the presence of squamous epithelial cells (SEC), 
and purulence was determined by noting the presence 
of polymorphonuclear cells (PMN). Sputum sam- 
ples were considered of good quality according to 
the following assessment criteria: >0 PMN per low- 
power field (LPF; criteria from McCarter and Robin- 
son16), >25 PMN/LPF (Van Scoy»), <25 SEC/LPF 
(Geckler et al. 15), <10 SEC/LPF (Murray and Wash- 
ington19) or PMN > SECs (Barlett20). 
Statistical methods 
All analyses were conducted using Stata version 11 
(StataCorp, College Station, TX, USA). The proportion 
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Figure 2 Flow diagram of eligible participants who were able to produce sputum samples. HIV = human immunodeficiency virus. 
of good quality sputum according to the different as- 
sessment criteria between the two nebulisers was 
assessed using an exact McNemar test; the difference 
in time to expectoration was compared using the 
Wilcoxon matched-pairs signed-rank test. 
Ethical approval 
The study was approved by the University of Cape 
Town Ethics Committee and the Institutional Review 
Board of Marquette University. Written informed 
consent was obtained from all patients at enrolment. 
RESULTS 
Study population 
A total of 123 individuals were eligible for the study, 
of whom 66 (53.7%) were HIV-positive, 55 (44.7%) 
were HIV-negative and two (1.6%) refused HIV test- 
ing. Median age was 39.0 years (interquartile range 
[IQR] 29.1-49.0) and 63 (51.2%) were women. Nine 
(7.3%) individuals refused to participate in the study: 
seven HIV infected individuals and two HIV-negative 
TB suspects. Five individuals (4.4%) were unable to 
produce a sputum sample (Figure 2). 
Sputum quality and time to induction 
Sputum quality was assessed in 109 paired sputum 
samples. Overall, the proportions of good quality spu- 
tum according to the different assessment criteria were 
higher among sputum samples induced by the HPN 
compared to those induced using the EPN (Table 1). 
According to McCarter and Robinson's criteria, 16 
83.5% of HPN and 74.3% of EPN-induced sputum 
samples were of good quality, whereas only 26.6% of 
HPN and 22.9% of EPN-induced sputum samples 
were assessed as good quality using Van Scoy's crite- 
ria. 17 The proportion of good quality sputum sam- 
ples according to Barlett's criteria20 was significantly 
higher in sputum samples induced by HPN compared 
to EPN. 
The median time to produce a sputum sample was 
2.2 min (IQR 1.13-4.1) for HPN and 2.5 min (IQR 
1.4-4.1) for EPN (P = 0.29). The median time was 
3.1 min (IQR 1.3-7.1) for HPN and 3.1 min (IQR 
1.8-4.8) for EPN when only the first induction was 
taken into account. 
Smear and culture results 
Three individuals were diagnosed with smear-positive 
TB. Two had smear-positive HPN and EPN samples, 
while the other individual had a smear-positive EPN 
sample but a smear-negative HPN sample. All six 
samples from these three individuals were culture- 
positive for TB (Table 2). 
Four individuals were diagnosed with smear- 
negative, culture-positive TB, of whom two grew 
M. tuberculosis in both samples (HPN- and EPN- 
induced). However; the HPN samples of the remain- 
ing two individuals were reported as culture-negative. 
The quality of the smear and/or culture-positive 
Table I Number and percentage of good quality sputum induced by the human-powered and electric-powered nebulisers 
according to different assessment criteria 
McCarter and Murray and 
Robinson16 Van Scoy'1 Geckler et al. '8 Washington'9 Barlett2° 
Nebuliser n(%) P value n(%) P value n(%) P value n(%) P value n(%) P value 
Human powered 91 (83.5) 0.08 29 (26.6) 0.63 94 (86.2) 0.11 67 (61.5) 0.88 30 (27.5) 0.05 
Electric powered 81 (74.3) 25 (22.9) 85 (78.0) 65 (59.6) 19(17.4) 
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Table 2 Smear- and/or culture-positive cases: sputum quality according to different assessment criteria 
McCarter and Murray and 
Smear Culture Robinson16 Van Scoy17 Geckler et al. 18 Washington'9 Barlett20 
HPN EPN HPN EPN HPN EPN HPN EPN HPN EPN HPN EPN HPN EPN 
+++ + Good Good Poor Poor Good Good Good Good Good Good 
+++ + Good Poor Good Poor Good Good Good Good Good Poor 
-++ + Good Good Poor Poor Good Good Good Poor Poor Poor 
--- + Good Good Poor Poor Good Good Good Good Poor Poor 
--- + Good Good Good Poor Poor Good Poor Good Poor Poor 
--+ + Good Poor Good Poor Poor Good Poor Good Poor Poor 
--+ + Good Good Good Poor Poor Good Poor Poor Poor Poor 
HPN = human-powered nebuliser; EPN = electric-powered nebuliser 
sputum samples varied greatly. The majority of the 
samples were assessed as good quality according to 
the criteria of McCarter and Robinson and Geckler 
et al., but were assessed as poor quality according to 
Van Scoy and Barlett. 
DISCUSSION 
To our knowledge, this is the first study to assess the 
efficacy of a nebuliser that does not require battery or 
electric power for sputum induction for TB diagnosis. 
We found that the HPN was comparable to the ultra- 
sonic electric nebuliser in terms of sputum quality 
when used to induce sputum in HIV-negative TB sus- 
pects and HIV-positive individuals. 
Sputum induction was successful in the majority 
of individuals (95.6%), and there was no difference 
in the time to sputum induction. This is important in 
under-resourced settings where human resources for 
health are scarce and staff would not be easily moti- 
vated to perform procedures that require additional 
time and may not be successful. The majority of the 
participants were able to produce induced sputum 
samples within 5 min, and none abandoned the pro- 
cedure due to discomfort or bronchospasm. This em- 
phasises yet again that sputum induction is safe, 
quick and easy to perform, as shown in several other 
studies. 10'12 
The prototype of the HPN was built with a spe- 
cific focus on resource-limited settings. The material 
used for the construction of the HPN is cheap and 
readily available, and the device is easy to construct 
and repair by non-engineers. These characteristics 
make the HPN an ideal device for resource-limited 
settings where highly specialised biomedical engi- 
neers are not available. 
The major limitation of this study is the lack of 
power to investigate the diagnostic yield for TB com- 
paring HPN- and EPN-induced sputum. The major- 
ity of TB-positive specimens were classified as poor 
quality by criteria that used SEC counts to assess 
specimen quality, which is consistent with findings 
from other studies. 16,21 The fact that some TB cases 
were missed by the HPN is most likely due to chance, 
but will certainly need further investigation. 
Another limitation of this study is the different 
make of the two nebulisers. The HPN was a jet nebu- 
liser whereas the EPN was an ultrasonic nebuliser. 
The study therefore could not strictly compare the 
electric vs. the human powered compressor system. 
As this was a substudy of an ongoing intensified case- 
finding study that had been using an ultrasonic nebu- 
liser previously, 22 it was felt that a change in nebuliser 
could possibly compromise the results of the main 
study. It was therefore decided that the jet HPN should 
be compared with the standard of care in this mobile 
HIV testing service. 
The HPN weighs less than 5 kg and measures 50 X 
55 x 38 cm. It does not require any electricity and it 
can be operated by lay community health workers. 
This device is suitable not only for remote clinics 
with unreliable electricity, but also for mobile services 
and community-based intensified TB case finding. 
Several recent community and workplace-based TB 
prevalence surveys in sub-Saharan Africa have shown 
the high burden of undiagnosed TB in communi- 
ties, 23-27 raising the question of whether a clinic-based 
approach alone will be sufficient for TB control. In- 
terventions to facilitate community-based TB and 
HIV diagnosis have been shown to be acceptable 
and feasible. 28-31 More importantly, a recent trial of 
community-based active TB case finding in Zimba- 
bwe provided evidence that active case finding can 
have a positive impact on TB control. 32 However, 
community-based TB diagnosis often relies on spon- 
taneously expectorated spot sputum samples, imped- 
ing TB diagnosis in individuals unable to produce 
sputum. Thus, the role of the HPN in community- 
based TB case finding merits further investigation. 
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OBJECTIFS : Investiguer la qualite des echantillons 
d'expectoration provoquee lorsqu'on utilise respective- 
ment un nebuliseur propulse par l'homme (HPN) et un 
nebuliseur propulse par Ic courant electrique (EPN). 
METH ODES : Chez chaque participant, on a preleve deux 
echantillons d'expectorations provoquees, utilisant respec- 
tivement l'HPN et l'EPN. La sequence des deux nebuli- 
seurs a ete attribuee au hasard. La proportion d'ex- 
pectoration de bonne qualite, en fonction de differents 
criteres d'evaluation, a ete comparee par un test exact 
McNemar. La difference dans la duree avant expectora- 
tion a ete comparee par le test « matched-pairs signed 
rank » de Wilcoxon. 
RESULTATS : Au total, 123 individus ont ete eligibles 
pour cette etude. Il ya eu refus de participation chez 
neuf d'entre eux et incapacite de produire un echantillon 
RtSUMt 
de crachats chez cinq. La proportion d'expectorations 
de bonne qualite a ete plus elevee dans les echantillons 
de crachats induits par HPN par comparaison avec les 
echantillons de crachats obtenus apres 1'EPN. La duree 
median avant production d'un echantillon de crachats a 
ete de 2,2 min (IQR 1,13-4,1) pour 1'HPN et de 2,5 min 
(IQR 1,4-4,1) pour 1'EPN. 
CONCLUSION : L'HPN produit une expectoration de 
bonne qualite et ce dans les 3 min. Cet appareil n'exige 
pas l'utilisation d'electricite et est adapte non seulement 
aux dispensaires eloignes, oil 1'acces au courant electrique 
est irregulier, mais aussi pour les services mobiles et pour 
les depistages intensifies des cas de tuberculose (TB) au 
sein de la collectivite. Des recherches complementaires 
doivent investiguer le rendement en mature de TB dans 
les echantillons de crachats induits par 1'HPN. 
RESUMEN 
OBJET VO5: Investigar la calidad de las muestras de 
esputo inducido que se obtienen mediante la utilizaciön 
de un nebulizador accionado en forma mecänica (HPN) 
y un nebulizador electrico (EPN). 
METODOS: Se obtuvieron de cada participante dos 
muestras de esputo inducido; una muestra se obtuvo 
mediante el use de un HPN y la otra con un EPN. La se- 
cuencia de los nebulizadores se asignö de manera alea- 
toria. La proporciön de muestras de buena calidad, segün 
diferentes criterios de evaluaciön, se comparö mediante 
la prueba exacta de McNemar. Se comparö ademäs el 
lapso hasta la obtenciön de la expectoraciön con la 
prueba de Wilcoxon para datos emparejados. 
RE SU LTA DOS: Ciento veintitres personas cumplieron 
con los requisitos del estudio. Nueve personas rehusa- 
ron participar y cinco no pudieron producir muestras de 
esputo. La proporciön de muestras de esputo de buena 
calidad fue mäs alta en las muestras inducidas con ei 
nebulizador mecänico que con ei nebulizador electrico. 
La mediana del lapso hasta obtener la muestra de esputo 
fue 2,2 min (IQR 1,13-4,1) con ei HPN y 2,5 min (IQR 
1,4-4,1) con ei EPN. 
CONCLUSION: EI HPN induce una muestra de esputo 
de buena calidad en un tiempo de 3 min. El dispositivo 
funciona sin electricidad y es adecuado, no solo en los 
consultorios alejados que no cuentan con un aprovisio- 
namiento fiable de energia electrica, sino tambien en los 
servicios möviles yen las campanas comunitarias de büs- 
queda intensificada de casos de tuberculosis. Se precisan 
nuevas investigaciones que evalüen ei rendimiento diag- 
nöstico de las muestras de esputo inducidas por ei HPN. 
6 Feasibility, yield and cost of an active TB case finding 
program linked to a mobile HIV testing service in Cape 
Town, South Africa 
6.1 Introduction 
Active TB case finding in HIV infected individuals has been recommended by the 
WHO as part of the `Three I's' policy initiative [1,2]. Screening of household 
contacts of infectious TB cases has also been recommended for a long time [3,4,5], 
but population-wide mass-screening has been widely discouraged due to high cost, 
low cost-effectiveness and poor sustainability [6,7]. However, more recently a 
study from Zimbabwe has shown a decline of TB prevalence from 6.5 to 3.7 per 
1000 adults following community-level active TB case finding [6], which led to 
reactivated interest in population-wide interventions. 
Active TB case finding aims at reducing barriers for early TB case detection such as 
delays in the person presenting to a health facility and the health worker 
identifying the person as a TB suspect and initiating appropriate investigations. 
The ultimate goal of active TB case finding is to reduce TB transmission in the 
community through improved case detection and reduction in diagnostic delays. 
The yield of active TB case finding determines the number needed to screen and is 
context specific, depending on local TB prevalence, the function of local TB control 
services, HIV prevalence and the specificity and sensitivity of the screening tool 
[8]. Other important parameters framing decisions on implementing active TB case 
finding include the feasibility and cost of screening, the laboratory capacity, 
diagnostic tests available and treatment outcomes in newly detected cases. 
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The WHO is currently developing guidelines on screening for TB disease with the 
aim to inform national TB screening strategies based on the local epidemiological, 
demographic and health system situation [7]. However, the development of 
guidelines is complicated by significant gaps in knowledge regarding mass 
screening strategies in high TB and HIV prevalence settings. In particular, 
screening strategy, the type of diagnostic test, cost-effectiveness of active TB case 
finding and the treatment outcomes of actively detected cases remain unclear. 
We report the results of a study investigating the feasibility, uptake, treatment 
outcomes and cost of an active TB case finding program linked to a mobile HIV 
testing service in Cape Town, South Africa. 
6.2 Methods 
6.2.1 Setting 
This study was conducted at a mobile HIV testing service over 19 months from 
May 2009 to February 2011. The service operated in underserviced peri-urban 
areas in greater Cape Town, South Africa, and has been described in detail 
elsewhere [9]. In brief, this nurse-run and counsellor-supported unit provided free 
HIV counselling and testing in combination with free screening for other chronic 
conditions (hypertension, diabetes and obesity) and TB. Rapid HIV testing was 
performed according to the guidelines of the Provincial Government of the 
Western Cape [10]. The mobile unit was parked at township shopping centres, taxi 
ranks, stations, and the road side. The service was not formally advertised and 
hence attracted ambulatory clients who spontaneously accessed HIV testing or 
other services. 
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6.2.2 Mobile clinic procedures 
All individuals accessing the mobile clinic were registered using a biometric 
fingerprint system, with no names or other personal identifiers in the registration 
process (Figure 6.1). They were then seen by a nurse for rapid HIV testing and 
chronic disease screening including TB symptom screening, followed by a one-to- 
one counselling session. All individuals with symptoms suggestive of TB (TB 
suspects) received a referral letter to their nearest clinic for further evaluation as 
indicated. Figures 6.1 and 6.2 demonstrates the different steps a patient had to 
undergo when accessing the mobile clinic and active TB case finding programme. 
6.2.3 Study procedures 
6.2.4 Screening 
All HIV negative adults with symptoms suggestive of TB and all HIV positive or 
diabetic adults regardless of symptoms were eligible for the study. All eligible 
individuals were identified as such by the nurse. The lay counsellor collected 
detailed contact information from eligible individuals and referred them to the 
study nurse for participation in the study (Figure 6.1). Individuals who consented 
to participate in the study were asked about symptoms, health seeking behaviour, 
previous TB episodes, educational status, employment and history of 
imprisonment. They were asked to provide one sputum sample and were 
encouraged to do so by sputum induction, but could choose to provide a spot 
sample. Sputum samples were sent to the laboratory within 24 hours. The samples 
underwent fluorescent microscopy and liquid culture. 
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Figure 6.1: Procedures and patient flow in the mobile clinic 
Q Mobile clinic van Q 
Registration Nurse 
Nurse 
" Rapid H IV testing 
" Screening for chronic disease 
" TB symptom screening 
" Referral letter for patients 
with TB symptoms 
e 
Counsellor 
Counsellor 
" Counselling 
" Contact 
information 
i 
Counsellor 
" Counselling 
" Contact information 
U...... 
Waiting area outside the mobile van 
TB Nurse 
" Consent 
" Questionnaire 
" TB information 
" Sputum induction 
The numbers in black circles refer to the pictures in Figure 6.2. 
©, 
Sputum 
tent 
 
Figure 6.2: Pictures showing the different procedures in the mobile service 
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Typical township in Cape Town, where the mobile clinic operated. 
51 
Mobile Clinic parked at the entrance of a township. 
O Patients waiting to be registered. 
52 
O Weight and height is measured as part of the registration process. 
ý' 
} i 
0 HIV testing using a rapid HIV test. 
4ý; - a 
ý.., 
®ý '. 
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\V 
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/l 7rº 4 
54 
0 Counselling 
© Counsellor explains the meaning of CD4 counts using a road to health card. 
55 
O Research nurse prepares for sputum induction. 
O Research nurse labels containers. 
0 Research nurse packs containers for transport. 
0 Sputum induction inthe sputum tent. 
The numbers in black circles refer to the positions in the procedures and patient flow in 
the mobile clinic (Figure 6.1). 
56 
0 Patient is in the sputum tent. Research nurse explains the procedure. 
6.2.4.1 Sputum induction: 
Individuals were asked to rinse their mouth with water before the procedure. 
Sputum induction was performed in an open-roofed tent using 15-20 ml sterile 3% 
hypertonic saline solution and an ultrasonic Flo-Eolo nebuliser (CA-Mi, Pliastro, 
Italy) powered by a generator. Individuals breathed through the nebuliser 
mouthpiece until a satisfactory sample was produced or he/she wished to abandon 
the procedure. The procedure was performed without a nose clip. 
6.2.4.2 Laboratory procedure 
Sputum samples were analysed within accredited laboratories using standardized 
protocols and quality control procedures. Following decontamination with N- 
acetyl-L-cysteine sodium hydroxide, centrifuged sputum deposits were examined 
for acid-fast bacilli using auramine 0 fluorescent stain and cultured using 
mycobacterial growth indicator tubes (MGIT, Becton- Dickinson, Sparks, Maryland, 
USA). Bacillary density was graded as scanty, 1+, 2+, and 3+, and all such smears 
were defined as "smear-positive". The time to automated culture growth detection 
was recorded. Culture isolates positive for acid-fast bacilli were identified as 
Mycobacterium tuberculosis or as Mycobacterium other than tuberculosis (MOTT) 
complex and assessed for genotypic resistance using the MTBDRplus assay (Hain 
Lifescience). Isolates also underwent phenotypic resistance testing for rifampicin 
and isoniazid by automated liquid MGIT culture (using the modified proportion 
method and standard protocols). 
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6.2.4.3 Follow-up 
TB results were received from the laboratory on a daily bases by post and email. 
The laboratory contacted the programme manager or research nurse by phone for 
smear-positive results, who then contacted individuals with smear- and/or 
culture-positive TB to inform them of their positive result and referred them to a 
clinic of their choice. In the referral letter clinic nurses were asked to repeat 
sputum smears and cultures and perform chest radiograms if indicated. Multiple 
attempts were made to contact individuals either by phone, home visit or letter. 
Home visits were particularly time consuming and challenging in squatter camps 
and informal settlements. Individuals who were contacted face to face were asked 
to provide a second sputum sample to confirm the positive TB result. Clinics were 
contacted to ascertain dates of TB treatment initiation, TB register number and 
treatment outcomes. The research nurse performed clinic visits to check the TB 
register if the TB clinic nurse was unable to provide the information by phone. 
Individuals who did not attend the clinic were contacted again to encourage 
linkage to care. The Cape Town municipality's HIV, TB and STI unit was informed 
to notify TB cases where contact with the individuals could not be established. 
6.2.5 Definitions 
Active case finding in this program was defined as TB symptom screening followed 
by submission of sputum samples. TB screening was defined as sputum induction 
(or spot sputum). The 'traditional WHO symptom screen' was defined as any of the 
following: cough>2 weeks, weight loss, fever, night sweats or haemoptysis. The 
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`new WHO symptom screen' was defined as having any of the following symptoms: 
current cough, fever, weight loss, night sweats or haemoptysis [2,11]. 
6.2.6 Cost analysis 
An incremental cost analysis investigating the costs of adding TB screening 
through sputum induction to an existing mobile HIV testing service was performed 
adopting a health service provider perspective. Financial costs included the costs 
of human resources (clinical nurse practitioner, programme manager, counsellor), 
equipment (tents, nebuliser, generator), consumables (gloves, masks, tubes 
disinfectant), transport, laboratory tests and rent. Costs were divided into capital 
and recurrent costs [12], and capital costs were annualized and discounted at 6% 
per year [13]. Cost data from previous years were adjusted for inflation to 2011 
constant costs [14] and converted to US dollars (USD 1.00 = ZAR 7.40) [15]. Owing 
to the incremental nature of the cost analysis, resources shared with other 
interventions such as screening for HIV and other diseases were excluded from the 
analysis. Some of the resources were joint resources and were allocated 
proportionally. In order to analyse what staff time had been spent exclusively on 
TB screening activities, time-motion studies of all staff involved were conducted 
over one week in August 2010 and two weeks in January 2011, with a total of 13 
complete screening days being observed. The two time periods were chosen, as 
attendance rates and working conditions varied according to season. Additionally, 
the research nurse kept a log file to estimate staff time spent on follow-up of 
individuals with positive smears and/or cultures. Cost of first line TB treatment 
was obtained from the literature [16,17], for patients who died or defaulted 
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treatment costs were allocated proportionately based on their time spent on 
treatment. 
6.2.7 Measure of effectiveness 
Effectiveness was measured as the rates of smear- and/or culture-positive disease, 
and the proportion of individuals with TB disease with a positive treatment 
outcome (cured or treatment completed). Treatment initiation dates, treatment 
outcomes and date of outcomes were determined by contacting TB clinics. The 
research nurses verified the outcomes by checking clinic TB registers. 
6.2.8 Screening strategy and sensitivity analysis 
Different screening strategies were assessed regarding their yield, treatment 
outcomes and cost. Screening strategies only differed with regards to HIV positive 
individuals. All HIV negative individuals with symptoms suggestive of TB (TB 
suspects) were assumed to undergo sputum investigations. Strategy I (base 
scenario) screened all HIV infected individuals regardless of symptoms. Strategy II 
assessed what would have been seen if screening was of all individuals with 
symptoms suggestive of TB according to the new WHO symptom screen. Strategy 
III assessed the effect of screening all individuals with CD4 counts 5200 cells/µl or 
unknown CD4 counts regardless of symptoms and all individuals with CD4 counts 
>200 cells/µl and symptoms suggestive of TB according to the new WHO symptom 
screen. Strategy IV assessed the effect of screening all individuals with symptom 
suggestive of TB according to the traditional WHO symptom screen. Sensitivity 
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analyses were conducted for different levels of staff salaries, assuming that the 
outcomes would remain the same. 
6.2.9 Statistical analysis 
All analyses were carried out using Stata version 11.0 (Stata Corp. LP, College 
Station, TX, United States of America). Proportions were calculated for categorical 
variables, and medians and interquartile ranges (IQR) for continuous variables. 
Differences in proportions were assessed using Xz test and differences in medians 
were assessed using Wilcoxon rank sum test. The mean cost per examined sputum, 
TB case and TB case with positive treatment outcome was calculated by summing 
the cost of all resources and dividing them by the number of sputum samples, TB 
cases diagnosed and TB case with positive outcomes. 
6.2.10 Ethics statement 
Written informed consent was obtained from all individuals participating in the 
study. Data collection and analysis was approved by the University of Cape Town 
Ethics Committee and Partners Human Subjects Institutional Review Board and 
the London School of Hygiene and Tropical Medicine Ethics Committee. 
6.3 Results 
6.3.1 Operational data 
TB screening was performed on 181 days over a period of 19 months at 58 
different sites. The majority of sites were in deprived areas, near townships and 
squatter camps. A total of 6,309 adults accessed the services of the mobile clinic, 
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85 were not tested for HIV, 5551 tested HIV negative, 370 were newly diagnosed 
with HIV and 388 were known HIV positive. Overall HIV prevalence in individuals 
tested was 12.0%. The median number of adults tested for HIV per day was 34 
(IQR 27-41). The median number of individuals screened for TB was 6 (IQR 3-8), 
with a maximum number of 23 individuals per screening day. 
6.3.2 Uptake of TB screening 
A total of 1,385 individuals were eligible for TB screening through sputum 
induction: 627 were HIV negative, 370 were newly diagnosed HIV positive and 388 
were known HIV positive (Figure 6.1). 1130 (81.6%) of all eligible individuals 
underwent screening. Individuals who were not screened were younger, more 
likely to be HIV positive and had a higher body mass index compared to individuals 
who underwent TB screening (Table 6.1). Failure to undergo screening was more 
likely in the first year of the study compared to the second year. 
The majority of individuals (62.9%) who failed to complete TB screening said they 
did not have time to wait or they absconded without seeing the TB nurse. The 
remaining 164 individuals (37.2%) were missed because the nurses or counsellors 
did not refer them for screening. The proportion of individuals who absconded was 
highest in newly diagnosed HIV infected individuals (85.4%). 
Among the individuals undergoing TB screening a considerable proportion was 
unable to produce a sputum sample or sputum results were inconclusive due to 
contamination (Figure 6.3). Overall 60.9% of all eligible individuals had an 
interpretable sputum result Proportions with interpretable sputum results were 
64.3%, 55.9% and 61.6% among HIV negative, newly diagnosed and known HIV 
infected individuals respectively. 
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Table 6.1: Baseline characteristics for clients eligible for the study stratified 
by screening 
Variables 
Total Not screened Screened p N=1395 N=265 N=1130 
Age 
Median 
35.2 (27.6-44.7) 32.8 (26.6-42.1) 35.9 (27.9-45.7) 0.01 (IQR) 
Men N (%) 498 (35.7%) 92 (34.7%) 406 (35.9%) 0.71 
HIV status 
Negative 
Newly diagnosed 
positive 
Known positive 
CD4 cell count at 
screening (cell/µl) in 
HIV infected 
individuals 
Body mass index 
N (%) 637 (45.7%) 103 (38.9%) 
N (%) 370 (26.5%) 82 (30.9%) 
N (%) 388 (27.8%) 80 (30.2%) 
Median 
(IQR) 
Median 
(IQR) 
426 (302-606) 423(300-603) 
534 (47.3%) 
288 (25.4%) 0.05 
308 (27.3%) 
479 (308-631) 0.23 
24.6 (21.4-29.7) 25.7 (21.8-30.5) 24.4 (21.4-29.4) 0.03 
Diabetes N (%) 58 (4.2%) 10 (4.0%) 48 (4.3%) 0.84 
Study year 
Year 1N (%) 827 (59.3%) 183 (69.1%) 644 (57.0%) 
<0.01 
Year 2N (%) 568 (40.7%) 82 (30.9%) 468 (43.0%) 
Figure 6.3: Flowchart of individuals participating in the study 
HIV- individuals 
with TB symptoms 
Elligible for 
screening 
Underwent 
screening 
Able to provide 
sputum 
Sputum result 
available 
(non-contaminated) 
627 (100%) 
534 (82.2%) 
491(78.3%) 
403 (64.3%) 
Newly diagnosed 
HIV+ individuals 
370(100%) 
288(77.8%) 
244(65.9%) 
207 (55.9%) 
Known HIV+ 
individuals 
388(100%) 
308 (79.4%) 
277 (71.4%) 
239(61.6%) 
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6.3.3 Baseline characteristics 
A total of 1130 individuals participated in the study and underwent screening. The 
median age was 35.9 years and 35.9% were men (Table 6.2). Financial insecurity 
was high with 22.7% of individuals reporting no regular income. Among 
individuals with regular income, employment or regular work accounted for only 
35.3%. The median income was ZAR 1000 (equivalent to USD 135) per month. The 
majority of individuals lived in informal settlements or squatter camps (63.1%) 
and had less than 12 years of school education (78.0%). 
Median body mass index was 24.4 (IQR 21.4-29.4) A quarter of individuals had had 
TB before and 21.2% lived with somebody who had been treated for TB within the 
last year. The median CD4 count was 434 cells/µl (IQR 316-617) in newly 
diagnosed and 403 cells/µl (IQR 288-570) in known HIV infected individuals. 40% 
of the known HIV infected individuals were on ART at the time of screening with a 
median time on ART of 3.1 years (IQR 1.1-6.5). 
The most prevalent symptom among HIV negative TB suspects was cough (84.3%), 
followed by night sweats (74.0%) and weight loss (53.2%). Overall 497 (93.1%) of 
the 534 HIV negative TB suspects screened positive for symptoms suggestive of TB 
according to the traditional WHO symptom screen. The remaining 37 were 
asymptomatic and diabetic (N=10) or reported cough for less than 2 weeks 
(N=27). A total of 174 (60.4%) of the newly diagnosed and 183 (59.4%) of the 
known HIV infected individuals screened positive according to the new WHO 
symptom screen. Cough was the most prevalent symptom among both newly 
diagnosed (43.1%) and known HIV infected individuals (43.2%). 
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Only 20.7% (N=170) of all individuals reporting symptoms had previously sought 
health care for their current symptoms. Of those who had sought health care 
61.8% had undergone sputum investigations and 31.8% had had a chest 
radiogram. 
6.3.4 Yield of TB screening 
Among all HIV negative individuals or individuals with unknown HIV status who 
accessed the mobile service and benefited from active case finding, including those 
who were unable to provide a sputum sample, prevalence was 0.2/100 (95% Cl 
0.1-0.4) for smear-positive TB and 0.5/100 (95%CI 0.3-0.7) for culture-positive 
TB. Among individuals newly diagnosed with HIV, TB prevalence was 2.2/100 
(95%CI 0.9-4.2) for smear-positive and 4.9/100 (95%CI 2.9-7.6) for culture- 
positive disease. Prevalence was 0.3/100 (95%CI 0.0-1.4. ) for smear positive and 
3.0 (95%CI 1.6-5. ) for culture-positive TB in individuals with known HIV infection. 
The overall prevalence of smear positivity among individuals providing a sputum 
sample was 2.0/100 (95%CI 1.2-3.0) (Table 6.3). Prevalence of smear positive TB 
was 2.2/100 (95%CI 1.1-4.0), 3.3/100 (95%CI 1.4-6.4) and 0.4/100 (95%CI 0-2.0) 
in HIV negative TB suspects, newly diagnosed and known HIV infected individuals, 
respectively. Prevalence of culture-positive TB was 5.5/100 (95%CI 4.2-7.1) 
overall. In HIV negative TB suspects, newly diagnosed and known HIV infected 
individuals prevalence of culture-positive TB was 5.3/100 (95%CI 3.5-7.7), 
7.4/100 (95%CI 4.5-11.5) and 4.3/100 (95%CI 2.3-7.4), respectively. Median time 
to culture positivity was 13.5 days (IQR 8-22). All isolates were sensitive to 
rifampicin and isoniazid. 
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Table 6.3 Tuberculosis prevalence in patients submitting a sputum sample 
Variables 
Total 
N=1011 
HIV- 
N=491 
Newly 
diagnosed HIV+ 
N=243 
Known 
HIV+ 
N=277 
Smear result 
Overall positive N (%) 20 (2.0%) 11(2.2%) 8 (3.3%) 1 (0.4%) 
Scanty N (%) 3 (0.3%) 1 (0.2%) 2 (0.8%) 0 (0.0%) 
1+ N(%) 6 (0.6%) 3 (0.6%) 2 (0.8%) 1 (0.4%) 
2+ N (%) 6 (0.6%) 4 (0.8%) 2 (0.8%) 0 (0.0%) 
3+ N (%) 5 (0.5%) 3 (0.6%) 2 (0.8%) 0 (0.0%) 
Culture result 
Negative N (%) 746 (73.8%) 346 (70.5%) 180 (74.1%) 220 (79.4%) 
Contaminated N (%) 162 (16.0%) 88 (17.9%) 36 (14.8%) 38 (13.7%) 
MOTT N (%) 47 (4.7%) 31 (6.3%) 9 (3.7%) 7 (2.5%) 
M. tuberculosis N (%) 56 (5.5%) 26 (5.3%) 18 (7.4%) 12 (4.3%) 
Days to culture Median 13.5 (8-22) 12 (7-17) 13 (8-22) 19 (14.5-27) 
positivity (IQR) 
6.3.5 CD4 counts and WHO symptom screens in HIV infected 
individuals 
TB prevalence was highest in patients with CD4 counts : 5200 cells/µl 
(28.6%; 
95%CI 9.7-30.9), followed by patients with missing CD4 counts (7.7%; 95%CI 9.5- 
25.1). TB prevalence was 5.3% (05%CI 2.0-11.1), 4.3% (95%Cl 1.6-9.1), 2.8% 
(95% 0.9-6.3) in patients with CD4 counts of 201-350,351-500, >500 cells/µ1, 
respectively. 
The new WHO symptom screen had a sensitivity of 87.7% (95%CI 69.3-96.2) and 
specificity of 39.4% (95%CI 35.0-43.9). Sensitivity was 100% (95%CI 71.5-100.0) 
and specificity 29.8% (95%CI 17.3-44.5) in patients with CD4 counts <_200 cells/µl. 
The traditional WHO symptom screen had a sensitivity of 83.3% (95%Cl 65.3- 
94.4) and specificity of 46.1% (95%CI 41.6-50.7) in HIV positives. 
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6.3.6 Contact rates, treatment initiation and treatment outcomes 
Successful contact for follow-up after screening was made with 50 (89.3%, 95%CI 
78.1-96.0) of the 56 individuals diagnosed with TB (Table 6.4). Contact success 
was higher in smear-positive individuals (95.0%, 95%CI 75.1-99.9) compared to 
smear-negative/culture-positive individuals (86.1%, 95% 70.5-95.3) The reasons 
for not being able to contact individuals were: imprisonment (N=1), relocation to 
an unknown area (N=3) and demolishment of the area where the individual had 
lived (N=2). The median time to successful contact from time of positive result was 
4 days (IQR 1-10). Medium time to contact was shorter for individuals with smear- 
positive TB (1 day, IQR 0-2) compared to individuals with smear-negative/culture- 
positive TB (6 days, IQR 4-20). 
Of the 50 individuals contacted, a total of 42 were confirmed to have started TB 
treatment by contacting the clinic and checking the clinic TB register. Treatment 
initiation rates were 89.5% (95%CI 66.9-98.7) in smear-positive and 80.7% 
(95%CI 62.5-92.5) in smear-negative/culture-positive cases. Two individuals had 
refused treatment and six individuals had not started treatment at their nearest 
clinic. Several attempts were made to contact these individuals, but all of them had 
moved to an unknown destination. Median time between screening and treatment 
initiation was 27 days (IQR 7-54) overall, 6.5 days (IQR 4.5-8) for smear-positive 
and 45 days (IQR 32-57) for smear-negative/culture-positive cases. Median time 
between successful contact and treatment initiation was 1 day (IQR 0-8). 
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Table 6.4: Contact rates and treatment success in patients diagnosed with 
tuberculosis 
Variables 
Total 
N=56 
Smear + 
N=20 
Smear -/culture + 
N=36 
Successful contact N (%) 50 (89.3%) 19 (95.0%) 31 (86.1%) 
Time to successful contact from Median 4(1-10) 1(0-2) 6(4-20) 
availability of positive result (days) (IQR) 
Treatment started 
No N (%) 2 (4.0%) 1 (5.3%) 1 (3.2%) 
Unknown N (%) 6 (12.0%) 1 (5.3%) 5 (16.1%) 
Confirmed N (%) 42 (84.0%) 17 (89.5%) 25 (80.7%) 
Time to treatment from screening Median 27 (7-54) 6.5 (4.5-8) 45 (32-57) 
date (days) (IQR) 
Time to treatment from Median 24(3-50) 1.5(0-6.5) 43(29-74) 
availability of positive result (days) (IQR) 
Time to treatment from contact Median 1 (0-8) 0.5 (0-25) 2 (0-23) 
date (days) (IQR) 
Treatment outcome 
Treatment completed or cured N (%) 34 (81.0%) 12 (70.6%) 22 (88.0%) 
Died N (%) 2 (4.8%) 1 (5.9%) 1 (4.0%) 
Defaulted N (%) 5 (11.9%) 3 (17.6%) 2 (8.0%) 
Treatment interruption N (oho) 1 (2.4%) 1 (5.9) 0 (0.0%) 
Overall treatment success rate was 81.0% (N=34/42) (95%Cl 65.9-91.4). 
Treatment success was 70.6% (95%CI 44.0-89.7) for smear-positive and 88.0% 
(95%CI 68.8-97.5) for smear-negative/culture-positive cases. Two individuals died 
on treatment, two defaulted and one interrupted treatment, but restarted 
treatment 3 months after defaulting. 
Of the 42 individuals who had initiated treatment, seven started before a 
successful contact could be made (Figure 6.4). In these cases, the initiation of 
treatment was not triggered by the positive sputum result. All patients with 
symptoms suggestive of TB received a referral letter from the mobile HIV clinic. 
These seven individuals had presented with their referral letter to a primary care 
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clinic and where started on TB treatment based on clinical presentation and 
investigations performed at the clinic. 
Figure 6.4: Losses between tuberculosis diagnosis to treatment completion 
56 patients diagnosed with TB 
50 contacted successfully 
42 initiated treatment 
7 initiated treatment before 
being successfully contacted 
i defaulted II6 completed 
treatment treatment 
35 initiated treatment as a result of being contacted 
4 defaulted 11 2 died 11 1 interrupted 8 completed treatment treatment treatment 
6.3.7 Costs and cost effectiveness 
The total cost of the screening program was USD 83,559. USD 22,367 (26.8%) were 
spent on laboratory tests, USD 37,427 (44.8%) on staff salaries, USD 17.652 
(21.1%) on TB treatment, the remaining USD 6,108 (7.3%) were spent on 
transport, office rent and utilities, communication, generator and supplies. The 
costs were USD 1,117 per TB case detected and USD 2,458 per TB case with a 
positive treatment outcome (cured or treatment completed) (Table 6.5). 
Outcomes and costs for different screening strategies are presented in Table 6.5 
and compared to the base scenario (strategy I: sputum induction in all HIV infected 
individuals regardless of symptoms). Strategies differed only with regards to 
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sputum induction in HIV infected individuals. All HIV negative TB suspects were 
assumed to undergo sputum induction. Strategy II-IV did not significantly differ 
with regards to costs. Strategy IV (sputum induction in HIV infected individuals 
screening positive according to the traditional WHO symptom screen) was the 
most cost-effective strategy. However this strategy would have missed five TB 
cases resulting in one smear-positive case not being cured and one smear- 
negative/culture-positive case not completing treatment. 
Table 6.5: Outcomes, costs and cost-effectiveness indicators for 
tuberculosis screening 
Costs and outcomes 
Strategy Strategy Strategy Strategy 
I II III IV 
(Base case) 
Number needing sputum induction 1130 891 920 856 
Number of induced sputum 1012 814 841 780 
Number of TB cases detected 56 52 52 51 
Number of TB cases with positive outcome 
(cured or treatment completed) 
34 33 33 32 
Total cost of the program (2011 USD) 83,559 70,142 71,901 67,408 
Cost per TB case detected (2011 USD) 1,177 1,019 1,053 996 
Cost per TB case with positive outcome 
(cured or treatment completed) (2011 USD) 
2,458 2,126 2,179 2,107 
Screening strategy for HIV infected individuals (all HIV negative patients with symptoms suggestive of TB 
are screened in each of the strategies) 
Strategy I (Base case) Sputum induction in all individuals regardless of symptoms 
Strategy II Sputum induction in all individuals with symptoms suggestive of TB 
according to the new WHO symptom screen 
Strategy III Sputum induction in all individuals with CD4 counts 5 200 cells/µl or 
unknown CD4 counts regardless of symptoms and all individuals with CD4 
counts > 200 cells/µI and symptoms suggestive of TB according to the new 
WHO symptoms screen 
Strategy IV Sputum induction in all individuals with symptoms suggestive of TB 
according to the traditional WHO symptom screen 
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6.3.8 Sensitivity analysis 
Sensitivity analyses were performed for different levels of staff salaries assuming 
the same effectiveness. Substituting the clinical nurse practitioner by a staff nurse 
would have reduced the cost per TB case diagnosed by 9.1% to USD 1,015 and the 
cost per TB case with positive treatment outcome by 10.9% to USD 2,190. Further 
reduction in costs would have been achieved if TB screening had been performed 
by a lay counsellor and follow-up of TB cases, supervision and program 
management was performed by a clinical nurse practitioner. The costs per TB case 
diagnosed would have been reduced to USD 705 (36.9%) and the cost per TB case 
with a positive treatment outcome to USD 1,681 (31.6%). 
6.4 Discussion 
This study showed a high uptake and yield of community-based active TB case 
finding. It highlighted the substantial losses between TB diagnosis, contacting the 
client, treatment initiation and treatment completion or cure. This study is unique 
in that it followed patients beyond the diagnosis of TB and ascertained treatment 
outcomes. Once a patient had started TB treatment, treatment success was more 
than 80%, which was as high as reported from clinics in the Western Cape [18]. 
Costs were USD 1,177 per TB case diagnosed and USD 2,458 per successfully 
treated TB case. 
Cost-effectiveness is influenced by various parameters, among them the yield of 
screening. The yield depends on the local TB control program, the target 
population, screening algorithms, prevalence of HIV infection and severe immune- 
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suppression, the number of specimens obtained (induced or not induced) and the 
diagnostic tests employed. The service described in this study was accessed by a 
severely socio-economically deprived population as evidenced by high 
unemployment, low income and low levels of education. In addition few 
individuals had sought medical attention for their symptoms prior to accessing the 
service. It is well documented that TB patients and suspects present late to 
stationary health facilities, which contributes to delays in diagnosis, morbidity and 
mortality [19]. Whether active TB case finding reduces these delays and/or results 
in diagnosis of otherwise undiagnosed TB is currently unknown. 
HIV prevalence and prevalence of severe immuno-suppression in this mobile HIV 
testing service was low compared to stationary services [9]. In addition half of the 
HIV positive individuals knew their status already and 40% of the known positives 
were on ART at the time of screening. This and the fact that only one sputum 
sample was examined explains the lower yield of screening in HIV infected 
individuals in this study compared to studies screening individuals at stationary 
HIV testing sites [8,20] and at time of ART eligibility screening [21,22,23]. 
A recent study from South Africa reported results from active TB case finding in 
women accessing antenatal care [24]. Despite the women being symptomatic only 
half of them were able to produce a spot sputum sample. Few other active case 
finding studies report the percentage of sputum samples obtained [25,26]. In 
Uganda 78% of individuals with chronic cough were able to produce a spot sputum 
[25]. Rates were near to 100% in a population-based TB prevalence survey in 
Zambia, where sputum production was assisted by simple breathing techniques 
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[26]. In our study 88% of HIV positive individuals with and without symptoms and 
92% of HIV negative TB suspects were able to produce a sputum sample. While 
these results provide some evidence for the benefit of sputum induction, the 
additional yield and costs were not assessed. 
The choice and number of diagnostic tests used for screening depends on 
availability, feasibility, yield and cost. We chose to investigate all samples by 
microscopy and culture as smear-negative/culture-positive individuals contribute 
to transmission [27,28]. The yield of culture was more than double compared to 
microscopy with an additional cost of USD 12 per sample. A pilot study in lay 
health care workers showed that two inductions were not acceptable due to time 
constraints and discomfort [29]. We therefore decided to investigate one and not 
two induced sputum samples. A second sputum sample would have increased the 
yield, but also the costs. A population-based active TB case finding study from 
Zimbabwe investigated two sputum samples with fluorescent microscopy only. 
The additional yield of the second sample was 17% using microscopy, but the 
additional yield of culture was not assessed [6]. 
TB diagnosis in this study was made on the bases of one positive sputum result. 
False positive results due to cross-contamination occur at a frequency of 2-5% in 
low TB incidence settings [30,31,32]. An estimated 2.4% (95%CI 0.3-8.8) of all 
positive TB cultures were found to be false positive in the laboratory used for this 
study [33]. Assuming a cross-contamination rate of 8.8% a total of 5 false positive 
diagnoses would have been made in this study. However, we asked all individuals 
we contacted face to face for a second confirmatory sputum sample. A total of 29 
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interpretable sputum results (non contaminated) were available. Of those 24 
(82.8%) were culture positive for Mycobacterium tuberculosis. The remaining five 
patients were symptomatic and three of them had a cough for more than 2 weeks. 
The success of active TB case finding to decrease transmission relies on treatment 
success of actively found cases. Treatment success in actively detected cases 
initiated on treatment was comparable with outcomes from passively detected 
cases reported from clinics in Cape Town [18]. However we were unable to contact 
six individuals (10.7%), two (3.5%) refused treatment and treatment initiation 
was unknown for six. These results are similar to results from a population-based 
sero-prevalence survey in Cape Town reporting that seven (26%) of 27 individuals 
with culture-positive TB did not initiate treatment [34]. The same study showed 
that those who did start treatment had similar treatment success rates as passively 
detected TB cases (80%). Defaulters prior to treatment initiation are not reported 
as part of the routine TB outcome reporting, but rates of initial defaulting of 17- 
21% have been reported from stationary health care clinics in South Africa using 
passive case finding [35,36,37,38]. More recently a study from Cape Town 
reported initial defaulting rates of smear-negative/culture-positive TB cases as 
high as 39% [391 
Treatment outcomes might be even more important than the yield of screening. A 
new rapid diagnostic, the Xpert MTB/Rif with an overall sensitivity of 90% in TB 
suspects reduced the time to start treatment from 56 to 5 days and dropout rates 
from 39% to 15% in smear-negative, culture-positive cases in a primary health 
care clinic in Cape Town [39,40]. The reduction in diagnostic delay is particularly 
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important in mobile services, where contact success is higher the less time has 
passed since the person was seen. Contact success was higher in individuals with 
smear-positive disease, because results were available within 1-2 days, compared 
to individuals with smear-negative/culture-positive disease. Relatively more 
resources and time were spent to contact individuals with smear-negative/culture- 
positive disease, as patients' mobile phones stopped working or were lost, stolen 
or passed on and individuals had moved to different locations in the meantime. 
To our knowledge this is the first study assessing cost of community-based active 
TB case finding using a mobile screening unit. Three studies investigated the costs 
of active TB case finding in HIV infected individuals only; either as part of isoniazid 
preventive treatment programs [41,42] or at the time of ART eligibility assessment 
[23]. All studies were performed at stationary HIV testing sites or clinics. The 
prevalence of undiagnosed TB in these studies was 19-26% [23,42] and thus the 
inflation-adjusted cost per TB case diagnosed was more than three times lower 
(USD 318-358) compared to our screening program. None of these studies 
assessed treatment outcomes. 
This study has several strengths and limitations. The study was conducted as part 
of a routine service and provides an opportunity to understand the challenges 
faced by mobile services. Mobile services operate under time, space and weather 
constraints. As a result a considerable number of individuals were not referred or 
did not want to wait for TB screening. Furthermore the population accessing a 
mobile service is healthier, less health care seeking and more mobile than 
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individuals accessing stationary services, resulting in reduced yield, contact and 
treatment initiation rates. 
Cost was assessed using an incremental approach. The results will inform policy 
makers when considering adding active TB case finding to existing mobile HIV 
testing services. Different screening strategies were assessed, showing that 
symptom screening in HIV positives prior to sputum induction was more cost- 
effective than screening all HIV positive individuals regardless of symptoms. HIV 
prevalence is lower in mobile services [9,43,44] compared to stationary services 
and therefore a more pragmatic approach to TB symptom screening might be 
indicated. For the sake of simplicity the use of a universal symptom screening 
algorithm for both HIV negative and positive individuals should be considered. The 
potential secondary benefit of the program with regards to numbers of TB cases 
prevented was not taken into account in this analysis. Active TB case finding is 
likely to have some effect on transmission. Thus taking transmission into account 
would have increased the cost-effectiveness of the programme. 
This study was conducted at a single site and therefore the findings can only be 
generalised to similar settings with comparable levels of deprivation. TB diagnosis 
could not be established in 16% of individuals as a result of high contamination 
and single sputum investigation. The contamination rate was high probably due to 
population characteristics (poor mouth hygiene) or environmental factors 
(variable temperature, wind and dust). Previous studies conducted in the same 
laboratory reported considerable lower contamination rates [22,45,46]. 
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A recent study from Kenya concluded that the highest impact would be achieved 
when population-based active TB case finding was combined with universal HIV 
testing and improved diagnosis of smear-negative TB [47]. Our active TB case 
finding program provided integrated TB and HIV services combined with 
improved TB diagnostics. The population-based TB case finding study from 
Zimbabwe provided valuable evidence that active TB case finding can have a 
positive impact on TB control [6]. Our study serves as an example of a TB 
screening program integrating HIV and TB services with high uptake, yield and 
treatment success and relatively low costs. 
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Part II: Antiretroviral therapy 
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7 Study question part II 
This thesis aimed to investigate losses along the HIV care pathway first by 
conducting a literature review, second by describing losses along the HIV care 
pathway in a peri-urban settlement in the greater area of Cape Town (Figure 7.1), 
estimate ART coverage and investigate the association between ART coverage and 
TB risk in a cohort of HIV infected individuals receiving ART. 
Figure 7.1: Map of the study community, Masiphumelele 
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8.1 Abstract 
Scale-up of antiretroviral treatment (ART) has transformed the prognosis of 
people with HIV infection in sub-Saharan Africa. However, due to low HIV test 
uptake and losses at each step along the HIV care pathway, including assessment of 
ART eligibility, engagement in pre-ART care, initiation of ART and long-term 
retention on treatment, only a minority of the individuals in need ever receive the 
appropriate long-term care. This article describes this continuum of HIV care, 
quantifies losses along the pathway using systematic review and meta-analyses of 
published data and addresses possible interventions. Only 39% of HIV-infected 
individuals are estimated to know their sero-status. Of these, just 57% complete 
assessment of ART eligibility of whom approximately 50% require treatment at 
that time-point Of those not yet eligible, only 45% remain in pre-ART care. Of 
those who are eligible, just 66% start ART and 65% remain on therapy after 3 
years. These data highlight the huge losses occurring throughout the care pathway, 
especially prior to ART initiation. Data regarding interventions to address this 
issue are scarce, however. Research is urgently needed to identify effective 
solutions so that a far greater proportion of infected individuals can benefit from 
long-term ART. 
Key words: HIV, Linkage to care, ART, sub-Saharan Africa, Retention in care, HIV 
testing, pre-ART 
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8.2 Introduction 
The success of antiretroviral therapy (ART) roll-out in sub-Saharan Africa has been 
remarkable. Between 2004 and the end of 2009, almost 4 million people had 
initiated ART, leading to dramatic reductions in HIV-associated morbidity and 
mortality [1-5]. However, due to low HIV test uptake and losses along the pathway 
between HIV testing and ART treatment [6], only a minority of individuals in need 
of ART are estimated to ever start treatment [7]. This is further compounded by 
substantial additional losses that occur during long-term treatment [8,9]. 
The essential steps in the HIV care pathway are HIV testing, assessment of 
eligibility for ART, pre-ART care, initiation of ART and long-term retention on ART. 
The importance of linkage and engagement in care has received considerable 
attention in high-income countries [10-12] where successes have resulted in 
improved health outcomes for the patient [13,14] and reduced costs for the health 
care system [15]. Characterization of losses along the care pathway in high-income 
countries [15-17] have informed the development of potential interventions [11]. 
However, the scale of the challenge is so much greater in sub-Saharan Africa where 
millions of patients are in need of life-long treatment and health care systems are 
less well developed. It is unclear if interventions developed in high-income 
countries will be feasible in this resource-constrained setting. 
In the majority of sub-Saharan African countries large scale ART roll-out 
commenced from 2004 as treatment became affordable and major donor funding 
mechanisms were established [18]. Rapid implementation of vertically driven 
90 
programmes was successful in providing life saving treatment for large numbers of 
patients in need. However, this success was achieved with insufficient attention 
being given to the establishment of the necessary linkages and integration of HIV 
care within the broader health system. These are essential for the establishment of 
an effective continuum of care both before and during ART. 
Engagement in HIV care starts when an individual first tests positive for HIV 
(Figure 8.1). This should be followed by assessment for ART eligibility, which 
requires World Health Organization (WHO) clinical staging and/or CD4 count 
testing. CD4 count testing is a two-stage process, which requires that a patient's 
blood sample is obtained and sent for processing and then the patient has to return 
to receive this result (typically 1-2 weeks later). Patients who meet the national 
criteria for initiation of ART should commence ART without undue delay whereas 
patients not yet eligible should be retained in pre-ART care and undergo regular 
CD4 count monitoring until the eligibility threshold is reached. Once patients 
initiate ART, they should remain on uninterrupted treatment for life. Losses occur 
at different steps along this pathway, and may be temporary or permanent. The 
care pathway is not a simple linear process and the dynamic nature of linkage, 
retention, loss and re-engagement in care, especially in the pre-ART stage, makes 
this a challenging pathway to assess. 
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To date, the majority of studies from sub-Saharan Africa have focused on 
treatment adherence and retention of patients who have started ART [8,9,19-22]. 
However, much more needs to be understood about the earlier components of the 
care pathway. In addition, most studies have reported on rates and risk factors for 
loss to care, with little focus on potential interventions. In this article we review 
the continuum of HIV care and quantify losses along the pathway in sub-Saharan 
Africa. For the purpose of this review, we have divided the HIV care pathway into: 
(i) HIV testing; (ii) pre-ART care comprising assessment of ART eligibility, 
retention in pre-ART care prior to ART eligibility, initiation of ART; and (iii) 
retention in ART care (Figure 8.1). Where available, we used synthesized data from 
published systematic reviews, or from WHO reports. Where such data were either 
unavailable or a more comprehensive review was possible, we conducted 
systematic literature reviews and data synthesis using methods described in the 
appendix. Possible interventions and operational solutions aimed to reduce losses 
at each stage of the pathway are then reviewed and discussed. 
8.3 Losses along the pathway 
8.3.1 HIV testing 
The proportion of HIV-infected individuals in sub-Saharan Africa whose infection 
remains undiagnosed is often derived from population-based surveys in which 
participants are asked to provide details about previous HIV testing. However, a 
considerable proportion of those who report a previous negative test may have 
since seroconverted. Thus, the overall median estimate of 39% of people living 
with HIV in sub-Saharan Africa knowing their correct HIV status may be an over- 
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estimate [7]. This is suggested by some country-level studies. For example, the 
Kenya AIDS Indicator Survey linked HIV test results to perceived HIV status [99]. 
This revealed that among HIV-positive individuals, 56% reported they did not 
know their status, 28% mistakenly thought they were HIV-negative and only 16% 
actually knew their HIV-positive status [23]. Similarly, in a peri-urban South 
African community with high HIV prevalence, the prevalence of previously 
undiagnosed HIV was 46% despite the coverage of HIV testing being extremely 
high (71%) [24]. 
This huge reservoir of undiagnosed HIV in sub-Saharan Africa drives high rates of 
HIV-associated morbidity, mortality and HIV transmission and has devastating 
consequences for individuals and communities. Many patients either die without a 
diagnosis being made or the diagnosis is only established once patients have 
presented to the health facility with advanced symptomatic disease. The 
proportion of undiagnosed HIV in a given population depends on the nature of the 
epidemic (generalized or concentrated), HIV incidence, HIV test uptake and 
frequency of testing (Table 8.1). In countries with concentrated epidemics, 
targeted testing of high risk groups may be the most efficient strategy. Conversely, 
in countries with generalized epidemics and high HIV incidence, universal and 
frequently repeated HIV testing is likely to be the only strategy to reduce the huge 
burden of undiagnosed HIV [25]. 
94 
Table 8.1: Data from population-based surveys (source: World Health 
Organization, Towards Universal Access: Scaling up priority 
HIV/AIDS interventions in the health sector Progress Report 
2010) 
Percentage of Percentage of Percentage of people people who had an 
people who ever living with HIV who 
Adult HIV 
HIV test within the had an HIV test ever had an HIV test 
prevalence 
Country Year last 12 months 
Women Men Women Men Women Men Total 
3.4 
Congo 2009 
- 
6.5 
- 
7.1 22.5 
- 
17.7 
- 
35.2 
--- 
21.1 
--- 
30.9 
--- 
(3.1-3.8) 
Democratic 
--- -- --- --------- -- 
1.3 
Republic of 2007 4.1 3.8 8.6 9.2 8.7 - 10.7 (1.2-1.5) 
Congo 
6.3 
Kenya 2009 29.3 22.8 56.5 40.4 73.5 58.6 68.9 (5.8-6.5) 
1.6 
Sierra Leone 2008 4.1 3.4 9.4 7.0 20.2 - 19.8 (1.4-2.1) 
25'8 
Swaziland 2007 21.9 8.9 35.8 17.1 44.0 28.8 38.7 (24.9-36.9) 
United 5.8 
Republic of 2008 19.1 18.9 37.2 26.5 43.7 30.8 39.0 (5.4-6.2) 
Tanzania 
Zambia 2007 18.5 11.7 35.3 19.8 45.4 28.3 38.4 
13.7 
(13.1-14.4) 
8.4 Pre ART care 
8.4.1 Assessment of ART eligibility 
For individuals who test positive for HIV infection, the next key step in the care 
pathway is assessment of ART eligibility -a process that might be regarded as 
indicative of initial linkage to care. We conducted a systematic literature review 
and meta-analysis of studies in which the losses occurring at this step in the 
pathway were quantified (methods described in Web Appendix 8.9). Of the 22 
published studies we identified as eligible for inclusion (Table 8.2), the majority 
were conducted in South Africa (n=9) with the remainder from Ethiopia (n=2), 
Kenya (n=2), Malawi (n=2), Mozambique (n=1), Rwanda (n=1), Tanzania (n=1) 
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and Uganda (n=4). Eleven studies reported the proportions of patients enrolling 
into care post-diagnosis. Two studies were excluded because they were 
unrepresentative of the general population accessing clinics and hospitals; one was 
conducted in a mobile clinic [26] and another reported linkage to care in female 
sex workers in Rwanda [27]. 
The proportion of patients assessed for ART eligibility (reflecting linkage to care) 
ranged from 42% (95%CI 39-46%) to 70% (95%CI 68-72%), with an overall 
pooled estimate of 57% (95%CI 48-66%; t2 154.8). In 8 of the 11 studies, ART 
eligibility was assessed by CD4 cell count measurement and the proportions of 
patients in which this was successfully performed ranged from 55% (95%CI 51- 
60%) to 86% (95%CI 77-94%) with a pooled proportion of 66% (95%CI 54-78%; 
tie 309.9). However, only 5 of these studies reported the number of patients who 
returned for their test result, with proportions ranging from 30% (95%CI 26-34%) 
to 88% (95%CI 87-89%) and a pooled estimate of 51% (95%CI 25-78%; t2 924.8). 
This pooled estimate is similar to the finding of an earlier systematic review in 
which a median proportion of 59% completed ART eligibility assessment [6]. 
7.4.2 Proportion of individuals eligible for ART 
We next assessed the proportions of individuals with newly diagnosed HIV 
infection who were assessed and found to be eligible for ART according to national 
ART guidelines currently in use at the time of the study. We identified 16 studies 
eligible for inclusion (Table 8.3) of which seven were from South Africa. Ten 
studies reported on the proportions of patients who were eligible for ART based 
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on a CD4 count threshold of : 5200 cells/µl, but two were excluded for reasons of 
non-generalizability [27,28]. The proportion found to be eligible at this CD4 count 
threshold ranged from 21% (95%CI 20-22%) to 59% (95%CI 59-60%) with a 
pooled proportion of 40% (95%CI 27-55%; r2 392.6). Six studies also reported on 
the proportions eligible using a CD4 count threshold of : 5350 cells/µl, with 
proportions ranging from 45% (95%CI 44-47%) to 62% (95%CI 61-63%) and a 
pooled estimate of 57% (95%CI 50-63; i2 50.5). Six studies reported on the 
proportions of patients who were eligible for ART based on clinical criteria (WHO 
clinical stage 3 and 4). Proportions ranged from 49% (95%CI 48-51%) to 87% 
(95%CI 84-89%) with a pooled proportion of 64% (95%CI 53-74%; 12166.4). 
8.4.3 Pre-ART care prior to ART eligibility 
We identified only 5 studies reporting on retention in care of individuals not yet 
eligible for ART; four of these were from South Africa (Table 8.4). The duration of 
pre-ART care assessed was highly variable between these studies [29-32]. No 
study reported the fundamentally more important variable which is the proportion 
retained in care on becoming eligible for ART. Retention in pre-ART care in South 
Africa ranged from 41% to 46% [29-32]. The remaining study from Malawi 
estimated retention in pre-ART care to be 59% [33]. The median proportion 
retained in pre-ART care was 45%. As few studies were identified, all with 
considerable heterogeneity regarding time-cut offs, a pooled estimate was not 
calculated. Two of the five studies did not specify any time-cut off [29,33], while 
the other three studies assessed repeat CD4 count measurements or visits 6-12 
months after the initial eligibility assessment [30-32]. 
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Mathematical modeling suggests that retention in pre-ART care for individuals not 
yet eligible for ART increases the average life years saved [34]. This finding is 
supported by the South African study from the Free State showing that individuals 
who presented with an initial CD4 count >200 cell/uL and remained in pre-ART 
care had a two times reduced risk of mortality compared to individuals presenting 
with an initial CD4 count <200 cells/µl [31]. 
8.4.4 Initiation of ART 
We identified 19 studies which reported the proportions of ART-eligible 
individuals who went on to start ART (Table 8.5). We term this step in the 
continuum of care as 'linkage to ART'. Ten studies in seven sites were conducted in 
South Africa with the remainder conducted in Kenya (n=1), Malawi (n=4), 
Mozambique (n=1), Swaziland (n=1) and Uganda (n=2). One study reported that 
amongst TB co-infected patients, linkage to ART was 14% (95%Cl 12-17%) [35]. 
These patients have a very high mortality risk therefore this study was considered 
non-representative and was excluded from the meta-analysis. In the remaining 18 
studies, the proportion linking to ART ranged from 31% (95%CI 29-33%) to 86% 
(95%Cl 83-89%), with an overall pooled proportion of 66% (95%CI 58-73%; tie 
264.2). An earlier review of 14 studies found the median proportion of individuals 
initiating ART was 68% [6]. Eight of the studies included in our meta-analysis did 
not specify the time period within which patients could link to ART care. However, 
in a subgroup analysis there was no difference in the proportion linking to ART 
care comparing studies that used a time cut-off for determining linkage with those 
that did not (p=0.24). Studies which reported on time between HIV testing or 
98 
staging, and initiation of ART showed that the majority of patients started 
treatment within 1 month; however, two studies reported median delays of 
between 2.4 and 6.6 months [36,37]. 
Eight studies assessed the contribution of mortality as a potential cause for not 
starting ART and reported a median mortality of 5.5% (IQR 4.5-12%) among 
eligible patients waiting to start treatment [19,31,36,38-41]. However, in these 
studies, it is difficult to ascertain whether death is the cause or the result of not 
starting ART. Using assessment of clinic records or databases some studies have 
traced individuals who were thought to have not started ART [39,41]; between 3% 
and 19% of such patients were either retained in care in the same clinical service 
or had accessed treatment elsewhere. 
Estimates of individuals successfully linking to ART should ultimately inform 
health care providers how to address gaps and leaks in the system. For that reason, 
neither death due to late presentation nor informal transfers to other clinics 
should be part of the defaulter estimates. 
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8.5 ART care 
Patients receiving ART may leave clinical care for three reasons: death, transfer of 
care to another service (transfer-out) and loss to follow-up. Losses during ART are 
much better documented than those occurring earlier in the care pathway. Early 
mortality is typically very high in programmes in sub-Saharan Africa [42], 
accounting for between 8% and 26% of patients in the first year of treatment [43]. 
Systematic reviews have estimated that death accounted for around 40% of 
patient attrition during the first 2-3 years of treatment [8 44]. Key risk factors for 
this include a low baseline CD4 counts and advanced WHO stage of disease [43] 
and thus interventions upstream in the care pathway are needed to prevent late 
presentation. Long-term mortality risk decreases substantially, [43,45-47], 
especially once a CD4 cell count threshold of 200 cells/µl has been exceeded [48]. 
Early in the scale-up of ART in sub-Saharan Africa, treatment sites were few, 
patients were typically severely immunocompromised at the time of ART 
initiation, and prognosis was uncertain. Thus, transfer of patient care between ART 
clinics was relatively uncommon. However, over time the number of decentralized 
treatment sites has expanded considerably and patients are generally less 
immunocompromised when commencing ART; patient confidence in ART has 
grown; and, patients on long-term ART are usually healthy, potentially 
economically active and therefore mobile. These factors may explain why in some 
settings, rates of transfer between services have risen steeply [45,49]. In a South 
African cohort, the probability of patients transferring out during the first 6 years 
of the programme was approximately 20%, with the risk progressively increasing 
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with each sequential calendar year of enrolment [45]. However, data on true 
outcomes of patients transferred from one program to another are scarce [50,51]. 
If transfer of care is successful, then the patient is effectively retained within the 
national ART programme. Although, it is possible that some patients might be 
unsuccessful in linking to another service and hence are lost to follow-up. 
A huge challenge to rapidly expanding ART programmes in sub-Saharan Africa is 
the issue of retaining patients within care (i. e. preventing losses to follow-up). 
Patients are usually classified as 'lost to follow-up' if they fail to attend follow-up 
appointments over a specified duration without having been actively transferred 
to another ART clinic, and if they are not known to have died. A systematic review 
of 39 ART cohorts in sub-Saharan Africa conducted in 2010 reported an average 
retention of 65% at 3 year [8]. In recent years, many ART cohorts have rapidly 
increased in size with disproportionate increases in the numbers of patients 
compared to the number of health care workers. Losses to follow-up have 
reportedly grown substantially over successive calendar periods, indicating a 
growing problem with long-term retention in care [45,46,52]. A study from South 
Africa reported that patients starting ART in 2007-2008 had more than 4 times 
increased risk of being lost to follow-up than patients initiated in 2002-2004 [45]. 
Defining a patient as `lost to follow-up' is often based on exclusion of other known 
reasons for failure of the patient to attend. However, this may conceal considerable 
unascertained mortality. A systematic review summarizing studies that traced 
individuals lost to follow-up showed that on average 46% of such individuals had 
actually died [53]. A study from South Africa reported that 78.0% of such deaths 
107 
occurred within the first 3 months after their last clinic visit [52], strongly 
suggesting these deaths were the reason and not the result of being lost to follow- 
up. 
Another complexity in reporting rates of loss to follow-up is that patients may 
cycle in and out of care. Thus, patients who fulfil the widely used definition of loss 
to follow-up at one time point might re-engage with care at a later stage and thus 
cease to be lost to follow-up. A systematic review of this issue conducted in 2011 
identified 9 studies from sub-Saharan Africa and found that an average of 12% of 
individuals on ART had previously interrupted but subsequently restarted 
treatment [54]. A study from a South African township reported 40% of defaulters 
resumed therapy within 3 years of defaulting [55]. 
8.5.1 Cumulative losses along the pathway 
No study has yet measured the cumulative losses occurring along the entire care 
pathway. This would require long-term prospective demographic surveillance, 
although such a process in itself would likely alter the outcomes of interest. An 
alternative approach is to combine pooled estimates of losses from each of the 
steps in the care pathway that we have described. However, using data in this way 
from cross-sectional studies with typically short duration of follow-up is 
methodologically flawed [6]. A critical issue is that the care pathway is not a simple 
linear process and patients clearly cycle in and out of care; a patient who fails to 
complete one step in the pathway may re-engage with the treatment pathway at a 
later time-point and ultimately receive successful long-term ART. Thus, use of the 
individual estimates of the losses described thus far and summarized in Figure 8.2 
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might erroneously lead to the conclusion that of all HIV-infected individuals in the 
community, only 7% (0.39 x 0.57 x 0.50 x 0.66) would start ART and 5% (0.039 x 
0.57 x 0.50 x 0.45) would be retained in pre-ART care for some duration. 
Figure 8.2: Cumulative losses along the HIV care pathway as reported by 
cross-sectional studies addressing each step in the pathway. 
HIV infected individuals in the community 
39% 
Individuals knowing 
their sereostatus 
57% 
Individuals completing 
assessment for ART eligibility 
Individuals eligible for ART 
Individuals initiating ART 
Individuals retained on ART 
11 
Individuals not yet 
eligible for ART 
Individuals retained in 
pre-ART care 
The proportions (%) shown indicate the proportions of individuals who successfully 
complete each step in the pathway 
The assertion that these are likely to be extreme underestimates of the true 
proportions receiving care is supported by detailed data from a well characterised 
high HIV prevalence community in South Africa. In a population-based HIV and 
CD4 count survey, 54% of all HIV-infected individuals knew their positive HIV 
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sero-status [24]. A study of this community from the same period also showed that 
63% of HIV-infected individuals were assessed for ART eligibility by CD4 count 
measurement within 6 months of diagnosis, 26% were eligible for ART (CD4 count 
: 5200 cells/µl) and 
66% started ART within 6 months of diagnosis [29]. Combining 
these estimates of losses along the HIV care pathway in this community would lead 
to an estimated ART coverage in the community of 6% (0.54 x 0.63 x 0.26 x 0.66), 
whereas in reality the population based survey reported a coverage of 33.5%, 
which is more than 5-fold higher [24]. This illustrates the complexities involved in 
studying the HIV care pathway and the need for better means of assessment. 
8.6 Interventions 
Multiple interventions are needed to address high rates of patient attrition at every 
stage of the HIV care pathway. Strategies to reduce deaths among patients who 
have started ART have been described elsewhere [56], and so we should rather 
focus on strategies to increase HIV diagnosis and engagement of patients in pre- 
ART care and to reduce losses to follow-up throughout the pathway. 
Interventions listed in Table 8.6 fall into two categories. They either aim to 
increase the efficiency and capacity of services, or to improve the accessibility and 
acceptability of these services. Interventions to increase HIV testing include task- 
shifting (testing through lay health care workers) [57-59] and provider-initiated 
testing [60-62] as well as mobile, community, home-based and workplace services 
[63-68], which bring the service nearer to the patient and thus increases 
accessibility, which might in turn increase acceptability. Other interventions aimed 
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to increase acceptability of testing are self-testing [69] and incentivised testing [70, 
71]. More recently, community-based strategies for HIV testing and ART delivery 
have been developed [64,72,73] as a way to further expand access to care. By 
virtue of being placed in the community, these strategies are decentralised and use 
task-shifting to engage lesser trained health staff, and thus might be more cost- 
effective [74]. 
Very few studies (n=4) have assessed interventions aimed at reducing losses in the 
pre-ART period. These have examined point of care CD4 count testing [75,76], 
more efficient referral systems [77], transport vouchers [77] and regular visits to 
refill trimethoprim-sulphmethoxazole prophylaxis [78]. In contrast, many studies 
have reported on interventions to reduce loss to follow-up of patients on ART [79]. 
Some of these interventions are structural such as task shifting [80-84], 
decentralisation [57,82,84-87], integration [88,89] and continuous drug supply 
[90,91], whereas others are aimed at the individual such as adherence counselling 
[92,93] and transport reimbursement [90,94,95]. 
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Few interventions have been assessed for their efficacy and cost-effectiveness in 
randomized controlled trials [63,68,71,80,96] and most observational studies 
have assessed feasibility rather than effectiveness [69,88,97]. Evidence for a 
positive effect of, for example, transport vouchers and secured drug supplies 
comes mainly from risk factor analysis and semi-qualitative studies [90,91,94, 
95]. Some interventions have only been assessed for one specific step in the 
pathway, but not for others. An example is adherence counselling, which has been 
shown to have some effect on retention in ART care [92,93], but the effect of 
counselling on retention in pre-ART care or on linkage to ART care has not been 
formally assessed. However, related interventions such as prevention of mother to 
child transmission (PMTCT) provide some rationale for this [98]. 
Integration of care has mainly concentrated on tuberculosis and PMTCT programs 
[89,99] or the beneficial effects derived by other health services through the 
integration of HIV care [100]. The lack of a common conceptual framework on 
what integration means has impeded more rigorous evaluation of the impact of 
integration on retention and testing [101]. One study conducted in nine countries 
in sub-Saharan Africa, found that providing ART in an integrated approach 
resulted in substantially less defaulting from care compared to vertical ART 
delivery [102]. As HIV is chronic disease integration is important not only to 
improve retention, but also to provide comprehensive care (Table 8.7). This has 
been conceptualised in the WHO's Integrated Management of Adolescent and Adult 
Illness programme [103]. 
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Table 8.7: Comprehensive HIV care 
Trimethoprim-sulphamethoxazole prophylaxis 
Isoniazid preventive therapy 
Intensified tuberculosis case finding 
Cryptococcal antigen screening 
Cervical cancer screening 
Prevention of mother to child transmission 
Prevention of transmission to sexual partners 
services 
Tuberculosis 
Mental health 
Sexual transmitted diseases 
Antenatal care 
Family planning 
Chronic services 
Mental health 
Chronic disease (e. g. diabetes, ophthalmological services etc) 
Care of the elderly services 
Social support 
8.7 Conclusion 
Substantial losses occur at every stage of the HIV care pathway for HIV-infected 
individuals in sub-Saharan Africa. Assessment of these losses is complex as 
engagement in care; loss to care furthermore, return to care is a dynamic, non- 
linear and time-dependent process. To date, no study has yet defined the 
cumulative losses throughout the pathway. Data regarding interventions to 
address these losses are scarce, especially with regard to the care pathway prior to 
ART initiation. Research is urgently needed to identify effective solutions so that a 
far greater proportion of HIV- infected individuals can gain the benefits of ART. 
The "test and treat" approach to reducing HIV transmission proposes that very 
high coverage of HIV testing and immediate initiation of ART regardless of the 
stage of HIV progression would substantially reduce HIV transmission [104], and 
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has been met with considerable enthusiasm. The data in this review serve as a 
reminder of the huge operational challenges that will be faced in implementing 
such a strategy. Considerable investment and energy must be devoted to 
identifying effective interventions to strengthen the care pathway thereby 
permitting more effective implementation of current policy. As the care pathway is 
strengthened, then the `test and treat' strategy will become a more viable strategy. 
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8.9 Web Appendix: Methods 
8.9.1 Search strategy and data abstracts 
We aimed to identify studies reporting retention between HIV testing and 
initiation of ART and during long-term ART in sub-Saharan Africa. We searched 
three electronic databases for primary studies: Medline, Embase, and Global Health 
using the compound search strategy summarized in Supplement Table 8.8, and 
searched the bibliographies of retrieved articles for additional studies. Our search 
was limited to studies conducted in sub-Saharan African published from 2000 until 
the end of the search period (June 2011). We additionally searched for conference 
abstracts from all conferences of the International AIDS Society (2000-2010), and 
all Conference on Retroviruses and Opportunistic Infections (2000-2010). No 
language restriction was applied. 
129 
Studies were entered into an electronic database (EndNote X1) to screen 
potentially eligible studies by title and abstract. The full-length articles of all 
studies considered eligible upon initial screening were obtained and reviewed for 
eligibility; conference abstracts were screened first by title, then by full abstract. 
All reviews were done independently, in duplicate (GD and KK). Using a standard 
data extraction form, GD and KK extracted relevant data, including study site, 
sample size, dates of data collection, study design and outcomes and time cut-offs 
for outcomes. The results of the search are presented in Supplement Figure 8.3. 
8.9.2 Data analysis 
We calculated point estimates and 95% confidence intervals for the proportion of 
patients linking to care at various stages of the care pathway. The variance of the 
raw proportions was stabilised using a Freeman-Tukey type arcsine square-root 
transformation and estimates were pooled using a DerSimonian-Laird random 
effects model. We calculated the i2 statistic to assess between-study heterogeneity 
as this is less affected by the number of studies than the more commonly used 12 
statistic. For the overall proportion of patients linking to care, we ran a subgroup 
analysis to compare studies that used a time cut-off for determining linkage with 
those that did not. All P-values were two-sided, and a p-value of <0.05 was 
considered significant. Analyses were conducted using Stata (version 11, 
www. stata. com) and StatsDirect (version 2.5.2). 
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Supplement Table 8.8: Search strategy 
SET 
HIV 
1 Hiv 
2 Aids 
3 HIV 
4 HIV-1 
5 ACQUIRED IMMUNODEFICIENCY SYNDROME 
6 Set 1-5 were combined with "or" 
Retention 
7 PATIENT DROPOUTS 
8 LONG TERM CARE 
9 CONTINUITY OF PATIENT CARE 
10 patient dropouts 
11 long term care 
12 loss to follow-up 
13 retention in care 
14 attrition or defaulting 
15 pre-art or (pre adji treatment) or (art adj1 initiation) 
16 screening for art 
17 art eligibility 
18 eligible for art 
19 eligibility for art 
20 eligible for arv 
21 art-eligible 
22 Engaging 
23 Engagement 
24 continuum of care 
25 Continuity 
26 Set 7-25 were combined with "or " 
27 Set 6 and 26 were combined with "and" 
28 Set 27 was limited to years "2000-current" 
Country 
29 DEVELOPING COUNTRY 
30 AFRICA SOUTH OF THE SAHARA 
31 AFRICA 
32 sub-saharan 
33 all sub-Saharan countries included as Mesh and text term combined with or 
34 Set 29-33 were combined with "or " 
35 Set 28 and 34 combined with "and" 
Words written in capital letters were used as MeSH headings, the others were used as free text. 
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Supplement Figure 8.3: Flowchart of papers included in the review 
755 potentially eligible citations 
identified for screening 
" 749 potentially relevant citations 
obtained from keyword searches on 
electronic databases 
"6 potentially relevant citations 
-------------- 
61 studies selected for full text review 
" 48 articles 
" 13 abstracts 
-------------- 
37 publications retained for analysis 
" 31 articles 
"6 abstracts 
Screen 1 
694 excluded 
" 169 duplicates 
" 523 irrelevant on basis of title 
and/or abstract 
2 conference abstracts- 
retrieved the published paper 
Screen 2 
24 excluded 
" 14 ineligible articles 
L" 10 poor quality studies 
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Introduction 
HIV counseling and testing (I ICT) services are important entry 
points for prevention and care 111. Studies from different countries 
have shown that individuals take precautions to protect their 
partners once they know they are HIV positive 12,3,41 and 
modeling studies have found HC'Y to offer substantial clinical 
benefits and to be cost-effective even in settings where linkage and 
access to care is limited 151. 
The past decade has seen a rapid global scale-up of I IC'l' I61. 
Recent surveys from Tanzania, the Democratic Republic of the 
Congo, Kenya, Zambia, Swaziland and South Africa reported that 
between 8.6 and 56.6% of women and 9.2 and 43.0% of men ever 
had an H1V test 16,71. HC'I' uptake is associated with a range of 
socio-demographic factors, and is generally lower among men, 
younger and older age groups, those with limited education and 
income 16,8,9. Identifying characteristics of individuals who have 
never tested is important to develop services targeted at first time 
testers and thus to achieve universal access to HUT. 
Sexually active individuals in high HIV prevalence settings are 
at continuous risk of infection and should therefore test at regular 
intervals. The World Health Organization (WHO) recommends 
annual testing in high HIV prevalence settings as do the 2010 
South African guidelines 110,111. A recent study from South 
Africa found annual screening to be very cost-effective even in the 
Western Cape, the province with the lowest rates of HIV infection 
in South Africa 151. Despite the importance of annual testing, 
population surveys from six sub-Saharan African countries showed 
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a median of only 19% of women and 10% of men had an HIV test 
in the 12 months preceding the survey [6]. Even though South 
Africa is above average with 24.7% of the population reporting a 
test within the last 12 months in 2008, it is still sub-optimal [71. 
This study was conducted in a well characterized peri-urban 
community in the Western Cape, South Africa [12,13. The study 
community has been exposed to 9 years of community-based HIV 
prevention research and has seen provider-initiated HIV testing 
and antiretroviral therapy (AR"I') roll-out earlier than most other 
communities in South Africa. This community provides a unique 
opportunity to examine the effect of high HCT coverage and 
frequent testing. The aims of this study were to measure HIV 
prevalence and HCT uptake, to determine predictors for previous 
HIV testing and to assess the association between the yield of 
previously undiagnosed HIV and time of last negative test. 
Methods 
Ethics statement 
Written informed consent was obtained from all individuals 
participating in the study. Data collection and analysis was 
approved by the University of Cape 'T'own Ethics Committee and 
Partners Human Subjects Institutional Review Board and the 
London School of Hygiene and Tropical Medicine. 
Setting 
The study was based in a peri-urban township in the greater 
area of Cape Town, South Africa. Regular household censuses 
have shown that the community has undergone a rapid population 
growth from 5000 residents in 1996 to 17000 in the most recent 
census in August 2010 [121. Adult HIV prevalence was 23% in 
2005 and 25% in 2008 as measured in previous population based 
HIV prevalence surveys. 
The community was served by a single public-sector primary 
care clinic, which provided outpatient care including HCT and 
ART free of charge. A nearby hospital (5 km away) provided all 
secondary care, including inpatient and antenatal services. The 
hospital also provided ART for some HIV-infected individuals 
from the community. ART provision at the primary health care 
clinic and hospital began in 2004. Since 2005, there has been a 
significant scale-up of the ART program in this community, with 
13% of all individuals infected with HIV receiving ART in 2005 
and 21 % in 2008 [141. 
Voluntary counseling and testing services have been available to 
all individuals accessing either the local clinic or the hospital since 
2001 with provider-initiated testing routinely given to any patient 
accessing TB services whose HIV status was unknown; this was 
extended to all pregnant females accessing the hospital or clinic in 
2002 and patients accessing STI services in 2007. HIV testing 
rates rose from 4% of the total population per year in 2001 to 20% 
in 2006 [15]. The total number of tests performed in the primary 
health care clinic or hospital among residents of this community 
was more than 10500 between January 2004 and March 2009 
[16]. The community has also been served by a mobile HCT 
service 1-2 days per month since July 2008. The mobile HC'I' 
service has done more than 1000 tests in this community. 
Community-based cross-sectional survey 
A population-based HIV sero-prevalence survey was conducted 
between September and December 2010. A house-to-house 
enumeration of the community in August 2010 provided a 
database of 12520 residents 15 years or older of whom 1300 
residents were randomly selected for inclusion in the study (10% of 
the community). Simple random sampling was performed using 
Stata 11.0 (Stata Corp. LP, College Station, 'I'X, United States of 
America). Each adult resident in the community had an equal 
chance of being selected for the survey. The census 2010 data were 
used as a sampling frame. Field workers invited the selected 
individuals to attend the mobile HIV testing service. Field workers 
visited households of selected individuals up to 5 times to 
encourage participation. No study procedures were performed in 
people's homes. Consent, questionnaires and HIV testing were 
performed at the mobile HIV testing service when a potential 
participant attended the service. 
Mobile HIV testing service 
The mobile HIV testing service used in this study has been 
described elsewhere [17]. In brief, this nurse-run and counselor- 
supported unit provides free HCT services in combination with 
free screening for other chronic conditions (i. e. hypertension, 
diabetes and obesity) and TB. HIV testing is performed according 
to the Provincial Government of the Western Cape guidelines 
[18]. Whilst the South African guidelines for HIV testing 
recommend written informed consent, the mobile, community 
based nature of this service led to the agreement by local health 
authorities to allow verbal consent in clients voluntarily accessing 
this service since 2008. Individuals approaching the mobile 
services give verbal consent for HIV testing which is recorded 
on the consultation form. 
The mobile testing service was parked in front of the primary 
school in the centre of the community. It operated on weekdays 
and weekends as well as after hours to ensure that individuals with 
regular work had an opportunity to participate. 
Participants could choose one of three options to receive their 
result: i) to test and receive their HIV result together with 
screening for chronic diseases, ii) to provide blood and not receive 
their HIV result, but undergo screening for chronic diseases or iii) 
to only provide blood and not receive their HIV result. Individuals 
who consented to rapid HIV testing and tested positive were 
subsequently staged according to the WHO staging manual and 
underwent a point of care CD4 count test (Alere ["PimaTM CD4 
Analyser, Waltham, MA, USA) using venous blood samples. All 
participants were compensated for transport and time with ZAR 
70 (approximately 9.6 US dollars) gift vouchers. 
Data collection and management 
Age, sex, nationality, migration history and previous HIV 
testing experience were recorded via a short questionnaire. Data 
were double entered and verified in EpiData version 3.1. 
For HIV testing experience this included asking whether they 
had tested for HIV before and whether this was <3 months ago, 
3-6 months ago, 6-12 months ago, 1-2 years ago or >2 years ago. 
Where individuals had tested on the mobile clinic before, this 
information was available from their previous records accessed 
using a biometric system. Recent migrants were defined as 
individuals who had moved into this community from either 
within South Africa or from neighboring countries within the 3 
years preceding the survey. 
Individuals who tested HIV positive and chose to receive their 
result were asked as part of the questionnaire if they were aware of 
their positive sero-status. Individuals who were unaware of their 
positive sero-status underwent the routine procedure of the mobile 
testing service for newly diagnosed HIV positive individuals. These 
procedures included clinical staging, CD4 count testing, pregnan- 
cy tests for women, screening for sexually transmitted disease, 
referrals to primary health care clinics and targeted counseling. AU 
newly diagnosed H1V positive individuals were called by their 
counselor 7 days aller diagnoses to ensure that they received 
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enough support to deal with the new diagnosis. All counselors were 
extremely experienced and as such able to confirm if an individual 
was unaware of their scro-status. Twelve individuals who initially 
said that they were unaware of their HIV positive scro-status 
admitted to the counselor that they had known their positive scro- 
status before. This information was used to amend the data. For 
patients who chose to test anonymously and tested positive 
(N = 16) no additional information could be collected by the 
counselors. 
Table 1. Characteristics, HCT coverage and HIV prevalence 
(N = 1144). 
Variables N Percent 95% Cl 
Characteristics of participants 
Testing and receiving result 1078 94.2 92.9; 95.6 
Women 
Statistical analysis 
All analyses were carried out using Stata version 11.0 (Stata 
Corp. LP, College Station, 'IX, United States of America). 
Proportions and confidence intervals were calculated for catcgor- 
ical variables, and medians and interquartile ranges for continuous 
variables. The proportion of individuals who tested for 111V within 
the last year was calculated using individuals at risk for testing as a 
denominator. 't'hus, the denominator excluded individuals wh , 
had tested HIV positive more than one year ago. The prevalence 
of newly diagnosed HIV in individuals who had tested before 
excluded individuals known to be 111V positive from the 
denominator. 
Differences in proportions between study participants who had 
tested previously and study participants who had never tested were 
calculated using cross-tabulation and g2 test.. Risk ratios 
investigating association between age, gender, nationality, migra- 
tion and previous 111V testing were calculated using a binominal 
model. Differences in median CD I counts in individuals newly 
diagnosed with H1V, known to be HIV positive but not on ART 
and individuals on ART was assessed using the Kruskal-Wallis 
test. 
Results 
Characteristics of the study population 
Of 1300 individuals randomly selected from the community, 
1144 (88.0%) participated. Among the 156 individuals who did 
not participate in the study two had died before the study started, 
five refused to participate, and the remaining 149 did not attend 
the mobile HC'I' service despite multiple visits to their households. 
Individuals who did not participate in the study were older 
(median age 31; IR linterquartile ranged 27-38) and more likely 
to be men (76.2%) compared to individuals who participated in 
the study (median age 28; IQR 23-35,48.6% men) (table 1). 
1'he majority of study participants were South African and 
approximately one quarter had migrated to the study community 
within the last 3 years. Most migrants came from a neighboring 
province, the Eastern Cape, (52.6%) while 11.9% came from 
elsewhere in the Western Cape and 22.6% from neighboring 
countries. Non-South Africans (77.1%) were more likely to have 
recently migrated to the study community compared to South 
Africans (32.3%). 
Prevalence and predictors of previous HIV testing 
71.0% (95% (: 1 68.3 73.6) of study participants had previously 
had an HIV test and more than one third (37.5%) had tested in the 
12 months preceding the survey (table 1). The proportions of 
women, South Africans and long term residents were higher 
among individuals who had previously tested for HIV than among 
individuals who had never tested (table 2). In multivariate analysis 
women and South African nationals were more likely to have a 
previous H1V test. Migrants and younger and older individuals 
were less likely to have been tested before. 
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588 51.4 48.5; 54.3 
Age -20 years 134 11.7 9.9; 13.7 
Age 20-34.9 years 714 62.4 595; 65.2 
Age X35 years 296 25.9 23.4; 28.5 
Moved into the community 309 27.2 24.6; 29.8 
during the past 3 years 
Previous HIV testing 
Previously tested for HIV 812 71.0 68.3; 73.6 
Tested within the last year 386 37.5 34.6; 40.5 
HIV prevalence 
Newly diagnosed HIV+ 118 10.3 8.6; 12.1 
Known HIV+ 142 12.4 10.5; 14.3 
HIV- 884 77.3 74.8; 79.7 
doi: 10.1371 /journal. pone. 0025244. t001 
HIV prevalence 
Overall the proportion of people tested who agreed to receive 
their result was high (94.2%, 95%Cl 92.9-95.6). A total of 66 
individuals chose to test anonymously among whom 16 (24.2%) 
tested positive. 
Overall HIV prevalence was 22.7% (95%C1 20.3-25.3). just 
over half (54.6%, 95%C1 48.3-60.8) of the HIV-infected 
individuals knew their scrostatus (table 1). Among the 142 H1V 
infected individuals who knew their positive scrostatus, 87 were on 
AR'! (61.3%, 95°/C1 52.7-69.3). "l'he median CD4 count was 389 
cells/uL (IQR 269-611) in individuals newly diagnosed with HIV, 
430 cells/uL (IQR 287-631) in individuals known to be 111V 
positive but not on ART and 440 cells/uL (IQR 295-627) in 
individuals on ART. CD4 counts were not significantly different 
across the three groups. 
HIV prevalence and the proportion of undiagnosed 111V was 
associated with age and sex (figure 1). HIV prevalence was 12.1% 
(95%CI 7.4-16.8) in women 15-25 years of age compared to 
41.8% (95%Cl 35.8-47.8) in women aged 25.1-35. I11V 
prevalence in men was highest among the 35.1-45 year olds 
(37.5%, 95% 26.7-48.3). The proportion of positive tests that were 
new HIV diagnoses was significantly higher in men (62.1%, 
95%CI 51.0-72.3) compared to women (37.0%; 95%C1 29.8- 
44.7). 
Prevalence of previously undiagnosed HIV 
Prevalence of previously undiagnosed HIV was 18.4% (95%C1 
14.2-22.4) in individuals who had never tested for F11V and 8.5% 
(95%C1 6.4-10.6) in individuals who reported HIV testing prior to 
the survey (p<O. 001). Prevalence of previously undiagnosed HIV 
was 4.5% (95%Cl 2.3--6.6), 8.0% (95%Cl 3.9-12.0) and 20.0% 
(95%Cl 13.2-26.8) in individuals who had their most recent HIV 
test within 1 year, 1-2 years and more than 2 years prior to the 
survey. 't'here was no difference in prevalence in individuals last 
tested <3 (4.1%), 3-6 (4.9%), 6-12 (4.9%) months prior to the 
survey. A sensitivity analysis excluding the 16 individuals who 
tested positive but did not want to receive their test results revealed 
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2. Comparison of previously tested and untested individuals (N =1144). 
Variables 
Previously tested Never tested p value Predictors of for HIV (N=812) for HIV (N=332) (X2 test) previous HIV test 
Women 486 59.9 56.5; 63.2 102 30.7 25.7; 35.7 <0.01 1.33 1.33; 
. 
143 <0.01 
Age <20 years 75 9.2 7.3; 11.4 59 17.8 13.8; 22.2 <0.01 0.79 0.68; 0.91 <0.01 
Age 20-34.9 years 532 65.5 62.1; 68.8 182 54.8 49.3; 60.3 1.00 
Age X35 years 205 24.3 22.3; 28.4 91 27.4 22.7; 32.5 0.87 0.81; 0.95 <0.01 
South African 758 93.3 91.6; 95.1 276 83.1 79.1; 87.2 <0.01 1.29 1.06; 1.57 0.01 
Moved into the community 187 23.1 20.2; 26,1 122 37.2 31.9; 42.5 <0.01 0.83 0.80; 0.95 0.02 
during the past 3 years 
doi: 10.1371 /jou rnal. pone. 0025244. t002 
similar prevalence estimates except for the prevalence estimate in 
individuals last tested <3 months ago (1.2%). 
In long-term residents, prevalence of previously undiagnosed 
HIV was 3.9% among those tested within 12 months and 6% 
among those tested within 1-2 years prior to the survey . 
Individuals who had recently moved into the community had a 
higher prevalence of previously undiagnosed HIV: 6.1% in 
individuals tested in the past 12 month and 14.3% in individuals 
tested 12 years ago. 
Discussion 
This cross-sectional population based scro-survcy fraud a peak 
1-11V prevalence in the age group 25.1-35 in women (41.8%) and 
35.1-45 in men (37.5(N) in this pcri-urban community. Almost 
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half (45.4%) of the individuals infected with HIV were unaware of 
their H1V positive scro-status despite 71.0% of the population 
reporting that they had previously had an H1V test. Younger and 
older individuals, immigrants, individuals who had recently moved 
to the community and men were less likely to have previously 
tested for HIV. The prevalence of undiagnosed 11IV was strongly 
associated with a history of IIIV testing. Even among individuals 
who reported their most recent negative HIV test in the 12 months 
prior to the survey, the prevalence was 4.5%. CDC count 
distributions were similar in H1V positive individuals on ART 
and not ART probably due to high ART coverage in this 
community 1191. 
In this community 71.0% had previously tested for HIV and 
37.5% had an HIV test within the last 12 months. This is 
substantially higher than the corresponding national estimates 
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Age (years) Age (years) 
Overall HIV prevalence and 95% confidence intervals 
Gender 15-25 years 25.1-35 years 35.1-45 years >45 years 
Women 12.1 (7.4-16.8) 41.8 (35.8-47.8) 39.5 (28.2-50.7) 14.8 (5.0-24.6) 
Men 3.0 (0.6-5.4) 19.5 (14.4-24.6) 37.5 (26.7-48.3) 12.2 (1.7-22.7) 
Figure 1. HIV prevalence by age and sex. 
doi: 10.1371 /journal. pone. 0025244. g001 
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from 2008 of 50.8% and 24.7%, respectively 171. HCT services 
were strengthened and provider-initiated as well as voluntary 
testing was implemented as early as 2002 through the ongoing 
research program in this community which might explain some of 
the differences. Furthermore HCT has been scaled up on a 
national and provincial level over the last years. 17]. In April 2010 
a national HCT campaign was launched aiming to test 15 million 
people for H1V by June 2011. This might have led to increased 
testing rates in the months before this survey. 
In a community with such high testing rates one would expect 
the majority of HIV infected individuals to be aware of their HIV 
positive scro-status. The high proportion (45.6%) of undiagnosed 
HIV in this community may be due to a very high incidence. 
This study was not designed to measure HIV incidence. However 
a 4.5% prevalence of undiagnosed HIV in individuals reporting a 
negative test within the last 12 months translates into an 
incidence of 12.4 per 100 person-years assuming that the 
infection occurred at the mid-point between the last negative 
test and the positive test. Even when excluding individuals who 
tested positive, but did not want to receive their results, as these 
individuals might have known their positive scro-status before, 
the H1V incidence remains at 8.5 per 100 person-years. The 
method used to calculate these incidence estimates has not been 
validated and thus the estimates should be viewed with caution. 
They are, however in keeping with the incidence of 7.2 per 100 
person-years reported from a cohort in this community in 2004- 
2005 [20]. Similar incidence rates of 6.4 per 100 person-years 
have been reported in women in rural and urban in KwaZulu 
Natal, South Africa 1211. These incident rates are in stark 
contrast to a recent estimate of 1.3 per 100 person-years using 
data from three national surveys [22]. National incidence 
estimates provide an average of incidence estimates across South 
Africa therefore very high incidence in some communities [23] 
might be compensated for by low incidence in others. In addition, 
it is well recognized that the South African HIV epidemic is 
heterogeneous with wide inter- and infra- provincial variation in 
HIV prevalence and incidence rates. 
Individuals tested more recently are a self-selected group who 
might be at higher risk of HIV infection, which might bias the 
HIV incidence estimate. With almost a third of the population 
reporting that they had moved to the community in the last 3 years 
incidence might be overestimated due to high risk of HIV infection 
in migrants [24,25]. Restricting the analysis to long-term residents 
only, reveals an HIV incidence estimate of 6.1 / 100 person-years, 
which is still extremely high. The HIV prevalence of 12.1 % 
among young women provides further evidence for a very high 
HIV incidence in this community. 
The high incidence in this community and the high prevalence 
of HIV in women aged 25.1-45 show that current prevention 
efforts - even in a setting where HIV prevention research is 
conducted - are failing. HIV prevalence estimates from this 
community with a peak prevalence of 41.8% in women and 37.5% 
in men are as high as reported from rural Kwazulu Natal, the 
South African province hardest hit by the HIV epidemic [26]. 
This community was exposed to more intensive prevention 
messages and better resourced HIV services than most other 
South African communities as evidenced by higher HCT coverage 
and the lower prevalence of newly diagnosed HIV in repeat testers 
in long-term residents as compared to recent migrants. 
However prevention tools in 2011 are still very limited and these 
data would indicate that testing and awareness alone are 
insufficient to reduce HIV acquisition risk. Of note, a high HIV 
incidence has also been reported from the CAPRISA 004 
microbicide trial in KwaZulu Natal, South Africa. Women 
participating in the CAPRISA 004 trial were all exposed to a 
package of prevention consisting of condoms, monthly testing and 
risk reduction counseling, but even so HIV incidence was reported 
at 9 per 100 person-years in the placebo assigned study group 1271. 
Clearly there is a need for additional and innovative prevention 
programs to reduce HIV incidence. 
The high prevalence of undiagnosed HIV even in individuals 
who reported testing negative within the 3 months preceding the 
survey underscores the importance of counseling individuals on 
the window period as well as frequent repeated HIV testing 
especially for those at high risk of HIV infection. However, 
another reason for the high prevalence of undiagnosed HIV 
despite recent testing might be the low sensitivity of rapid HIV 
tests due to poor adherence with correct testing procedures in 
routine clinical practice and previous testing in the `window 
period' during serocoversion [28]. 
Any annual screening program for a chronic and possibly fatal 
disease using a cheap point of care rapid test with a yield of 4.5% 
should be cost-effective [5]. With a yield of 4.5% in individuals 
who had tested negative in the 6 months preceding the survey even 
more frequent testing might he justified. 
Previous testing experience and awareness of the HIV positive 
sero-status was assessed by self report which might be influenced 
by social desirability bias. In addition the exact time of testing 
might have been influenced by recall bias resulting in misclassi- 
fication. Some of the individuals participating in the survey had 
tested at the mobile clinic before (N = 50). All but two reported the 
correct time of previous test. Bias and chance could explain the 
steady prevalence of 4-5% in individuals tested within 0-3 
months, 3-6 months and 6-12 months prior to the survey. 
However an alternative explanation is that individuals testing at 
higher frequency might have a higher risk of HIV infection or that 
anonymous testers who tested positive in this survey knew their 
status already. Excluding those individuals did not change the 
overall results. 
This study found that men, non-South Africans, younger and 
older individuals and individuals who had moved to the 
community within the last 3 years were less likely to have ever 
tested before, consistent with other studies from South Africa 
[7,25,29,30]. More importantly the yield of newly diagnosed HIV 
was twice as high in individuals who had never tested before 
compared to individuals who reported a prior HIV test, 
emphasizing the need for frequent testing and expanding services 
to segments of the population which are hard to reach. This study 
highlights again that men are particularly underserviced as almost 
two thirds of HIV infected men were unaware of their HIV 
positive sero-status. 
Among the limitations of this study are: a non-attendance rate 
of 12%. Reasons for non-attendance were temporary absentee- 
ism (prolonged visits to the neighboring province), work 
commitment and silent refusals. These data are similar to other 
population based HIV sero-prevalence surveys from sub- 
Saharan Africa reporting absenteeism rates of 0.8-35.2% and 
refusal rates of 2.7-35.9% [31,32,33]. HIV prevalence found in 
this survey is consistent with estimates from previous surveys 
from the same community [34], thus non-response bias due to 
differences in age and gender between attendees and non- 
attendees seems negligible. 
Fear of stigma and lack of confidentiality have been shown to be 
a major barrier for HIV testing [35,36,37,38,39,40]. The high 
uptake of open (non-anonymous testing) is particularly encourag- 
ing and might be attributed to a well functioning and efficient 
ART program, reduced stigma due to a long period (9 years) of 
community-based HIV prevention research in this community 
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and the fact that none of the team members working on the mobile 
HCT service were part of the community. 
In conclusion this study showed a high burden of undiagnosed 
HIV despite high HCT coverage. The yield of previously 
undiagnosed HIV was 4.5% in individuals with a negative HIV 
test within 12 months preceding the survey. This suggests a very 
high HIV incidence. 'The results emphasize the importance of 
repeat testing perhaps even more frequently than annually. It 
underscores the notion that innovative and effective prevention 
interventions in addition to post test counseling are urgently 
required. 
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Abstract 
Background: Antiretroviral therapy (ART) has been scaled-up rapidly in Africa. Programme reports typically focus on loss to 
follow-up and mortality among patients receiving ART. However, little is known about linkage and retention in care of 
individuals prior to starting ART. 
Methodology. Data on adult residents from a periurban community in Cape Town were collected at a primary care clinic 
and hospital. HIV testing registers, CD4 count results provided by the National Health Laboratory System and ART registers 
were linked. A random sample (n=885) was drawn from adults testing HIV positive through antenatal care, sexual 
transmitted disease and voluntary testing and counseling services between January 2004 and March 2009. All adults 
(n = 103) testing HIV positive through TB services during the same time period were also included in the study. Linkage to 
HIV care was defined as attending for a CD4 count measurement within 6 months of HIV diagnosis. Linkage to ART care was 
defined as initiating ART within 6 months of HIV diagnosis in individuals with a CD4 count X200 cells/µl taken within 6 
months of HIV diagnosis. 
Findings: Only 62.6% of individuals attended for a CD4 count measurement within 6 months of testing HIV positive. 
Individuals testing through sexually transmitted infection services had the best (84.1%) and individuals testing on their own 
initiative (53.5%) the worst linkage to HIV care. One third of individuals with timely CD4 counts were eligible for ART and 
66.7% of those were successfully linked to ART care. Linkage to ART care was highest among antenatal care clients. Among 
individuals not yet eligible for ART only 46.3% had a repeat CD4 count. Linkage to HIV care improved in patients tested in 
more recent calendar period. 
Conclusion: Linkage to HIV and ART care was low in this poor perl-urban community despite free services available within 
close proximity. More efforts are needed to link VCT scale-up to subsequent care. 
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Introduction 
South Africa is home to one-sixth of the world's population 
living with I-1IV and has the largest antiretroviral therapy (ART) 
programme in the, world 11,21. ART roll out began nationally in 
late 2003 and by the middle of 2008,568,000 adults and children 
were receiving ART. This translated into around 40% of eligible 
adults receiving ART in 2008 131, although the latest guidelines 
recommend earlier initiation for certain patients, thus increasing 
the numbers eligible for ART and widening the treatment gap [41. 
In an eflbrt to increase access to prevention and care, South 
Africa launched an ambitious national campaign in April 2010 
aiming to test 15 million people for HIV and to reach 1.5 million 
people with ART by June 2011. Increased HIV testing may 
impact on risk behavior in the short-term 15 1.1 Iowcvver, there is 
also a need to ensure that those who need treatment are linked to 
the appropriate services while those not eligible for treatment are 
monitored and started on AR'1 when appropriate. A study from 
Durban, South Africa, reported that almost two-thirds of newly 
diagnosed patients accessing care in a semi-private hospital were 
lost to care between 111V diagnosis and getting a CD4 count, and 
another one in five patients were lost between CD4 testing and 
ART initiation 16,7. Another study from South Africa found that 
only 45% of eligible patients started ART in a public sector ART 
project in Free State. Mortality and 'CB incidence in patients 
failing to initiate ART was more than 2 times higher compared to 
patients initiating ART 181. 
The impact of ART on mortality, morbidity, TB incidence 
19,101 and HIV transmission 11 at a population level depends on 
ART coverage. ART coverage defined as the number of patients 
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receiving ART at a point in time, divided by the number needing 
treatment is determined by timely HIV diagnosis and effective 
linkage to ART. This study investigates linkage to HIV and ART 
care using a random sample of individuals testing HIV positive 
either provided-initiated (through antenatal care (ANC), tubercu- 
losis (TB), sexually transmitted infection (STI) services) or client- 
initiated (through voluntary counseling and testing (VCT) services) 
in a peri-urban township in the Western Cape Province in South 
Africa. Linkage to care was defined first as attending for a CD4 
count measurement within 6 months of a positive HIV test and 
second as the proportion of eligible individuals starting ART 
within 6 months of their HIV diagnosis. 
from NHLS. The date of CD4 count was the date the client provided 
blood. Third, data from residents who initiated ART care at the 
primary health care clinic or hospital were obtained from electronic 
ART registers at the clinic and hospital. 
These three databases were merged on first name, surname, 
medical record number and date of birth. In cases where 
identifiers did not match completely two researchers (PG and 
KK) independently confirmed that records in different databases 
were from the same individual. Concordance between the two 
researchers was 97%. Cases where the two researchers disagreed 
were discussed until consensus was reached. For all subsequent 
analysis data was stripped of all personal identifiers. 
Methods 
Setting 
The study was based in a peri-urban township in the greater 
area of Cape Town, with a population of approximately 15,000 
people and a measured adult HIV prevalence of 23% in 2005 
[12]. The community is served by a single public-sector primary 
care clinic, which provides outpatient care including ART free of 
charge. A nearby hospital (5 km away) provides all secondary care 
for the population, including inpatient and antenatal services. The 
hospital also provides ART for some HIV-infected individuals 
from the community. 
HIV testing, CD4 count measurements and ART services 
Client-initiated HIV testing services have been available to all 
individuals accessing either the local clinic or the hospital since 
2001. Clients who tested on their own initiative are referred to as 
having tested through VCT services. Provider-initiated testing was 
routinely provided to any patient accessing TB services whose HIV 
status was unknown. This was extended to all pregnant females 
accessing the hospital or clinic in 2002 and patients accessing SI'I 
services in 2007. All testing required signed consent. All CD4 count 
tests were free for patients and performed by the centrally located 
National Health Laboratory Services (NHLS) in Cape Town. 
ART provision at the primary health care clinic and hospital 
began in 2004. 
Linkage to HIV and ART care 
Linkage to HIV care was defined as attending for a CD4 count 
measurement within 6 months of HIV diagnosis. We did not 
ascertain if individuals actually received their CD4 counts. 
Linkage to ART care was defined as initiating ART within 6 
months of HIV diagnosis in individuals with a CD4 count X200 
cells1µ1 taken within 6 months of HIV diagnosis. Having a repeat 
CD4 count was defined as having had a repeated CD4 count in 
individuals not yet eligible for ART (CD4 count >200 cells/. d) 
and tested before 2009. 
Data collection 
We collected data from 3 sources. First, the primary care clinic 
and hospital HIV testing registers provided all data on HIV infected, 
adult community residents (? 18 years) diagnosed between January 
2004 and March 2009. Data at the primary health care clinic were 
missing for the period from February 2008 to August 2008. For each 
test encounter recorded in the registers, we retrieved data on client 
identification variables (first name, surname, date of birth, and 
medical record number); place of residence; sex; test acceptance; test 
result and service. For HIV infected individuals who tested more 
than once, the earliest positive HIV test was considered. Second, 
data on CD4 counts performed at either the primary care clinic or 
the hospital in the period from 2004 to October 2009 were obtained 
PLoS ONE I www. plosone. org 
Ethics 
Written informed consent was obtained from all individuals 
initiated on ART and screened for ART. Individuals testing for 
HIV arc routinely entered into the HIV testing register. Informed 
consent was not obtained from HIV positive individuals not 
linking to care, as this was a retrospective study and individuals 
were not actively follow-up. Data collection and analysis was 
approved by the University of Cape Town Ethics Committee and 
Partners Human Subjects Institutional Review Board and the 
London School of Hygiene and Tropical Medicine. 
Statistical analysis 
A random sample (n = 885) of adults testing HIV positive 
through ANC, STI and VCT services between January 2004 and 
March 2009 was selected for this analysis. All adults testing 
positive through TB services were included in this analysis to 
ensure an adequate sample size in this group. 
All analyses were carried out using Stata version 11 (Stata Corp. 
LP, College Station, TX, United States of America). Proportions 
were calculated stratified by service. Total proportions were 
calculated taking the different sampling proportions into account. 
Risk ratios investigating associations between age, sex, calendar 
period and timely linkage to HIV care, CD4 count X200 cells/µl 
and repeated CD4 counts were estimated for each service. Risk 
ratios were calculated using a log binominal model [13]. 
Results 
HIV testing and HIV prevalence 
A total of 8515 records of HIV tests were available for adult 
members of the community. The majority of individuals tested 
through VCT (n=5345,62.8%) services (Table 1). The overall 
HIV prevalence among those tested was 23.5% with the highest 
prevalence among patients tested through TB (37.9%) and VCT 
services (24.9%) (x4 test, p<0.01). The median age of individuals 
tested was 26 (interquartile range (IQR), 22-32) and 67.9% were 
women. HIV prevalence was 21.6% in men and 24.4% in women. 
A total of 2002 clients tested HIV positive. Their median age 
was 28 years (IQR, 24-33) and the majority were women (70.3%). 
The proportion of women testing HIV positive was 100% in ANC, 
66.2% in STI, 38.8% in TB and 66.4% in VCT clients. 1330 
(66.4%) individuals tested HIV positive through VCT, 332 
(16.6%) through ANC, 237 (11.8%) through STI and 103 
(5.1%) through TB services. 
Linkage to HIV and ART care 
Linkage to HIV and ART care was assessed in a random 
sample of 47% of individuals testing HIV positive through ANC, 
STI and VCT services and 100% of individuals testing through 
TB services: 150 tested through ANC, 113 through STI, 662 
through VCT and 103 through TB services. Only 62.6% (95%CI 
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Table 1. Number (%) of individuals who tested for HIV and 
who were found to be positive stratified by type of clinical 
service. 
2000 
O VCT 
ANC STI TB VCT 
service service service service Total 
Positives N (%) 332 (16.6) 237 (11.8) 103 (5.1) 1330 (66.4) 2002 (100) 
All HIV testing records available for the period from January 2004 until March 
2009 from adult patients were included in this analysis. 
ANC = antenatal care, STI = sexual transmitted infections, TB=tuberculosis, 
VCT=voluntary counseling and testing. 
doi: 10.1371 /journal. pone. 0013801. t001 
59.6-65.5) of' clients attended for a CD4 count measurement 
within 6 months of testing Ii1V positive (Table 2) and 26.3% 
(95%CI 23.5- 29.0) did not have any recorded CD4 count test. 
The proportion of individuals attending for a CD4 count 
measurement within 6 months was highest among individuals 
tested through ANC (81.3%) and S'I'1 (84.1 %) services and lowest 
among those who learnt of their status via VC'I' (53.5%) ('f'able 2). 
Among individuals with a CD4 count measurement within 6 
months, 34.1% (95%CI 30.4-37.7) were eligible for ART according 
the South African Department of Health criteria (CD4 count X200 
cells/µl) at the time of the study (fable 2). Low CD4 counts were 
more prevalent among individuals tested through '1'B (54.9%) and 
VC'1' services (42.6%). In individuals attending for a CD4 count 
measurement within 6 months the median time between HIV test 
and CD4 count measurement was: 2 days (IQR 2 6) for ANC, 3 
days (IQR 2-4) for S'l'l, 3 days (IQR 2-5) for'I'B and 2 days (IQR 
2-4) for VCh clients. Overall 4.3% of clients attended for a CD4 
test at the same day as the H1\, ' test. The majority of clients attended 
for CD4 count testing within I week (84.9%), 14.2% within 8 days 
and 3 months and only 0.9% within 3 and 6 months. 
In individuals with a delayed first CD4 count measurements, the 
mean time betwccn HIV diagnosis and first CD4 count was 490 
11500 
ö 1000 
E 
3 Z 
500 
Figure 1. Number of clients testing HIV+, with timely CD4 
counts, eligible for ART and initiating ART estimated using 
proportions from table 2. ART=antiretroviral therapy, ANC=ante- 
natal care, STI = sexual transmitted infections, TB =tuberculosis, 
VCT=voluntary counseling and testing. 
doi: 10.1371 /jou rnal. pone. 0013801. g001 
days (IQR 345-769). Among patients with delayed first CD4 
count measurements, 33.2% (95%CI 24.3-42.1) had a CD4 count 
X200 cells/µl and 26.2% (95%CI 17.8-34.8)-43.2) had a CD4 
count of 201-350 cells/µl. 
Only 66.7% (95% CI 60.2 73.1) of eligible individuals with a 
timely CD4 count accessed ARE care within 6 months of 111V 
testing (fable 2). Linkage to AR'I care was highest among 
indiv ideals tested through ANC services (72.2%). Among 
individuals not yet eligible for ART only 46.3% (95%CI 41.4- 
51.1) ever had a repeat CD4 count. Median time between the first 
and the second CD4 count was 236 days. 
Figure 1 summarizes the number of people tested through 
different services and the numbers linking to HIV and ART care 
by service using the proportions estimated from the random 
sample. 
Table 2. Percentage of individuals linking to HIV care (as defined by attending for a CD4 cell count measurement), distribution of 
CD4 count measurements, percentage of patients subsequently initiating ART and percentage of clients non-eligible for ART 
returning for a repeat CD4 count. 
Variables 
ANC (n=150) 
% (N) 
STI (n=113) 
% (N) 
TB (n=103) 
% (N) 
VCT (n=622) 
% (N) 
Total 
% 
First CD4 count after HIV test s6 months 81.3 (122) 84.1 (95) 68.9 (71) 53.5 (333) 62.6 (59.6-65.5) 
>6 months 2.0 (3) 2.7 (3) 13.6 (14) 14.8 (92) 11.1 (9.2-13.1) 
None 16.7 (25) 13.3 (15) 17.5 (18) 31.7 (197) 26.3 (23.5-29.0) 
First CD4 count within 6months of HIV test 5200 cells/NI 14.8 (18) 22.1 (21) 54.9 (39) 42.3 (141) 34.1 (30.4-37.7) 
>351 cells/NI 
ART Initiation within 6 months of HIV test In Yes 
eligible individuals with timely first CD4 count 
No 
Repeat CD4 count In Individuals with a first CD4 Yes 
count >200 cells/µI 
No 
60.7 (74) 45.3 (43) 21.1 (15) 33.9 (113) 40.6 (36.8-44.4) 
72.2 (13) 52.4 (11) 71.8 (28) 67.4 (95) 66.7 (60.2-73.1) 
27.8 (5) 47.6 (10) 28.2 (11) 32.6 (46) 33.3 (26.9-39. ") 
48.5 (47) 57.6 (38) 34.5 (10) 42.3 (96) 46.3 (41.4-51.1) 
51.5 (50) 42.4 (28) 65.5 (19) 57.7 (131) 53.7 (48.9-58.6) 
ANC=antenatal care, STI=sexual transmitted infections, TB=tuberculosis, VCT=voluntary counseling and testing. 
doi: 10.1371 /journa l. pone. 0013801. t002 
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Table 3. Factors associated with linkage to HIV care (attending for a CD4 count measurement within 6 months of HIV diagnosis) 
stratified by service. 
Variables ANC STI TB VCT 
RR (95% Cl) RR (95% Cl) RR (95% Cl) RR (95% CI) 
Female NA 1 1 1 
Male NA 0.93 (0.79-1.09) 1.01 (0.82-1.25) 1.10 (1.01-1.33) 
Age<30 years 1 1 1 1 
Aga230 years 0.97 (0.90-1.04) 1.17 (1.01-1.35) 1.07 (0.84-1.35) 1.16 (0.96-1.26) 
Tested in 2004-2006 1 NA 1 1 
ANC=antenatal care, STI =sexual transmitted infections, TB -tuberculosis, VCT=voluntary counseling and testing. 
NA = not applicaple. 
doi: 10.1371 /journal. pone. 0013801. t003 
Predictors of low CD4 count, linkage to HIV, and 
repeated CD4 counts 
Risk ratios investigating predictors for linkage to HIV care 
showed that linkage to care in '1'B (RR 1.67,95%CI 1.27--2.21) 
and VC'1. ' (RR 1.60,95%CI 1.40-1.84) clients was more likely in 
2007-2009 compared to 2004-2006 (table 3). This was not the 
case for ANC (RR 0.97) clients who were slightly less likely to link 
to HIV care if tested more recently (table 3). Linkage to ART care 
could only be assessed in VC'1' clients due to the small sample size 
in the other groups. Neither age (RR 0.85,95%CI 0.67-1.09) nor 
sex (RR 1.03,95% C1 0.81-1.31) nor year of testing (RR 1.02, 
95% CI 0.81-1.30) predicted linkage to HIV care in VC1 clients. 
The risk of having CD4 count measurement X200 cells/µl was 
higher in individuals aged more than 30 years regardless which 
service they tested through (table 4). Repeated CD4 counts were 
1.3 times more likely in individuals more than 30 years of age, but 
this result only reached significance in the VC'I' clients (RR 1.25, 
95% CI 1.00 1.55). 
Discussion 
This study evaluated the proportion of individuals linking to 
H1V care in a public sector service in Cape 't'own, South Africa. 
Only 63% of patients attended for a CD4 count measurement 
within 6 months of diagnosis. Although a substantial proportion of 
patients had CD4 counts X200 cells/µ1 (34%) and were therefore 
eligible for ART according to South African guidelines 1141, only 
67% of these started ART within 6 months. Among those who did 
have a timely (a)4 count but ývrre not Net eligible Gor . AR'l . only 
46% returned for a repeat CD4 count after a median time of 8 
months. Individuals testing through ANC services had better 
linkage to HIV and ART care and higher CD4 counts at time of 
111V diagnosis compared to individuals accessing the other 
services. 
HIV is a chronic disease and comprehensive H1V care needs to 
be provided within a continuum of care (151. ART is just one of 
the components of HIV care and care of individuals not yet 
requiring ART is equally important (16(. The continuum of HI\' 
care starts when an individual is diagnosed with HIV. ART 
eligibility should be assessed when individuals are newly diagnosed 
and in regular (6 monthly) intervals thereafter. Individuals not yet 
eligible for ART should receive comprehensive HIV care 
including cotrin uxazolc, isoniazid preventive therapy, screening 
for '1'B and cervical cancer, contraceptive advice, counseling and 
social support until they become eligible for ART. Following 
initiation of ART individuals needs to be supported within the 
same framework to ensure good adherence and retention in care. 
We identified a number of important issues in our study. First, 
people who tested on their own initiative were least likely to have a 
timely CD4 count measurement done, underscoring the need to 
ensure that scale up of VCh programmes will he accompanied by 
clear plans to ensure that those who test positive go on to receive 
appropriate care. Second, almost a third (28%) of eligible patients 
with TB did not receive ART despite recommendations in favour 
of concomitant treatment since 2003 (17(, and ART being 
associated with a 64-95% reduction in mortality in such patients 
(10,18,19,20(. This underscores the importance of integrating 
II1V and I'B sci'ices 12 1(. 
Table 4. Factors associated with having a CD4 count X200 cells/µI within 6 months of HIV diagnosis. 
Variables ANC STI Tb VCT 
RR (95% CO RR (95% CO RR (95% CO RR (95% Cl) 
Female NA 111 
Male NA 0.82 (0.36-1.86) 0.97 (0.62-1.50) 1.27 (0.99-1.63) Adow 
Age<30 years 1111 
AgeZ30 years 2.42 (1.03-5.68) 2.00 (0.92-4.35) 1.10 (0.68-1.78) 1.40 (1.07-1.82) 
Tested in 2004-2006 1 NA 11 
In 2007-2009 1.32 (0.57-3.08) NA 1.18 (0.75-1.85) 0.94 (0.74-1.19) 
=antenatal care, Sri = sexual transmitted infections, TB = tuberculosis, VCT =voluntary counseling and testing. 
10.1 371/journal. pone. 00 13 80 1 1004 
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This study shows that men and younger adults fail to access 
health services efficiently. Only 30% of clients tested for H1V were 
men. This is consistent with studies showing that HIV-infected 
men are less likely to access treatment [22,23], present with more 
advanced stages of HIV disease 1241 and have a higher mortality 
risk during ART [25,26,27,28,29,30,31,32]. Repeated CD4 
counts were less likely in individuals under 30 years of age as 
also reported elsewhere[331. 
It is important to note that less than half of patients whose first 
CD4 count was above the ART eligibility threshold came back for 
a repeat test. One way of improving ART uptake, and thus reduce 
mortality among patients who are otherwise lost to care, might be 
to change the CD4 threshold to 350 cell/µl in line with the latest 
World Health Organization recommendations [34]. 
Our overall finding that 33% of patients eligible for ART were 
lost to care is consistent with several reports from elsewhere in 
southern Africa. In a programme report from South Africa, only 
55% of patients had a CD4 count measurement within 8 weeks of 
HIV diagnosis and 81% of eligible patients were on ART at 3 
months follow-up 16,71. Out of 2483 patients eligible for AR'T' in 
Uganda 637 (26%) did not start ART; a third of these patients 
died before ART initiation and another quarter were alive but not 
taking ART [25]. In Mozambique only 57% of patients testing 
HIV positive entered HIV care and 31% of patients eligible for 
ART started ART within 3 months [35]. 
In our study only 63% of patients testing positive for HIV 
attended for a CD4 count measurement within 6 months. These 
outcomes are worse than those recently reported by a public-sector 
clinic in Johannesburg where 84.6% of patients who tested positive 
for HIV had a CD4 count measurement. The majority of these 
patients did not return for their CD4 result within 12 weeks [36]. 
Data from the same clinic in Johannesburg showed that among 
patients not yet eligible for ART only 26% returned for a 
scheduled pre-ART medical visit within one year compared to 
43% of our patients not yet eligible for ART returning for a repeat 
CD4 count [37]. 
Substantial improvement in linkage to HIV care for TB and 
VCT patients was observed in more recent years in this study and 
yet this was not accompanied by improvements in linkage to ART. 
Failure of linkage to HIV and ART services translates into 
incomplete ART coverage at population level, seriously under- 
mining the potential for reductions in mortality, morbidity, TB 
incidence and HIV transmission. 
The study has several strengths and limitations. Strengths 
include that the study was conducted in a routine clinical program 
where CD4 count testing and ART were provided free. Thus, the 
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Unstructured treatment interruption of antiretroviral therapy 
in clinical practice: a systematic review 
Katharina Kranzer' and Nathan Ford2 
1 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK 
2 Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa 
Summary OBJECTIVE To characterize the frequency, reasons, risk factors, and consequences of unstructured 
anti-retroviral treatment interruptions. 
METHOD Systematic review. 
RESULTS Seventy studies were included. The median proportion of patients interrupting treatment was 
23% for a median duration of 150 days. The most frequently reported reasons for interruptions were 
drug toxicity, adverse events, and side-effects; studies from developing countries additionally cited 
treatment costs and pharmacy stock-outs as concerns. Younger age and injecting drug use was a fre- 
quently reported risk factor. Other risk factors included CD4 count, socioeconomic variables, and 
pharmacy stock outs. Treatment interruptions increased the risk of death, opportunistic infections, 
virologic failure, resistance development, and poor immunological recovery. Proposed interventions to 
minimize interruptions included counseling, mental health services, services for women, men, and ethnic 
minorities. One intervention study found that the use of short message service reminders decrease the 
prevalence of treatment interruption from 19% to 10%. Finally, several studies from Africa stressed the 
importance of reliable and free access to medication. 
CONCLUSION Treatment interruptions are common and contribute to worsening patient outcomes. 
HIV/AIDS programmes should consider assessing their causes and frequency as part of routine moni- 
toring. Future research should focus on evaluating interventions to address the most frequently reported 
reasons for interruptions. 
keywords HIV, unstructured treatment interruption, antiretroviral therapy 
Introduction 
Antiretroviral therapy (ART) has dramatically reduced 
HIV-associated mortality and morbidity in high- and low- 
income countries (Palella et al. 1998; Egger et al. 2002; 
Jahn et al. 2008; Floyd et a!. 2010; Mahy et al. 2010). 
Treatment outcomes reported from cohort studies and 
clinical trials have improved over time as a result of 
improved drug efficacy, reduced toxicity, and simplified 
treatment through reduced pill burden and dosing intervals 
(Boyd 2009). Despite these improvements, consistent 
adherence and uninterrupted treatment remain major 
challenges (Lazo et al. 2007; Byakika-Tusiime et al. 2009; 
Lima et al. 2009; Glass et al. 2010; Bastard et a!. 2011). 
Ensuring high levels of adherence is desirable for the 
treatment of any chronic conditions (Jackevicius et al. 
2002; Kopjar et al. 2003; Cramer 2004; Osterberg & 
Blaschke 2005) but is particularly important for treatment 
of HIV in resource-limited settings, where less robust 
regimens are used and an extremely high level of adherence 
(>95%) is required to prevent the development of drug 
resistance (Bangsberg et al. 2006). There are many chal- 
lenges to maintaining such high levels of adherence (Mills 
et at. 2006; Nachega et al. 2010). Among these, treatment 
interruptions are an inconsistently reported yet common 
phenomenon in clinical practice, often occurring as a result 
of treatment fatigue or in an attempt to minimize side- 
effects. Common toxicities such as lipodystrophy and 
metabolic side-effects related to prolonged use of ART may 
improve when treatment is stopped (Tuldra et al. 2001; 
Mocroft et at. 2005; Mussini et al. 2005; Calmy et al. 
2007). However, the majority of individuals who discon- 
tinue treatment only do so temporarily, as they experience 
a rapid decline in CD4 count and increase in viral load 
0 2011 Blackwell Publishing Ltd 1297 
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following discontinuation of therapy (Poulton et at. 2003; 
Skiest et al. 2004; EI-Sadr et a!. 2006; Sungkanuparph 
et al. 2007). 
The potential for provider-directed, structured treatment 
interruptions as a way to limit antiretroviral exposure (and 
therefore both toxicities and costs) was abandoned after 
randomized trials and cohort studies found an increased 
risk of opportunistic infection and death (El-Sadr et al. 
2006; Mugyenyi et a!. 2008; Seminari et al. 2008). 
Nevertheless, patient-initiated unstructured treatment 
interruptions are a reality of routine clinical care and have 
been reported in both developed (Holkmann Olsen et al. 
2007) and developing country settings (Kranzer et al. 2010). 
To better characterize the frequency, reasons, risk 
factors, and consequences of unstructured treatment 
interruptions in routine clinical practice, we conducted a 
systematic review of available studies reporting on 
unstructured treatment interruptions. 
Methods 
Criteria for selection of studies 
We aimed to identify studies reporting on unstructured 
ART treatment interruptions in clinical practice. Unstruc- 
tured treatment interruption was defined as discontinua- 
tion of all ART drugs for any period of time, after which 
treatment was resumed. We considered that any interrup- 
tion was undesirable, and thus did not limit our search to 
specific causes or durations. We excluded studies reporting 
on structured treatment interruptions, defined as physician- 
initiated, cyclical interruptions guided by CD4 count or 
viral load. We also excluded studies only reporting on 
patients experiencing virologic failure. We included both 
cross-sectional and cohort studies, but excluded editorials, 
case studies, case reports, and reviews. 
Search strategy 
We searched three electronic databases for primary studies: 
Medline, Embase, and Global Health using the compound 
search strategy summarized in Table S1 and searched the 
bibliographies of retrieved articles for additional studies. 
Our search was limited to studies published and conducted 
from 1996 (the time when highly active ART became 
available) until the end of the search period (March 2011). 
We also searched for conference abstracts from all 
conferences of the International AIDS Society (April, 
1985 July, 2010), and all Conference on Retroviruses and 
Opportunitistic Infections (January, 1997-February, 2010) 
and the PEPFAR implementers meeting 2007-2009. No 
language restriction was applied. 
Study selection and data extraction 
Studies were entered into an electronic database (EndNote 
X1) to screen potentially eligible studies by title and 
abstract according to our pre-defined inclusion and exclu- 
sion criteria. Full-length articles of all studies considered 
eligible upon initial screening were obtained and reviewed 
for eligibility; conference abstracts were screened first by 
title, then by full abstract. All reviews were carried out 
independently, in duplicate. After agreeing on eligibility, 
we abstracted the following information using a stan- 
dardized extraction form: definitions of treatment inter- 
ruption, frequency and duration of interruption, reasons, 
risk factors, consequences of treatment interruption, and 
proposed interventions. Whenever required, we attempted 
to contact study authors for clarification by email. 
Finally, we assessed full articles for determinants of 
methodological quality using a pre-defined assessment 
framework. The following factors were assessed: definition 
and objectivity of treatment interruption provided, appro- 
priateness of the statistical analysis. Studies investigating 
consequences or treatment failure (e. g. mortality or viral 
rebound) were assessed for adjustment for potential 
confounding and use of objective outcome measures. 
Results 
Characteristics of included studies 
The study selection process is summarized in Figure 1. Our 
initial search yielded 813 potentially relevant publication 
and 577 potentially relevant conference abstracts, from 
which 47 publications and 23 abstracts were considered 
eligible for inclusion. Three studies considered potentially 
eligible were excluded because it was unclear whether 
patients restarted treatment (i. e. interruption) or not (i. e. 
discontinuation); authors were contacted but did not 
provide clarification (Berenguer et al. 2004; Braitstein 
et al. 2007; Ayuo et al. 2008). Sixteen studies were from 
Africa, 14 from North America, two from Australia, one 
from South America, two from Eastern Europe, three from 
Asia, and 32 from Europe. The majority of studies (63) 
reported results of treatment interruptions in adults from 
the general population; of the remainder, two studies were 
among children, one was among adolescents, one was 
among injecting drug users, one was among men who have 
sex with men, one was among recurrent prisoners, and one 
was among women. We judged the methodological quality 
of studies included as full-length articles to be moderate: a 
third of studies (15/47) provided a definition and objec- 
tivity of treatment interruption; almost all (46/47) used an 
appropriate statistical analysis approach, and where 
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3 CROI, 573 IAS, 1 PEPFAR potentially 813 potentially relevant citations 
relevant conference abstracts identified identified from electronic databases 
Full text of 97 publications reviewed 
13 abstracts eligible, but 
published and thus 
included as a full length 
publication 
23 abstracts included in the review 
Figure I Study selection process. 
50 studies excluded: 
" 21 no treatment interruption (discontinuation of 
therapy, but no resumption) 
" 13 structured treatment interruption 
"4 discontinuation of only 1 or 2 drugs 
"7 case reports and editorials 
"4 patients with virologic failure only 
"1 treatment interruption in primary HIV infectioi 
47 publications included in the review 
appropriate the majority (23/25) adjusted for confounders 
and used an objective outcome measure (29/30). 
Definition of treatment interruption and measurement 
We found substantial variation and uncertainty in the 
definition of treatment interruption applied by the indi- 
vidual studies. Twenty-eight did not define the duration of 
treatment interruption, while of the 42 studies that did 
specify a definition, duration ranged from 24 h to 1 year 
(Figure 2). Two cross-sectional studies investigating self- 
reported treatment interruptions defined interruption as 
28 
Figure 2 Definition of treatment interrup- 
tion and their frequencies. 
discontinuation of all drugs for more than 24-48 h in 
the 4 weeks preceding the survey (Glass et al. 2006; 
Marcellin et al. 2008). Two studies investigating short 
interruptions defined a maximum duration of treatment 
discontinuation of 1 month (Oyugi et al. 2007) and 
3 months (Taffe et al. 2002). 
The methods used to determine treatment interruptions 
varied: self-report (21/70), electronic medication moni- 
toring (4/70) data, prospectively collected by clinicians 
(7/70), information extracted from clinical records (7/70), 
pharmacy prescriptions in combination with clinical 
records (3/70), pharmacy prescriptions only (2/70), 
Jo -i` 11, ý'ý ti 3a 
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combination of data collected by clinicians and/or self- 
report and/or prescriptions (4/70). Twenty-two studies did 
not describe the method used to identify treatment inter- 
ruptions. 
Pharmacy stock outs and poor access to drugs were 
reported in three of the four studies from developing 
countries (Adeyemi & Olaogun 2006; Wenkel et at. 2006; 
Pasquet et al. 2010). 
Frequency and duration of treatment interruption 
Forty-two studies reported frequencies of treatment 
interruptions, either as proportions (35), rates (1), or 
proportions and rates (3) of interruption, or as rates or 
proportions of discontinuation and resumption (3) 
(Table 1). The proportion of treatment interruptions 
ranged from 5.8% [adults in Switzerland (Glass et al. 
2006)] to 83.1% [recurrent prisoners in the USA (Pai et al. 
2009)]; the median proportion of patients interrupting 
treatment was 23.1 % (IQR 15.0-48.0). Rates of treatment 
interruptions ranged from 2.0 per 100 person-years in the 
United Kingdom (Bansi et al. 2008), to 6.0 in the Euro- 
SIDA study (Holkmann Olsen et a!. 2007). Eleven studies 
reported on the mean or median duration of treatment 
interruptions, with durations ranging from 11.5 days 
(Oyugi et al. 2007) to 18 months (Holkmann Olsen et al. 
2007) (median 150 days). Treatment interruptions were 
frequently reported as recurrent events, with up to three 
interruptions per person reported in South Africa (Kranzer 
et al. 2010) and Senegal (Uhagaze et al. 2006), five in 
Switzerland (Taffe et al. 2002), six in the EuroSIDA study 
(Holkmann Olsen et al. 2007), and an average of two in 
Uganda (Oyugi et al. 2007). 
Reasons for treatment interruption 
Twenty-two studies, 18 from developed countries and four 
from Africa, investigated reasons for treatment interrup- 
tions (Table 2). Toxicity, adverse events, and side effects 
were the most frequently reported reasons, with between 
6% (Saitoh et al. 2008) and 80% of patients reporting 
these reasons (Chen et al. 2002). Other reasons included 
pill burden (Moore et al. 2009), intercurrent illness 
(Wolf et a!. 2005), patient's decision (Krentz et al. 2003; 
Sommet et al. 2003; Gibb et al. 2004; Pavie et al. 2005; 
Saitoh et al. 2008; Moore et al. 2009), treatment 
fatigue (Saitoh et al. 2008), social and psychiatric issues 
(Uhagaze et al. 2006; Saitoh et al. 2008), perceived lack of 
benefits (Tarwater et al. 2003; Gibb et al. 2004) and 
physician's decision (Wolf et al. 2005) because of drug 
interactions, surgery, or other reasons. A study from 
Australia found that 38% of patients interrupted treatment 
for solely clinical reasons and 29% for solely lifestyle 
reasons (Grierson et al. 2004). Costs were the main reason 
for treatment interruptions (>60%) in two studies from 
Nigeria (Adeyemi & Olaogun 2006; Wenkel et al. 2006). 
Risk factors for treatment interruption 
Sixteen studies (12 from developed countries) reported on 
risk factors for treatment interruption. The most com- 
monly reported risk factors were younger age (Mocroft 
et al. 2001; Gandhi et at. 2004; Li et at. 2005; Nacher 
et at. 2006; Holkmann Olsen et at. 2007; Moore et at. 
2009; Kranzer et a/. 2010) and injecting drug use (Taffe 
et al. 2002; Compostella et at. 2005; Touloumi et at. 
2006; Kavasery et at. 2009; Moore et at. 2009) (Table 3). 
The effect of gender and CD4 count on treatment 
interruption was inconsistent across studies: a high CD4 
count (baseline or current) was associated with interrup- 
tions in some studies (Taffe et al. 2002; Touloumi et al. 
2006; Holkmann Olsen et al. 2007; Moore et al. 2009; 
Kranzer et at. 2010) while others reported an association 
between low CD4 count and treatment interruptions (Li 
et al. 2005; Touloumi et at. 2006; Kavasery et at. 2009). 
Socioeconomic variables such as employment, income, 
education, and being homeless were also identified as risk 
factors for interruption in some studies (Taffe et al. 2002; 
Oyugi et at. 2007; Marcellin et al. 2008; Das-Douglas 
et al. 2009; Kavasery et al. 2009). One study reported that 
the odds of treatment interruption among homeless and 
marginally housed patients was six times higher if their 
health care plan included consumer cost-sharing (Das- 
Douglas et at. 2009). Finally, a study from Cameroon 
reported that pharmacy stock shortages were identified as a 
major risk factor for treatment interruption (Marcellin 
et at. 2008). 
Consequences of treatment interruption 
Thirty-eight studies reported on various consequences of 
treatment interruption, comprising mortality, opportunis- 
tic infections, immunological and virologic changes, the 
development of resistance mutations, neurocognitive 
impairment, and decreased health-related quality of life. 
Consistent with the findings of structured interruption 
studies, unstructured treatment interruptions were com- 
monly associated with a higher risk of death and oppor- 
tunistic infection and a lower probability of increased CD4 
cell counts (Hogg et at. 2002; Taffe et at. 2002; Schrooten 
et at. 2004; Holkmann Olsen et al. 2007; Pai et al. 2009; 
Zhang et al. 2010; Kaufmann et al. 2011). Furthermore, 
a high prevalence of neurocognitive impairment (Munoz- 
Moreno et al. 2010) and lower health-related quality of life 
300 0 201 1 Blackwell Publishing Ltd 
Tropical Medicine and International Health VOLUME 16 NO 10 PP 1297-1313 OCTOBER 2011 
K. Kranzer & N. Ford ART Interruptions - systematic review 
Eä 
:: orb 
aäö:: 
c 0 
0o ääöß 
ta Q. ~4 ýy% 
öýE 
ö 
HW 
ao 
z 
ö 
Ao 
p 0 
a 
4 
L 
V 
V 
W 
v 
H 
ýI 
v 
ýý 
ýö 
aO . 
0. 
- 
Fy 
a 
C 
Q7 
V 
O 
00 
I tV II1II111 
CCQC 
I 
00 1III1III 00 1 0- 
OOO 1ý MMNOOONOh "I OO 
NN tV h . -ý NMN ý'i NNM ýn N 
CN ON 
OM ýO ýO Oý ýn NTOÖ In 
\O --N0 r+ N Vn NMN\, O 0 00 0Ih--- 
\D hN Oý M .ýM ý1 NM 
L >y 
LLLLLLyÖÖ 3 
0o ao 00 0. 
}o 
md3 AIIAAAAAAaIIAIAA 
C6 u $ -05'? aa 
zpzpezxxxazx-x `mow °'ü ve &öaöa$aaS. aäa'&c oý 2 'ö y 8' 2CGwwwwwwr. >üq°Cw 
Cn iii cis iii iii ýn 
OdD 
oG 
u. v 
-ö -v "ö 
ý 
-ö -v "v ö öö0000? 
"0 y u a, v 
-t oyc u2 ä4ä -9 -9 
1 
-9 °E 8-0080 o Üy 
! i! 
U1LI 
ä uÜ yÜ yul ä "ä ucý yä uÜ yÜÜu äuä u 
y 
>1 
1% N V) 00 1 W) 
0N 
0NÖ 
00 (Z 00 OtO"ý 
CýXN 
a, 
oao 
N C-4 I " NINIIIINNNI-a 
C-4 N 
I 
"=a to 3dk 
bb ýv ýo öb 'o ýo bb -moo ddddddxýddý3ddddd ýd 
ýt oý 
ö 0ö 0ö ýn nes pQOý 
t 18 
ý 
eq 
;N 
MN"O N., CN 
Öi ý 
Ceq qe . %) - 
N. 
_i vAv I 
;q oN N 
ýöýnA3 b3nRýöyö uöýýrýöy$ n>An 
0 2011 Blackwell Publishing Ltd 1301 
Tropical Medicine and International Health VOLUME 16 NO 10 PP 1297-1313 OCTOBER 2011 
K. Kra 
b 
I 
11 
1302 
ranzer & N. 
övö 
räö 
CC 
Cý. C öÖ up 
c2.0 b 12 
Ö 
C 
O 
"o 
ö 
1.. W 
ao 
z' 
0 
Aö 
ö 
cn ýO 
K 
a 
Q0 
C 0 n 
A 
$-3 
8$ 
4 
I 7 
Ford ART interruptions - systematic review 
IINIIIII ýn I 
\aö 
ýö0 
N .+ '+ IIIINI 
IIIIIIIII 
00 0 
IIINI `ý 
-0 III fN 
EI 
O1N0 
00 0 1o ýn I1p oo O Iý ON 
Ö .rNNNNO 1ý 
-IH- `t N- fV a0 1MNN 
7MN ÖN 
\D 00 
M 
. 
M-+ 
O0 Oh 
hM'. .r Oý ýD hM 111 to - 00 M 
"ö -9 
ö3V0 
AA1nIIn "5 aIIA 
v 
-o 'ý 
ä° 
ýC y3 eipa 
°ä°33ö 
.2 . 
`ý 
ý1ý 
? 
C4 CG ý+ 
. 
CýL utyýy ° 
° eya 
d'tý 
v'ýi rýi 
wRÖ. UUUwC`ü '7 6L 
ä'i ' 
Ix a Wn v) 3'i v) 1GN 5' 
-0 2 
>1 >1 
°3°äB°0ö 
y0 Ön 
vT wn y 
wZ 'D 
wt 
.Ö ° 60 Oü0°yü Öy' v O° 
NN 
aÜÜaU Ha UÜaa. a 
00 
O' Np Npp oS' 
. 
ýjý7 
pD 
^pp 
00 ap0ý 8 Ho ýýppp 
r'ý N-NN0NI/NNN1 
01 NN 
0 eý 
p 
vai 
Ü 
to a°L U aý0 
V ý`ý3 ý9 
S 
Y3 4 Y3 ö Ys Ys Yý !3 'f 
il 
4 
ddQddx5 ýd ýýý ý6 °dd 
aöb oö _ön ü$ öö öö ö°ö 
öö öö tlö 
ýö ý$ tl 
5ö 
ýö$ g$$$ 
0 2011 Blackwell Publishing Ltd 
Tropical Medicine and International Health VOLUME 16 NO 10 PP I2,97-1313 OCTOBER 20II 
K. Kranzer & N. Ford ART interruptions - systematic review 
övö 
-im 
C 
räö:; 
GG 
O 
p ýO ä aGi 
o 'er ý 
G4 äob 
ä 
r_ 
Kö 
GpýF'ý y 
G 
Vr 
Or 
LC Ö 
2 
'R 
F 
Aö 
L 
ö 
a 0 
N 
'D 
y 
7Q 
U 
q 
0 
'D 
m 
s -_ 
s 'O äo 
I 
d 
0 201 1 Blackwell Publishing Ltd 
ö 
ýO 
1I1 
ö 
00 
t\ 
M pý 
ý' 1IINIIIII1 
yyýýýC 
I 
W1 00 I - 
oa . -. Vi V) 
?ý ýY 00 V' M 
hh 
°e°yy n° 
S. 0 
x 
nnZ3önAnVnII 
'b .v 
a°ý `G" 
ö. cbc VY 
y 
OD ý 
Crý FN 
t0 
5Qý 
A 
'ice >C 
MoUV. 
t: 
QQy 
öööööööäö000$ö 
aaaaaa ri aUUä 
NN ýS ßb8 b8 gný°S SApS 'ýýS -NNSNNINNNdNNyNWN 
V 
w C7 ?äw ýn wt üý 
Iz 
f3 ýüv 
1ý 'ä "° Iii ? Y3 ýý . 
ý' 
Yt Yt Ys Ist 
ýý dä xa d U"- d ä' d 
Np 
ý, N ý" S 
ýp0ý 
QÖSS? pS 
OÖ 
1303 
Tropical Medicine and International Health VOLUME 16 NO 10 PP 1297-I313 OCTOBER 1011 
K. Kranzer & N. Ford ART Interruptions - systematic review 
Vmp pp O 
ö äý cOd ý-' 
ýbA 
p 'ý 
öc 
ý'\ öCöÖ 
. -u 
öjM ýv G 
"- r. C i. AOopöV -- Vc °ý0 " GZ,., pey00wG ti .ývup... 7 "u ü .. wö Wu490 
cý 
Z. w :ý 
ce .-Wx> 
C^ V6y1 .eeL 
to ti C. " GýJ 
öw' 
OGOGVY.. 
ý .ýY .yNh 
-0y o9 CCQv 
Nu -p aý re 'yuy'>, 
yýy \° lv II y 
>. ýd O 
y 
etl ý' my 7J U wy ö "7 ua ý+ OHL0VOw >~ p 
p' w eý 
e. Ö fý g_ -4 
- 
>. 'eu- -- 
m -- 
$, 
LeV e0 aO tr .ý.. Nm V= V w °p pQ eea 
äh C öo °' w 
>, C>"ü ýchia 
C"ö 
y "y >ay; 
Mw^WG 
fö it p 
ý+ fd yyQ 
802 to 
u\ ö ý^ Cri 4J yöL 'C '9 (ä "v 
°\ 
\ö 
y G6 'C r. rq 
\p 
"k ýCM '3 
M O\ uwu . 
-- 
. 
u+ 3 
.RöIer, 
öC\ 
uÜ7öN eua Uuw Cw ^C .ý .ý N^ ö `ý U 
1ý 
y a9 =uwObowyvU uui 
"uOG 
c2 
° c2. y. oy O7 J-! 1i1 yo 
"o- 0 29 
y2 
öyöyZ 
.5a3ZFGööa 
w_ ö ýo 
a ýo woo "° . y. 
ov ctl Soü :" 
ý' 
u ý'j ed oq pwo äi "n "v e0 w> 
up, uNFyÖh> 'O ý'ü äý .GÖ . 
°.; 
u aý Ö "" \° 
N 
ýG 'y 
u '`3 u to 'C ü 'e S 
001 d '> 
81(t. 
,m u= 
ui 
99u U ýn av 
cý° v o`°n 
äÄä 
F° ii 
~> 
aZ 
rlý 
zN"h N le 
14 
O00*NM 
CD 
ONO 
0 
.ýI. NN'. O N ýn oo «n hNN oo M Iý N 
Sy 
y 
Jd r. 
0 
00 
0 
nnnIInnInnIIInn 
i 
ms 
0 
t2 
"0 r. 
0 t: 2 D, *Z 
a1 ý. CuFw 
aaäa öav v" aC X aG a x" 
"ov ou 
vF 
Cp>ui. 
a. r. a >. aC >' vCQ -o >` a 
p -o -v -o -o oR -v > -o o a, -a oo>v -o 
yVl }yy yy yý 
r]! 
ý! ý. ry yy yVi 
4 }ý 
yy yy yN yy 0 fý7lj f. i FI VMM ý" iy VY ly 'ý Sý 1y ''ý` My 1y M 
(Op a (O[ .2 
(((Oýýý e tttO[[[111 ae .r te ý .L2 fffýýý111 fp[ möö d -12 t. uu ý""ý uUc ý""ý UU~NHb. U~~NMVU4UU 
vi MUaaa. Ua oG U P. UUa oG aa 
oÖ Np 0Ö0ÖÖÖÖ 
0NNN0N0000N II 
ýO Oý C 92. 
Go oh o\ o o., o- ooo$ a'. o [-+ NIININNNNN L 
G 
eý C 
Qu a+ id .ýV 
ÜZ 
ýn 
d 
Cý w ooG 
Ü 
(I, 
- 
. 
>. w vý 
w 
y C ýO p 
8 .: C 
G zt -; i 
ea 
-4 
2 is 13 + dy r3 la O+ 
~ FqQGD ýÖ ÖN Öl ^. 
pý}" 
uM C^ MMm 
rN4 
NN 
ýy'i ÖdH OÖ tý 
O 
3S 
"E 
y, 
t' iO 
yÖ pO 
1S 
u9 llS 
S~ 8S 
5Ö 
j5 "p 
N p0N, dNQ N' CNNNNNNNNNN 
Hd ýd aä "U" C7" c7 C7"ß" """ a" a vý 
304 ® 2011 Blackwell Publishing Ltd 
Tropical Medicine and International Health 
K. Kranzer & N. Ford ART interruptions - systematic review 
v x 
O 
Äö 
a IA i. y 
a'C -0 e 
Fä 
I 
I 
F" ýi 
bb 
ac -Z 
"n q 'ý eý° c ti 
v ýc 
cw 
O Y+ " 
211 
QHYO 
M ~nM v'P or , C_ G 
C "+O 
7ýy `p° p ý°y 
M 
yC GO 'O ö ý' 
MC 
'n 
°Cý\ 
rr . -. Uy~a 
Vl ev 
öN~° 
. -. 
C~- -C 
MC cý \ -p ,ý . 
`3 O 
Co c2w j; 
v' `äi ü G? ö ate. 
äC 
2502 82 u -O u, u 'S7 'O ww "w "O etl ö "'2 - 'ü u e4 O' O< ,2 .y ai Gy 
. 'ý A6 
t2 'k üC iE uw ýd O 
.7OO 
ai 
-C ý.. w 
ýä acý. ý "v 5, 
Mh 
Z-v 
OM 
00 ý 
N 
ö -`°0 3 
n 
I I 
n n 
i 
8 
p 
3 
F 
3 
1C 
' 
'O C 
0 
C 
0 
C 
a' 
ý 
.CP. 
C Oý w 
9 
O -IZ '13 
C 
r. 
O 
t: 
O O GL p 
0 
R 
aýi 
"Ö 
CD (D 
CD CD 
(D 
CD 
ö 0 
-C 
0 
N 
. -N 1 1 
u: c9ý 
ý7 w Z 
0.4 
13 ýý 8 -18 
N ýý ý E" v ýýý 
N 
7v 
U 
" 
VOLUME 16 NO 10 PP I297-I3I3 OCTOBER 2O1I 
(Krentz et al. 2003) were reported in individuals inter- 
rupting therapy. 
All studies investigating CD4 and viral load response 
during treatment interruption reported a substantial drop 
of CD4 count and increase in viral load compared with 
pre-interruption levels (Gonzalez et at. 2003; Sommet 
et at. 2003; Tarwater et al. 2003; Gibb et at. 2004; 
Achenbach et at. 2005; Burton et at. 2005; Giard et al. 
2005; Pavie et at. 2005; Wolf et at. 2005; Bedimo et al. 
2006; Hull et at. 2006; Sanchez et at. 2007; Saitoh et al. 
2008; Mussini et al. 2009; Sarmati et at. 2010). The 
influence of nadir CD4 counts, CD4 counts, and viral load 
levels prior to treatment interruption on CD4 decay was 
inconsistent, with some studies reporting an effect (Gonz- 
alez et at. 2003; Wolf et at. 2005; Hull et at. 2006; Mussini 
et al. 2009) while others reported no effect (Saitoh et at. 
2008). 
CD4 counts rose after resumption of therapy (Chen et at. 
2002; Sommet et at. 2003; Gibb et a!. 2004; Giard et at. 
2005; Wolf et al. 2005; Sanchez et al. 2007; Touloumi 
et a!. 2008; Mussini et at. 2009). The increase was biphasic 
with a steeper slope in the first months after re-initiation of 
therapy (Touloumi et at. 2008; Mussini et a!. 2009). 
However, CD4 recovery was incomplete: in studies 
reporting CD4 recovery, the proportion of patients expe- 
riencing an increase in CD4 counts to levels before 
treatment interruption at 24 months ranged from 28% to 
69% (Chen et al. 2002; Giard et al. 2005). One study that 
investigated the effect of treatment interruption in a prison 
setting found that patients with continuous ART treatment 
gained on average 0.67 CD4 cells per months compared 
with intermittently treated patients who lost cells at an 
average of 0.93 CD4 cells per month (Pai et at. 2009). 
The majority of studies reported that patients experi- 
enced virologic suppression once treatment was restarted 
(Chen et at. 2002; Yozviak et at. 2002; Gibb et al. 2004; 
Wolf et al. 2005; Touloumi et at. 2008; Mussini et at. 
2009). However, treatment interruptions were associated 
with an increased risk of rebound and virologic failure in 
developed and developing countries (Murri et at. 2002; 
Parienti et a!. 2004,2008; Spacek et at. 2006; Laher et at. 
2007; Oyugi et a!. 2007; Bansi et a!. 2008; Boileau et at. 
2008; Kouanfack et at. 2008; Knobel et a!. 2009; Datay 
et al. 2010; Ekstrand et a!. 2010). A study from Spain 
differentiated treatment interruptions because of patients' 
choice and adherence difficulties or physician's advice for 
toxicity, severe side effects, or intercurrent illness. After 
adjusting for drug regimen and adherence level, the risk of 
a detectable viral load (>500 copied/ml) or death was 3.62 
for the former and 1.36 for the latter, compared with 
continuous treatment (Knobel et at. 2009). A study among 
adults receiving boosted protease inhibitors (PI) reported 
0 2011 Blackwell Publishing Ltd 1305 
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that average adherence predicted viral suppression, 
whereas treatment interruption did not in multivariate 
analysis (Parienti et al. 2010). 
Four studies investigated the development of resistance 
mutations (Parienti et al. 2004; Spacek et al. 2006; Oyugi 
et al. 2007; Sanchez et al. 2007). In a study from France, 
interrupting treatment more than once was significantly 
associated with the development of resistance to the non- 
nucleoside-reverse-transcriptase inhibitors (NNRTI) class 
(hazard ratio 22.5,95% CI 2.8-180.3) (Parienti et al. 
2004). Among 19 treatment interrupters in Spain, nine had 
mutations in the reverse transcriptase gene and 17 had 
polymorphism in the protease gene, with L63P being the 
most commonly found (Sanchez et al. 2007). In Uganda, 
none of the patients with continuous treatment had 
evidence of resistance mutations, but 13% of patients with 
a history of treatment interruption had resistance muta- 
tions: all of them had mutations conferring nevirapine 
resistance, five had mutations conferring lamivudine resis- 
tance, and three had mutations conferring stavudine 
resistance (Oyugi et al. 2007). Another study from Uganda 
showed resistance to NNRTI class in 26 of 36 patients with 
detectable viral load with the most common mutation 
being K103N. Twenty-three of the 36 patients had the 
M184V/I mutation and three had genotypic resistance to 
PIs (Spacek et al. 2006). 
Interventions 
We only identified one intervention study. This randomized 
controlled trial from Kenya showed that short message 
service reminders either daily or weekly reduced the 
prevalence of treatment interruptions exceeding 48 h from 
19% to 10% (P = 0.03) (Pop-Eleches et al. 2011). 
Six studies investigating risk factors associated with 
treatment interruptions discussed possible interventions. 
Studies from developed countries suggested appropriate 
counseling on the consequences of drug discontinuation, 
encouragement of optimal adherence, offering of mental 
health services, addressing addictions, and providing ser- 
vices specifically engaging women and ethnic minorities (Li 
et al. 2005; Moore et al. 2009; Murri et a!. 2009). Studies 
from Uganda and Cameroon emphasized the importance of 
steady and reliable access to medication, as well as free 
access to ART and possibly food supply programs (Oyugi 
et al. 2007; Marcellin et al. 2008). A study from South 
Africa concluded that interventions should be targeted at 
men and during the first 6 months on ART (Kranzer et al. 
2010). 
When patients were asked to give at least one suggestion 
how to improve adherence and reduce treatment inter- 
ruptions: 46% suggested reduction in daily doses, 28% 
more detailed information about therapy, 27% more 
attention to side effects, 20% more time dedicated to 
adherence-related issues, 19% supervised treatment inter- 
ruptions, and 16% psychological help (Ammassari et a!. 
2004). 
Conclusions 
Recent research has highlighted the importance of non- 
adherence to and defaulting from antiretroviral care in 
contributing to poor program outcomes (Garcia De Olalla 
et al. 2002; Nieuwkerk & Oort 2005; Mills et al. 2006; 
Maggiolo et al. 2007; Rosen et al. 2007; Brinkhof et al. 
2009). Our review highlights that unstructured treatment 
interruptions, while far less frequently reported, are an 
important phenomenon both in developed and in devel- 
oping countries and may result in excess mortality and 
opportunistic infections, increased risk of virologic failure, 
and poor immunological recovery. 
Medication-taking behavior is characterized by adher- 
ence which is defined as `extent to which a patient acts in 
accordance with the prescribed interval, and dose of a 
dosing regimen' and persistence defined as `the duration 
of time from initiation to discontinuation of treatment' 
(Cramer et al. 2008). Persistence emphasizes the concept 
of continuous therapy and is influenced by both defaulting 
from antiretroviral care and treatment interruption' (Bae 
et al. 2011). Adherence and persistence are both impor- 
tant for optimal treatment outcomes, but their impact 
may vary dependent on the type of regimen prescribed 
and the duration and frequency of treatment interruptions. 
We found that the characterization of treatment inter- 
ruption in the literature to date is confused by heteroge- 
neous definitions. A quarter of studies provided no 
definition, while for those that did definitions varied from 
more than 24 h to more than 1 year of discontinuation of 
treatment. Only half of studies reported on median 
duration of interruption. Similar problems with regard to 
uniformity of definitions have been encountered in studies 
investigating loss to follow-up where definitions ranged 
from 1 to 6 months late for a scheduled consultation or 
medication pick-up (Rosen et al. 2007). In addition, the 
method of determination of treatment interruption varied 
considerably: over a quarter of studies using self-report, 
while a similar number did not specify the method used to 
identify treatment interruptions. 
The reported causes of treatment interruption are multi- 
dimensional and context-specific. However, research to 
date has largely assessed risk factors and reasons for 
treatment interruption, few in developing country settings. 
Studies from developing countries highlighted pharmacy 
stock outs and costs as important factors for treatment 
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interruptions. While several interventions have been 
proposed, only one has been formally assessed. 
Data synthesis is a desirable goal for systematic reviews. 
However, in view of the substantial degree of heterogeneity 
between studies with regard to definitions of treatment 
interruption and methods used to identify treatment 
interruptions, we decided against providing a data syn- 
thesis. In addition, because treatment interruptions depend 
on duration of ART, incidence would be a more 
informative measure, but few studies provided incidence 
estimates. Another limitation of our review, reflecting a 
limitation of the published evidence, is that only four 
studies investigated the association between treatment 
interruption and genotypic resistance. The sample size of 
these studies was small. One of these studies relied on 
self-report to identify treatment interruptions. Larger 
studies using objective measures of treatment interruptions 
are needed to confirm the association between treatment 
interruption and genotypic resistance. Finally, although 
our search strategy was extensive, yielding a high number 
of studies, we cannot exclude the possibility that our search 
strategy may not have captured all reports of treatment 
interruption. 
Our study highlights several directions for future 
research and practice. First, reporting on treatment 
interruptions should be encouraged, both to improve the 
quality of program outcome reports, and support better 
characterization and quantification of the problem. 
Second, more uniform reporting of treatment interruption 
should be encouraged to support comparability across 
studies, as has been proposed for treatment defaulting. 
The range of proposed interventions in the literature does 
not reflect the range of causes reported, with a notable 
absence of attention on some of the most frequently 
reported drivers of treatment interruption, including 
drug toxicity, adverse events, and side effects. This 
suggests that a first step to minimizing treatment inter- 
ruptions in many settings is simply to provide better care 
to patients. Finally, intervention studies should be 
planned to determine the effectiveness of approaches to 
minimize treatment interruption and encourage treatment 
resumption. 
In conclusion, treatment interruptions are common both 
in developed and in developing countries and are associ- 
ated with increased morbidity, mortality, and possibly 
genotypic resistance. Future research should focus on 
evaluating interventions to address the most frequently 
reported reasons for interruptions to support patients in a 
way that maximizes the chances of continuous and 
effective treatment. 
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Treatment Interruption in a Primary Care Antiretroviral 
Therapy Program in South Africa: Cohort Analysis of 
Trends and Risk Factors 
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Objective: To investigate antiretroviral treatment (ART) interruption 
in a long-term treatment cohort in South Africa. 
(event rate = 21.4 per 100 person-years). Factors associated 
with restarting treatment were female gender, older age, and time 
since defaulting. 
Methods: All adults accessing ART between 2004 and 2009 were 
included in this analysis. Defaulting was defined as having stopped 
all ART drugs for more than 30 days. Treatment interrupters were 
patients who defaulted and returned to care during the study, 
whereas loss to follow-up was defined as defaulting and not 
returning to care. Kaplan-Meier estimates and Poisson regression 
models were used to analyze rates and determinants of defaulting 
therapy and of treatment resumption. 
Results: Overall rate of defaulting treatment was 12.8 per 
100 person-years (95% confidence interval: 11.4 to 14.4). Risk 
factors for defaulting were male gender, high baseline CD4 count, 
recency of ART initiation, and time on ART. The probability of 
resuming therapy within 3 years of defaulting therapy was 42% 
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Conclusions: Defaulting treatment need not be an irreversible 
event. Interventions to increase retention in care should target men, 
less immunocompromised patients, and patients during the first 6 
months of treatment. Resumption of treatment is most likely within 
the first year of interrupting therapy. 
Key Words: antiretroviral, Africa, HIV, loss to follow-up, 
unstructured treatment interruption 
(JAcquir Immune Defic Syndr 2010; 00: 000-000) 
INTRODUCTION 
Access to antiretroviral therapy (ART) has improved 
substantially in resource-limited settings in Africa, Asia, and 
South America where 90% of people with HIV/AIDS reside. 
According to World Health Organization (WHO) estimates, 
more than 4 million people with HIV/AIDS in low-income and 
middle-income countries had initiated treatment by the end of 
2008. ' Despite this success, ensuring that patients remain in 
care over time remains one of the major challenges in 
resource-limited settings. Much attention has been paid to 
patient adherence 2-5 loss to follow-up, and mortality in ART 
programs in resource-limited settings. " A systematic review 
of 33 patient cohorts from 13 African countries reported that 
only between 46% and 85% of patients remained in care at 
2 years. " 
The realization that a substantial proportion of patients 
reported as lost to follow-up may have died has led to concern 
that there may be significant biases in program outcome 
reports of survival. 10 Another potential source of bias is the 
fact that a proportion of patients may only transiently default, 
returning to care at a later stage. Such unstructured treatment 
interruption has been reported to occur in around 20% of 
patients in industrialized settings. "-14 The proportion of 
patients who transiently interrupt treatment in resource-limited 
settings is largely unreported. 
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Treatment interruptions, planned or otherwise, have 
been found to increase the risk of opportunistic infection and 
death, 15-" with viral load increase and associated CD4 decline 
most pronounced in the first 2 months. 16"'8-20 Interruptions 
raise similar concerns with respect to drug resistance and 
increased mortality as suboptimal adherence. ' 1,15,21-23 How- 
ever, few studies have addressed the issue of unstructured 
treatment interruptions in resource-limited settings. The aim 
of this study was to investigate the frequency and risk factors 
of defaulting treatment and identify factors associated with 
subsequent return to care in a long-term treatment cohort in 
South Africa. 
METHODS 
Study Site and Data Collection 
The study was based in a periurban township in the 
greater area of Cape Town, with a population of approximately 
15,000 people and an estimated adult HIV prevalence of 23% 
in 2005.24 The community is served by a single public-sector 
primary care clinic which provides ART free of charge. 
ART provision began in 2004. From 2005 to 2009, ART 
services were partly provided according to the antiretroviral 
treatment protocol of the Western Cape and partly through 
a study funded by the National Institutes of Health (NIH). 
Patients enrolled in the NIH-funded study could access ART 
with a CD4 count below 350 cells per microliter or WHO stage 
3 disease as compared with 200 cells per microliter or WHO 
stage 4 disease in the provincial program. The NIH-funded 
study completed enrollment in 2007 after which all patients 
were treated in the provincial ART program. 
Initial evaluation for ART eligibility included medical 
history, physical examination, and CD4 cell count. A follow- 
up appointment was scheduled 1-2 weeks later when the 
laboratory results were reviewed, and ART eligibility was 
determined. Patients eligible for ART underwent 3 adherence 
counseling sessions before starting treatment. 
The initial follow-up schedule for those starting ART 
included 1 visit 2 weeks after ART initiation, followed by 
monthly visits until month 3. Patients who were stable on ART 
and did not experience any adherence problems were thereafter 
seen every 3 months. Three attempts were made to contact 
patients who had missed appointments. 
All patients aged ? 15 years accessing ART in the 
primary health care clinic between March 01,2004, and 
December 31,2009, were included in the analysis. 
Sociodemographic and clinical data at baseline and 
laboratory data were collected prospectively using a standard- 
ized data form. All laboratory tests were performed by the 
National Health Laboratory Services in Cape Town. 
Definitions 
"patients defaulting treatment" were defined as those 
who had not presented at the pharmacy for ART refills for 
more than 30 days. This category included patients who 
subsequently returned to care and restarted ART (treatment 
interrupters) and patients who had not returned to care at the 
time of censoring (loss to follow-up) (Fig. 1). 
Treatment interruption was defined as a patient-initiated 
episode of more than 30 days of stopping ART (same 
definition as defaulting) but who subsequently resumed 
treatment (Fig. 1). 
"Patients lost to follow-up" were those who stopped 
ART for more than 30 days and had not returned to care at the 
time of censoring (Fig. 1). 
Study Design 
In-program data on death, transfers outs, and loss to 
follow-up were collected prospectively. Death on ART was 
defined as any death within 3 months of drug refill. If the exact 
date of death was not recorded, it was estimated to be the 15th 
of the month after the last clinic appointment. 
Patients who had stopped ART for more than 30 days 
and resumed therapy were identified using the pharmacy 
dispensing data. The electronic pharmacy dispensing system 
records each time medication is dispensed to a patient. 
Treatment interruption was verified through folder reviews. 
The first endpoint was the time from ART initiation to 
the first time at which all drugs were stopped for a period of at 
least 30 days (default). Follow-up of patients on continuous 
therapy was censored at the date of death, date of transfer, or 
study end (December 31,2009). 
The second endpoint was treatment resumption, defined 
as the time from defaulting treatment for the first time to the 
time of restarting ART. Follow-up of patients for whom 
therapy was not resumed was censored at the date of death, 
date of transfer, date of migration, or study end. For 
a proportion of these patients (48%) vital status, date of 
death, date of transfer, and date of migration was determined 
by home visits. 
Statistical Analysis 
All analyses were carried out using Stata version 10.0 
(Stata Corp LP, College Station, TX). Frequency tables were 
produced for all categorical baseline characteristics. For 
continuous baseline characteristics, the median and interquar- 
tile ranges were reported. Standard survival analysis methods, 
including Kaplan-Meier estimates and Poisson regression 
models, were used to analyze the rate and determinants of 
defaulting therapy and of treatment resumption after defaulting 
treatment for the first time. The proportional hazards 
assumption for potential interaction between each variable 
and time was tested using the likelihood ratio test. A univariate 
Poisson regression model was used to determine risk for time- 
to-event outcomes for each exposure variable. Multivariate 
models were built through backwards elimination. Sensitivity 
analyses were conducted excluding individuals with unascer- 
tained vital status. All reported P values are exact and 2-tailed, 
and for each analysis, P<0.05 was considered significant. 
Ethical Approval 
The study was approved by the University of Cape Town 
Ethics Committee and the London School of Hygiene and 
Tropical Medicine Ethics Committee. Written informed 
consent was obtained from all patients at enrollment. 
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was defined as a patient-initiated 
episode of more than 30 days of 707 In cam: 
stopping ART and subsequently re- ell neVerdeWted 
suming treatment. ntinterrupter ` 
RESULTS 
Patient Characteristics 
A total of 1154 patients were included in the analysis 
(Table 1), and the median time of follow-up was 1.45 years 
TABLE 1. Baseline Characteristics of Patients (n = 1154) Who 
Enrolled in the ART Program Between 2004 and 2009 
Variable n (%) Median (IQR) 
Gender 
Women 752 (65.2) 
Men 402 (34.8) 
Age (yrs) - 
Residents in the study township 
Yes 1102 (95.5) 
No 40 (3.5) 
Unknown 12 (1.0) 
Transferred in from another ART service 
No 1046 (90.6) 
Yes 108 (9.4) 
Year of initiating ART 
2004 137 (11.9) 
2005 242 (21.0) 
2006 279 (24.2) 
2007 153 (13.3) 
2008 155 (13.4) 
2009 188 (16.3) 
WHO clinical stage* 
31.9 (27.3-37.5) 
1 106 (9.3) 
2 166 (14.5) 
3 585 (51.1) 
4 287 (25.1) 
Baseline CD4 (cell/p L)t - 122 (54-190) 
*Ten missing values. 
tone hundred fourteen missing values. 
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[interquartile range (IQR): 0.48-3.24]. The majority of 
patients were young women (65.2%) and residents in the 
township (95.5%). Before treatment initiation, the majority of 
patients were in WHO clinical stage 3 (51.1 %) and 4 (25.1 %), 
and median CD4 count was 122 cells per microliter (IQR: 
54-190). The number of patients initiating ART per year 
doubled from 137 in 2004 to 279 in 2006 and declined 
thereafter. 
A total of 291 patients defaulted treatment at least once 
(Fig. 1). Among these, 96 resumed therapy (treatment 
interruption), whereas 195 did not resume therapy during 
follow-up (lost to follow-up). Of the 96 individuals resuming 
therapy, 75 individuals had 1 episode of treatment interruption, 
19 had 2, and 2 had 3. The median time patients failed to 
receive ART was 228 days (IQR: 126-409) during the first 
episode of treatment default and 194 days (IQR 121-278) 
during the second episode. Thirty-five patients who had 
stopped treatment underwent rescreening that included clinical 
assessment, laboratory tests, and adherence counseling and yet 
did not resume therapy during the period of the study. 
Subsequent analyses investigated first episode of 
treatment interruption by analyzing the time to stopping 
treatment for the first time and resuming therapy thereafter. 
Factors Associated With the Probability of 
Defaulting Treatment 
The overall rate of treatment default for the first time was 
12.8 per 100 person-years [95% confidence interval (Cl): 11.4 
to 14.4]. The Kaplan-Meier estimate of the probability of 
defaulting treatment for at least 30 days was 14.9% (95% CI: 
12.7 to 17.4) by 1 year, 25.6% (95% Cl: 22.7 to 28.8) by 
2 years and 41.0% (95% Cl: 37.0 to 45.3) by 5 years from ART 
initiation (Fig. 2). 
Factors associated with increased risk of defaulting 
therapy in univariate analysis were male gender, higher 
baseline CD4 count, recency of ART initiation, and shorter 
duration on ART (Table 2). Defaulting rate was highest in the 
first 6 months of ART (18.2 per 100 person-years, 95% Cl: 
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8 14.7 to 22.5) but decreased thereafter and had more than halved 
after 2 years (8.8 per 100 person-years, 95% CI: 7.0 to 11.0). 
Gender, baseline CD4 count, time on ART, and date of 
initiation remained significantly associated with defaulting in 
the multivariate model. Men were 1.51 (95% CI: 1.18 to 1.93) 
times more likely to default treatment compared to women, as 
were those patients with a higher baseline CD4 count. The 
adjusted risk of defaulting treatment increased by 1.30 (95% 
Cl: 1.17 to 1.44) for each calendar year. Patients on treatment 
for more than 2 years had a lower risk of 0.69 (95% CI: 0.48 to 
0.98) of defaulting compared with patients during the first 6 
months of treatment. Similar results were found in a sensitivity 
analysis that excluded individuals whose vital status could not 
be ascertained. 
L. N 
3 
0- 
g 
Years from starting ART 
Number at risk 1055 673 482 344 188 64 
FIGURE 2. Kaplan-Meier plot showing the probability of not 
defaulting ART from the time of initiating ART up to the end of 
the fifth year of treatment. 
Factors Associated With the Probability of 
Resuming Therapy 
A total of 291 patients defaulted treatment at least once. 
The overall rate of treatment resumption after defaulting 
treatment for the first time was 21.4 per 100 person-years 
(95% Cl: 17.5 to 26.2) (Fig. 3). The Kaplan-Meier cumulative 
TABLE 2. Risk Factors for Defaulting Treatment 
Rate of Default of Unadjusted HR Adjusted HR of 
Number Defaulting Person-Years Treatment per 100 of Default of Default of Treatment 
Variable Treatment at Risk Person-Years (95% Cl) Treatment (95% Cl) P (95% Cl) P 
Gender 
Women 172 1544 11.1 (9.6 to 12.9) 1 - 1 - 
Men 115 692 16.6 (13.9 to 20.0) 1.49 (1.17 to 1.89) <0.01 1.51 (1.18 to 1.93) <0.01 
Age (yrs) 
s30 196 1473 13.3 (11.6 to 15.3) 1 - - - 
>30 91 762 11.9 (9.7 to 14.7) 0.90 (0.70 to 1.15) 0.40 - - 
Residents in the study township 
Yes 271 2168 12.5 (11.1 to 14.1) 1 - - - 
No 10 65 15.4 (8.3 to 28.7) 1.23 (0.66 to 2.32) 0.52 - - 
Transferred from another ART service 
No 268 2110 12.7 (11.3 to 14.3) 1 - - - 
Yes 19 127 15.0 (9.6 to 23.5) 1.18 (0.74 to 1.88) 0.48 - - 
WHO stage 
I or 2 57 499 11.4 (8.8 to 14.8) 1 - - - 
3 or 4 209 1608 13.0 (11.4 to 14.9) 1.14 (0.85 to 1.53) 0.37 - - 
Baseline CD4 count (cells/pL) 
X100 89 823 10.8 (8.8-13.3) 1 - 1 - 
101-200 103 716 14.4 (11.9 to 17.3) 1.33 (1.00 to 1.77) 0.05 1.32 (0.99 to 1.76) 0.06 
>200 73 530 13.8 (10.9 to 17.3) 1.27 (0.83 to 1.73) 0.13 1.39 (1.02 to 1.91) 0.04 
Year of initiating ART* 
2004 24 434 5.5 (3.7 to 8.2) 1.36 (1.24 to 1.48) <0.01 1.30 (1.17 to 1.44) <0.01 
2005 76 703 10.8 (8.6 to 13.5) 
2006 83 599 13.9 (11.2 to 17.2) 
2007 47 247 19.0 (14.3 to 25.3) 
2008/2009 57 253 22.6 (17.4 to 29.3) 
Time on ART 
<6 months 84 462 18.2 (14.7 to 22.5) 1 - I - 
6 months to 2 years 130 939 13.8 (11.7 to 16.4) 0.76 (0.58 to 1.00) 0.05 0.86 (0.65 to 1.15) 0.31 
>2 years 73 834 8.8 (7.0 to 11.0) 0.48 (0.35 to 0.66) <0.01 0.69 (0.48 to 0.98) 0.04 
The P value for test for departure from linear trend 0.35. 
HR, hazard ratio. 
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FIGURE 3. Kaplan-Meier plot showing the probability of 
resuming ART from the time of defaulting therapy up to 3 years 
after defaulting treatment. 
estimate of the probability of treatment resumption was 26.7% 
(95% CI: 21.7 to 32.7) in the first year, 37.1% (95% CI: 31.1 to 
43.9) in the second year, and 42.1% (95% CI: 35.2% to 49.7%) 
in the third year after stopping treatment. 
In univariate analysis a greater likelihood of resuming 
ART was associated with older age and shorter time since 
defaulting (Table 3); gender, residency, calendar year of 
defaulting, and CD4 count nearest to the time of defaulting 
was not associated with resuming treatment. 
In multivariate analysis, men were less likely to resume 
treatment compared with women (incidence risk ratio [IRR]: 
0.67,95% CI: 0.43 to 1.04, P=0.07); whereas patients >30 
years old were more likely to restart treatment (IRR: 1.80,95% 
Cl: 1.13 to 2.89). The likelihood of resuming treatment 
decreased significantly beyond one year of defaulting 
treatment (IRR: 0.40,95% Cl: 0.25 to 0.63). 
Of the 96 patients resuming therapy, 86 had a CD4 count 
measurement while receiving therapy and before the treatment 
interruption; the majority of these (80) responded to ART with 
an increase in CD4. Patients who resumed therapy were found 
to have a median CD4 count (150.5 cells/pL, IQR: 73-266) 
comparable to their baseline CD4 count before initiating 
therapy (138.5 cells/µL, IQR: 73-188). The median time 
between the measurement of CD4 count and resuming therapy 
was 13 days (IQR: 0-28 days). 
Excluding individuals with unascertained vital status 
revealed similar results with regards to parameter estimated, 
but the association with male gender became nonsignificant 
(incidence risk ratio: 0.81,95% Cl: 0.52 to 1.26, P=0.35). 
DISCUSSION 
To our knowledge, this is the first study from sub- 
Saharan Africa to report on unstructured treatment interrup- 
tions in a routine program setting. Our analysis shows 
that treatment interruption is a common phenomenon. 
The probability of ART defaulters to resume therapy within 
3 years was 42%. Most ART cohorts report on loss to follow- 
up, defined as not attending the clinic for more than 3 months, ' 
TABLE 3. Risk Factors for Resuming Treatment After Defaulting 
Rate of Restarting Unadjusted IRR of Adjusted IRR 
Number Person-Years Treatment per 100 Restarting of Restarting 
Variable Resuming Treatment at Risk Person-Years (95% CI) Treatment (95% CI) P Treatment (95% CI) P 
Gender 
Women 61 253 24.1 (18.7 to 31.0) 1 - 1- 
Men 32 182 17.6 (12.5 to 24.9) 0.73 (0.48 to 1.12) 0.15 0.67 (0.43 to 1.04) 0.07 
Age (yrs) 
s30 26 174 15.0 (10.2 to 22.0) 1 1 
>30 67 261 25.7 (20.2 to 32.6) 1.72 (1.09 to 2.70) 0.02 1.80 (1.13 to 2.86) 0.01 
Residents 
YCS 87 405 21.5 (17.4 to 26.5) 1 - -- 
No 5 14 34.5 (14.4 to 82.9) 1.60 (0.65 to 3.96) 0.30 -- 
CD4 count at time of defaulting (cells/pL) 
5200 36 155 23.4 (16.8 to 32.4) 1 - -- 
>200 57 280 20.3 (15.7 to 26.3) 0.87 (0.57 to 1.32) 0.52 -- 
Year of defaulting treatment 
2004/2005 9 60 15.0 (17.8 to 28.9) 1 - -- 
2006 23 122 18.8 (12.5 to 28.3) 1.25 (0.58 to 2.70) 0.57 -- 
2007 29 127 22.7 (15.8 to 32.6) 1.51 (0.72 to 3.19) 0.28 -- 
2008 32 93 21.4 (13.8 to 33.2) 1.42 (0.65 to 3.13) 0.38 -- 
2009 12 31 38.5 (21.9 to 67.8) 2.57 (1.08 to 6.09) 0.03 -- 
rune off ART 
<1 year 68 222 31.6 (24.2 to 38.9) 1 - 1- 
>1 year 25 213 11.7 (7.9 to 17.4) 0.38 (0.24 to 0.61) <0.01 0.40 (0.25 to 0.63) <0.01 
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and assume that loss to follow-up is an irreversible event. Our 
study shows that patients who fulfill the widely used definition 
of loss to follow-up at one time point might resume therapy 
later. In this cohort, the median duration of the first treatment 
interruption was 7.5 months. 
The median CD4 count of those resuming therapy was 
similar to their initial CD4 count before starting treatment, 
which underscores the potentially negative impact of in- 
terruption leading to a reversal in immunological recovery 
made although on treatment. Data from industrialized settings 
suggest that treatment interruption has detrimental effects on 
CD4 count, viral load suppression, and clinical progres- 
sion. ", 12,19 Programs that report patient attrition and the 
number of patients in care will not account for the potential 
that up to 14% of patients in care have interrupted treatment at 
least once. 
We were able to determine risk factors for defaulting 
ART and factors associated with resuming therapy. Male 
gender, high baseline CD4 count, recency of ART initiation, 
and the first 6 months of treatment were associated with 
a higher risk of defaulting. Treatment resumption was more 
likely in women, patients elder than 30 years and within the 
first year of stopping therapy. 
Our finding that men were at higher risk of defaulting 
treatment and less likely to resume treatment is consistent with 
studies showing that HIV infected men are less likely to access 
treatment, 25'26 have an increased risk for loss to follow-up in 
the pretreatment period, 27 present with more advanced stages 
of HIV disease, 28 and have a higher mortality risk on 
'ART . 
2'9'29-33 Strategies to diagnose HIV in men earlier and to 
link and to retain them in care might include the following: (1) 
extending clinic hours into evenings and weekends, (2) 
training male health care staff and counsellors, (3) offering 
additional adherence sessions to men, and (4) initiating male 
support groups. 
Individuals initiating treatment in more recent years 
were more likely to default, suggesting that programatic 
factors might influence retention in care. A study including 
data from 15 treatment cohorts from Africa, Asia, and South 
America showed that early patient losses were increasingly 
common when programs were scaled up. ' Increasing cohort 
size in an environment of scarce human resources for health 
has been suggested to influence both the scale-up capacity 
and the long-term retention in ART programs. 34 In the study, 
clinic resources and staffing were further reduced when 
enrolment for the NIH-funded study finished in 2007. In 
contrast, year of defaulting was not associated with resumption 
of treatment, suggesting that patient tracing was less 
influenced by cohort size (although this would vary according 
to tracing procedures). 
Treatment defaulting was more likely in patients with less 
advanced immunodeficiency at baseline. This may be explained 
by the fact that individuals who default treatment and stay alive 
do so because they feel better on treatment, a phenomenon that 
has been reported by other studies; s This finding is particularly 
important in view of the 2009 WHO guidelines recommending 
ART initiation at CD4 counts below 350 cells per microliter36 
and when considering initiation of ART regardless of CD4 
count as proposed in the "test and treat" strategy. 37 Initiating 
ART at the time of HIV diagnosis will result in increased 
numbers of relatively immunocompetent individuals on ART 
who may have a higher risk of defaulting treatment. Specific 
interventions aimed at these individuals need to be developed to 
ensure optimal retention in care. 
This study has several limitations. First, ascertainment 
of vital status for treatment defaulters was incomplete, which 
may have led to a misclassification of deaths as defaulters. 
However, sensitivity analysis excluding individuals with 
unascertained vital status did not influence our overall 
findings. Second, resumption of therapy was not ascertained 
in patients who moved to other communities, possibly 
resulting in underestimation of treatment resumption. Third, 
the clinical and immunological consequences of treatment 
interruption were not analyzed due to lack of laboratory data, 
in particular, the lack of capacity to perform routine viral load, 
and the small number of individuals resuming therapy. 
However it has been shown in industrialized settings that 
treatment interruption impacts negatively on CD4 count, viral 
load suppression, and clinical progression. ""12. '9 
We consider that the main finding of this study that 
a considerable proportion of treatment defaulters return to care 
is likely to be generalizable to similar settings. Nevertheless, 
risk factors for defaulting and resuming therapy might differ 
with regards to eligibility criteria and resources available for 
patient tracing. 
A strength of this study is that the relatively large sample 
size and follow-up time. This allows for an assessment of risk 
factors for defaulting and treatment interruption that in turn 
allows for several proposals to be made to limit defaulting and 
treatment interruption in similar programme settings. In 
particular, interventions to keep patients in care should be 
targeted at men, patients with higher CD4 counts and during the 
first 6 months of ART. Moreover, the finding that the probability 
of resuming therapy was highest in the first year after treatment 
defaulting suggests that efforts to bring patients back into care 
might be most successful early into defaulting treatment. 
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13.1 Abstract 
Background: Survival analysis using time-updated CD4+ counts during 
antiretroviral therapy is frequently employed to determine risk of clinical events. 
The time-point when the CD4+ count is assumed to change potentially biases effect 
estimates but methods used to estimate this are infrequently reported. 
Methods: This study examined the effect of three different estimation methods: 
assuming i) a constant CD4+ count from date of measurement until the date of next 
measurement, ii) a constant CD4+ count from the mid-point of the preceding 
interval until the midpoint of the subsequent interval and iii) a linear interpolation 
between consecutive CD4+ measurements to provide additional midpoint 
measurements. Person-time, tuberculosis rates and hazard ratios by CD4+ stratum 
were compared using all available CD4+ counts (measurement frequency 1-3 
months) and 6 monthly measurements from a clinical cohort. Simulated data were 
used to compare the extent of bias introduced by these methods. A literature 
review was conducted to identify methods used for time-updated CD4+ count 
analysis. 
Results: The midpoint method gave the least biased estimates for person-time 
spent with low CD4+ counts and for hazard ratios for outcomes in both the clinical 
dataset and the simulated data. The majority of studies (11 out of 21) conducting 
survival analysis with time-updated CD4+ counts did not specify the method used 
to estimate the time-point of change. 
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Conclusion: The midpoint method presents a simple option to reduce bias in time- 
updated CD4+ analysis, particularly at low CD4 cell counts and rapidly increasing 
counts after ART initiation. 
13.2 Introduction 
Observational prospective cohort data of patients on ART are often used to 
estimate the relationship between time-varying CD4+ counts and incident clinical 
events such as TB, death, opportunistic infections and malignancies. While within- 
subject CD4+ count variability [1,2,3] will inevitably introduce measurement error, 
measurement frequency and the choice of when to split time attributed to a certain 
CD4+ count value might also introduce bias. Measurement frequencies are either 
determined by the study protocol which specifies time intervals at which 
individuals are followed (interval cohort) or by prevailing guidelines within the 
health care service (clinical cohort) [4]. In the latter the frequency of visits and 
laboratory measurements may also be influenced by the severity of illness, access 
to and utilization of health care which might increase the bias. 
Differences in measurement frequency between two exposure groups have been 
shown to introduce bias when time to a specific biomarker level is used as a 
surrogate outcome [5]. The time-point when the CD4+ count is assumed to change 
might bias effect estimates especially when measurement intervals are wide or 
CD4+ counts are rapidly changing. Possible methods used assume that (i) the CD4+ 
count remains constant until the date of the next measurement or (ii) the CD4+ 
count remains constant from the mid-point of the preceding interval until the 
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midpoint of the subsequent interval or (iii) uses linear interpolation between two 
consecutive CD4+ count measurements to provide a midpoint measurement. 
We aimed to assess how these 3 different methods of dealing with time points 
influence effect estimates and rates using data from a clinical ART cohort with 
frequent measurements. The clinical ART cohort was based in Cape Town, South 
Africa and CD4 counts were measured monthly for the first 3 months and 3 
monthly thereafter. We further investigated the direction of bias using a simulated 
dataset. 
13.3 Methods 
13.3.1 Data collection 
Data collected in a peri-urban township in the greater area of Cape Town as part of 
the CIPRA-SA trial were used for this analysis [6]. The trial randomized patients to 
nurse or doctor-monitored HIV care and showed equivalence of the two 
monitoring strategies for treatment failure over 2 years. A total of 363 HIV-positive 
ART-naive patients with a CD4 cell count of 5 350 cell/uL or WHO stage 4 disease 
from this study community were enrolled in the trial in Cape Town. All patients 
received a standard ART regimen and were managed according to the South 
African National Guidelines [7]. 
CD4+ counts were measured at weeks -4,0,4,8,12 (relative to the start of ART) 
and then every 12 weeks. Incident TB was used as the outcome of interest. Start 
and end of TB treatment were determined by merging the ART register with the 
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electronic TB register on first name, surname, medical record number, date of 
birth, truncation of names and switching of first name and surname. This method 
was validated by clinical folder review in a similar dataset of 585 patients from a 
different study and revealed 96.1% sensitivity and 97.4% specificity. All identifiers 
were removed from the data after merging. 
Individuals who did not live in the study community and individuals who were on 
TB treatment at ART initiation and died or were lost to follow-up before they 
completed treatment were excluded from the analysis. 
13.3.2 Definition of study variables 
The exposure was time-updated CD4+count and the outcome was incident TB 
defined as starting TB treatment. Person-time accrued from ART initiation to the 
date of TB disease, death, becoming lost to follow-up or the 31st December 2008 
was calculated. Individuals who were on TB treatment at time of ART initiation 
were only included in the analysis after they had completed TB treatment. 
Individuals who developed incident TB were re-included in the analysis after 
completing TB treatment. Individuals only contributed time while they were on 
ART and person-time during treatment interruptions was excluded from the 
analysis. 
13.3.3 Time-updated CD4 count 
The data were analyzed in three different ways: the first analysis assumed that the 
CD4+ count changed at the date when the blood sample for CD4+ count 
measurement was drawn (date of measurement analysis) (Figure 13.1A); the 
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second assumed a change of CD4+count at the midpoint between two 
measurements (midpoint analysis) (Figure 13.1B); and the third calculated an 
additional CD4+ count using a linear interpolation between two consecutive CD4+ 
measurements and used the date when the blood samples were drawn and the 
midpoint between the two dates as the time point of change of CD4+ count (linear 
interpolation analysis) (Figure 13.1C). 
Figure 13.1: Illustration of the three different methods of modelling CD4+ 
count 
A: date of measurement 
Soot 
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Q 300 
8 
200' 
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C: linear interpolation 
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U 
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U 
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Months since ART initiation 
B: midpoint 
18 24 06 12 18 24 
Months since ART initiation 
Inthe patient shown, we actually observed 
11 CD4+ cell counts over the two years 
(grey line). We have illustrated what would 
have been modelled if only the results at 6 
month intervals (black diamonds) had 
been available. Dotted and dashed lines 
(black) are the CD4+counts assumed by 
the three different methods: data of 
measurement (A), midpoint (B) and linear 
interpolation (C). 
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13.3.4 Newly generated datasets 
A dataset including baseline CD4+ counts and 6 monthly CD4+ counts only was 
generated. From this dataset 15% of the follow-up CD4+ counts were randomly 
selected and removed to simulate the reality of missing data in clinical cohorts. A 
total of 100 datasets with 15% randomly missing follow-up CD4+ counts were 
generated. 
13.3.5 Statistical analysis 
All analyses were carried out using Stata version 11.0 (Stata Corp. LP, College 
Station, TX, United States of America). The association between time-updated 
CD4+ count and TB was explored describing the rate of incident TB and using 
crude Kaplan-Meier curves. Cox proportional hazard regression was used to model 
the relationship between time-updated CD4+ count and TB. Hazard 
proportionality was assessed by analysis of scaled Schoenfeld residuals. 
Events, person-time, rates, hazard ratios and standard errors were determined for 
the 100 datasets with 15% randomly missing follow-up data. The overall estimates 
were calculated according to the combination rules described by Rubin [8]. 
13.3.6 Simulated CD4+ dataset 
Simulated CD4+ count data by time since treatment initiation and baseline CD4+ 
strata, CD4i (t), were generated by fitting CD4i (t) = CD41 (to) + CD41 (tm) (1- 
e-rit) to empirical data from Nash et al. [9] by least-squares, where i was the CD4+ 
stratum at treatment initiation, t was time since treatment initiation, CD41(to) was 
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the average CD4+ level in strata i at treatment initiation, CD4j (tm) was a 
parameter determining the increase in CD4+ count in strata i after 5 years of 
treatment, and ri was a parameter determining the rate of CD4+ count increase in 
strata i. Each CD4+ stratum i was simulated separately and the results were also 
combined to generate a 'mixed' cohort of 25%, 17%, 18%, 15%, 25% of patients 
with baseline CD4+ of 25-50 cells/µl, 51-100 cells/µl, 101-150 cells/µl, 151-200 
cells/µl and 201-300 cells/µl respectively, to represent a mix of patients seen in a 
typical clinic. A clinical South African ART cohort was used to determine the 
proportions of patients in different CD4+ count strata for the mixed cohort [10]. 
The areas under the CD4+ curve (AUC) were calculated using date of 
measurement, midpoint or linear interpolation methods with either 6 monthly or 3 
monthly measurements. The AUC measures CD4 exposure. It is derived from the 
actual CD4+ values and the time spent with these values. Rates were calculated 
assuming constant rates within CD4+ count strata using TB rate estimates from 
published literature [11,12]. 
13.3.7 Ethical approval 
All patients in the CIPRA-SA trial signed informed consent forms. The trial was 
approved by the University of Cape Town Ethics Committee and Partners Human 
Subjects Institutional Review Board. The London School of Hygiene and Tropical 
Medicine Ethics Committee and the University of Cape Town Ethics Committee and 
Partners Human Subjects Institutional Review Board gave approval for the 
analysis of the anonymised data. 
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13.3.8 Literature review 
A literature review was undertaken to identify studies conducting survival analysis 
with time-updated CD4+ counts as either exposure variable or confounder to see 
which methods were used. The search was conducted in Medline and restricted to 
English literature published between January 2006 and August 2010. The search 
strategy included "CD4 lymphocyte count", "HIV", "proportional hazard model", 
"survival analysis", "cohort studies" as Mesh terms and text words and "current", 
"risk ratio", "repeated measurements", "hazard ratio", "updated" and "time- 
updated" as text words. Abstracts of identified studies were screened to assess if 
they fulfilled the inclusion criteria. Potentially relevant studies were further 
assessed by reading the full-text publication. 
13.4 Results 
13.4.1 TB incidence and hazard ratios by time-updated CD4+ count 
using clinical cohort data 
Overall TB incidence was 4.9/100 person-years (PY) (95% confidence interval 
(CI) 3.6-6.8). TB incidence rates were 14.7 in the lowest CD4+ count stratum ( 
5200 cells/µl), 3.1 in the middle CD4+ count stratum (201-350 cells/µl) and 2.9 in 
the highest CD4+ count stratum (>350 cells/µl) when using all available CD4+ 
counts and performing a date of measurement analysis (Table 13.1). The midpoint 
analysis revealed TB incidence rates of 16.0,3.1 and 2.8 for the three different 
CD4+ count categories. The total person-time spent at low CD4+ counts was less in 
the midpoint analysis compared to the date of measurement analysis. 
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TB incidence rates and hazard ratios (HRs) were different when using a dataset 
with 6 monthly CD4+ counts as compared to analysis using all available CD4+ 
counts (Table 13.1). With all three estimation methods, compared to the results 
with more frequent measures, rates were underestimated at low and high CD4+ 
counts, and overestimated at moderate CD4+ counts, with most marked 
overestimation in the midpoint analysis. 
Analyses using a dataset with 6 monthly CD4+ counts and 15% randomly missing 
follow-up CD4+ counts revealed more extreme variations in rates, but with the 
same pattern of underestimation at low and high counts, and overestimation at 
moderate counts (Table 13.1). The differences in rates and HRs compared to the 
analysis using all available data were most pronounced using the date of 
measurement analysis, and least pronounced using the midpoint analysis. 
13.4.2 Area under the CD4+ curve using simulated data 
The midpoint analysis estimated the AUC most accurately for cohorts with low 
(25-50 cell/uL), high (151-200 cells/µl) and mixed baseline CD4+ counts (Table 
13.2). The date of measurement analysis underestimated the AUC for all cohorts 
and time-points. The relative difference was most pronounced in cohorts with low 
baseline CD4 counts and short follow-up (1 year). The date of measurement 
analysis was less accurate with 3 monthly measurements than the midpoint 
analysis with 6 monthly measurements. 
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Table 13.2: Estimated area under the CD4+ count curve using simulated 
data and different methods to estimate the time-point of change 
of CD4+ count 
Baseline 
Cumulative area under the CD4+ count curve 
CD4+ count Date of Date of linear 
of the measurement measurement interpolation Midpoint 
cohort Time method method method method 
6 monthly 3 monthly 6 monthly 6 monthly 
True CD4+ counts CD4+ counts CD4+ counts CD4 counts 
25-SO 1 year 145 99 123 120 142 
cells/µl 5 years 1348 1272 1311 1307 1342 
51-100 1 year 180 138 160 157 177 
cells/µl 5 years 1435 1368 1403 1399 1430 
101-150 1 year 228 186 208 205 225 
cells/µl 5 years 1662 1597 1631 1627 1657 
151-200 1 year 282 238 261 258 278 
cells/µl 5 years 1862 1801 1833 1829 1856 
201-300 1 year 345 305 326 323 342 
cells/µl 5 years 2180 2121 2152 2148 2274 
Mixed 
1 year 237 194 216 213 233 
5 years 1704 1639 1673 1669 1699 
13.4.3 TB rates using simulated data 
Both the date of measurement and midpoint analysis underestimated TB rates for 
low CD4+ count strata (<200 cell/uL). Rates were less accurately estimated using 
the date of measurement analysis compared to the midpoint analysis (Table 13.3). 
Rates for some CD4 count+ strata could not be determined as no time was spent in 
those strata. For example a cohort with a baseline CD4 count of 151-200 did not 
accumulate any person-time in the CD4+ count strata 550 and 51-100. In addition 
cohorts with baseline CD4+ counts of 25-50 and 51-100 did not improve their 
CD4+ count beyond 400 over the 5 year period and thus did not accumulate any 
time in higher CD4+ count strata. 
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Table 13.3: Estimated rates of tuberculosis using simulated data and 
different methods to estimate the time-point of change of CD4+ 
count 
Cohort with Cohort with Cohort with 
baseline CD4+ baseline CD4+ baseline CD4+ 
count 25-50 count 51-100 count 151-200 
Mixed cohort 
cells/µl cells/µl cells/µl 
Date of Date of Date of Date of CD4+ True 
strata rates 
measure- Midpoint measure- Midpoint measure- Midpoint measure- Midpoint 
ment 
method 
ment 
method 
ment 
method 
ment 
method method method method method 
550 21.7 11.25 13.2 
51-100 12.8 9.69 10.12 
101-200 9.27 6.65 9.27 6.24 8.13 5.93 6.39 7.38 9.27 
201-300 5.48 5.42 5.73 5.39 5.48 4.75 5.18 5.48 5.48 
301-400 4.61 4.61 4.61 4.61 4.65 4.51 4.59 4.61 4.66 
401-500 4.23 4.23 4.23 
13.4.4 Literature review 
Titles and abstracts of 199 studies were screened for inclusion in the review. 25 
publications were identified for full-text review. A total of 21 studies fulfilled the 
inclusion criteria. Eight studies [11,13,14,15,16,17,18,19] performed a date of 
measurement analysis and 2 studies [20,21] performed a linear interpolation 
analysis (Table 13.4). The remaining 11 studies [22,23,24,25,26,27,28,29,30,31,32] 
did not specify the method of analysis. 
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13.5 Discussion 
This study shows that the time-point when a CD4+ count is assumed to change 
influences incidence rates of clinical events during ART and effect estimates in 
time-updated CD4+ count analysis. The analysis using modeled CD4+ count data 
showed that the midpoint method gives the least biased estimates both for person- 
time and rates. The choice of time-point when a CD4+ count is assumed to change 
had the greatest impact in cohorts with low baseline CD4+ counts and during the 
first year after ART initiation. While the absolute difference in effect estimates was 
small when analyzing data with frequent measurements, the choice of time-point 
was important in data with less frequent and missing measurements. Thus the 
frequency of measurement and the method used to determine the time-point of 
change in CD4+ count need to be taken into account when comparing effect 
estimates from different studies. However the majority of studies performing 
survival or Cox regression analysis with time-updated CD4+ count as exposure or 
confounder variable failed to describe how the time-point of change in CD4+ count 
was determined. 
The rate of change in CD4+ count is highest in the first months after initiation of 
ART [9]. The dataset including all CD4+ counts had a particularly high frequency of 
measurements in the first 3 months on ART, with testing done at 0,4,8 and 12 
weeks. Person-time spent with low CD4+ counts was overestimated in all analyses 
conducted on a dataset with only 6 monthly CD4+ counts compared to analysis 
using a dataset with all available CD4+ counts. As a result TB incidence rates were 
underestimated in the low CD4+ count strata. The difference in person-time spent 
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with low CD4+ counts was smallest in the midpoint analysis, but rates and hazard 
ratios were nevertheless strongly biased using the dataset with 6 monthly CD4+ 
counts. The bias was filze to a smaller number of events estimated to occur in the 
low CD4+ count strata, which was probably due to chance and small sample size. 
The midpoint analysis produced the least biased estimates for both rates and 
hazard ratios using a dataset with 6 monthly CD4+ counts and 15% missing follow- 
up CD4+ counts. The analysis using modeled CD4+ count data confirmed that the 
midpoint analysis estimated person-time and rates most accurately. 
Our study confirms and extends the findings of a study from Cote d'Ivoire [33]. In 
this study by Deuffic-Bruban et al., person-time spent at low CD4+ counts (<50 
cells/µl) was highest in the date of measurement analysis and lowest in the 
analysis assuming that the CD4+ count changed immediately to the level of the 
next measurement [33]. Estimates of rates of opportunistic infections were highest 
(249/100 PYs) in the analysis assuming an immediate change, followed by the 
linear interpolation (210/100 PYs) and date of measurement analysis (130/100 
PYs). However this study is not comparable to our study or to routine 
programmatic data because of the very high frequency of CD4+ counts (median 
time between the last CD4+ measurements 1-1.8 months) throughout the study 
(compared to a median of 3 months in our study) which means that the differences 
between methods will be less pronounced. Deufic-Burban et al. did not compare 
the results from the original dataset and datasets with less frequent measurements 
and thus they were unable to assess the extent of bias that would be seen in those 
situations. In contrast, we used the dataset with frequent measurements as a gold 
standard and compared it to a generated dataset with only 6 monthly 
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measurements (a dataset comparable to most clinical cohort data). Another 
further important addition in our study was that we used the mid-point method, 
which appeared to produce the least biased estimates. 
Limitations of the clinical cohort analysis are the small sample size, the small 
number of events and the relatively high baseline CD4+ count. The effect estimates 
calculated in full analysis were imprecise and the extent of bias due to different 
methods was uncertain from the clinical cohort analysis alone. However the 
analysis using modeled data confirmed that person-time at higher CD4+ counts 
and rates were more profoundly underestimated using the date of measurement 
method compared to the midpoint method. TB rates within CD4+ count strata 
were assumed constant in the modeled dataset which might not accurately reflect 
the reality. Thus estimated TB rates might be even more biased if true TB rates 
differ according to CD4+ count within CD4+ count strata. 
Analysis using time-updated CD4+ counts as exposure or confounder should 
consider using the midpoint method as a simple way to reduce bias. In addition 
authors should be encouraged to clearly describe the assumption underlying the 
time-point of change in CD4+ count and researchers conducting meta-analyses 
should contact authors to determine the method used. 
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14 Association between TB risk and ART coverage in a South 
African ART cohort 
14.1 Introduction 
Observational studies have demonstrated a reduction of TB risk by 54-92% in HIV 
infected individuals receiving ART [1]. The risk of TB decreases with rising CD4 
cell counts and increasing duration of treatment [2,3]. However whether ART has 
an impact on TB incidence at a population level will not only depend on the 
efficacy of ART in preventing TB disease, but also on population ART coverage, 
patient compliance and transmission dynamics. Mathematical modelling suggests 
that the effect of ART may be limited due to the high burden of TB that occurs prior 
to ART initiation and the persistence of higher TB risk in patients on long-term 
ART compared to HIV-negative patients [4]. 
Observational data from a peri-urban community in the Western Cape, South 
Africa have shown decreased TB prevalence and TB notification rates in the HIV- 
infected population after ART roll-out [5,6]. Further stratification according to ART 
status showed that while TB notification rates decreased significantly in HIV 
infected individuals on ART, TB notification rates remained relatively stable in 
HIV-infected individuals not on ART. Thus the decrease in TB notification rates 
might have been entirely due to immune recovery resulting in decreased risk of 
progression to TB disease. Decreased TB notification rates after ART roll-out have 
also been reported in a before-and-after study from Malawi [7]. Before-and-after 
studies lack a concurrent control group. Thus other factors such as migration, 
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mortality, changes in the national TB control program and changes in the 
notification system might have resulted in reduced TB notification rates. 
Mathematical models investigating the effect of ART on TB incidence do not take 
into account the effect of active TB case finding in ART programs, nosocomial 
transmission in clinics and non-random mixing of populations. HIV infections are 
likely to cluster in households and social networks [8], and the same is probably 
true for ART [9,10]. We therefore hypothesized that ART might have an impact on 
TB risk over and above the improvement of CD4 counts in individuals receiving 
ART. This study aimed to assess the impact of community ART coverage on TB risk 
in a cohort of HIV infected individuals receiving ART. 
14.2 Methods 
14.2.1 Study community 
The study was conducted in a peri-urban township in the greater area of Cape 
Town, with a population of approximately 17,000 people and a measured adult 
HIV prevalence of 23% in 2010 [11]. The community is served by a single public- 
sector primary care clinic which provides ART and TB treatment free of charge. A 
nearby hospital (5 km away) provides all secondary care for the population, 
including inpatient and antenatal services. The hospital also provides ART for 
some HIV infected individuals from the community. 
The clinic manages all TB patients resident in the community according to the 
National TB control program guidelines [12]. All patients initiating ART were 
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screened for active TB with symptom screening followed by smear and cultures for 
patients with symptoms suggestive of TB. The screening did not include testing for 
latent TB infection. Isoniazid preventive therapy has not been implemented in this 
community. 
ART provision began in 2004. From 2005 to 2008 ART services were partly 
provided according to the Antiretroviral Treatment Protocol of the Western Cape 
[13] and partly through a study funded by the NIH [14]. Patients enrolled in the 
NIH-funded study could access ART with a CD4 count below 350 cells/µl or WHO 
stage 3 disease as compared to 200 cells/µl or WHO stage 4 disease in the 
provincial program. The NIH-funded study completed enrollment at the end of 
2006 after which all patients were initiated in the provincial ART program. 
14.2.2 ART cohort 
Data on clinical variables, outcomes and laboratory records were routinely 
collected in all patients at the primary health care clinic and hospital. Data were 
entered in prospectively maintained ART cohort databases. 
14.2.3 CD4 counts 
Patients seen as part of the provincial program had a baseline CD4 count prior to 
initiating ART followed by 6 monthly measurements. CD4 counts were measured 
at weeks -4,0,2,4,8,12 and then every 12 weeks for patients participating in the 
NIH funded study. CD4 count measurements were performed by the NHLS and 
prospectively entered into the ART database. These data were supplemented with 
CD4 counts from a direct download of the NHLS. 
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14.2.4 Number of patients in care by calendar period 
The ART cohort database allowed for multiple entries and exits. Patients joined the 
cohort as a result of one of the following events: ART initiation, transfer in and 
restarting ART after defaulting. Exit events were deaths, loss to follow-up or 
transfer outs. A patient was defined to be in care at the end of a calendar year if the 
current treatment episode was ongoing. 
14.2.5 Incident TB 
Incident TB was defined as a TB episode starting with the start of TB treatment 
whether or not the individual had had previous TB. TB data were obtained from 
the local TB clinic and clinical folders from 2002 to 2010. The data were entered 
into an electronic TB register. The electronic TB register was merged with the ART 
register by first name, second name, truncation of names, switching of first name 
and second name, date of birth and gender. A total of 585 (40.4%) clinical folders 
of ART patients were reviewed and the incident TB information retrieved. This 
information was used to validate the merging process. The merging was 96% 
sensitive and 97% specific. 
14.2.6 ART coverage using mathematical modelling 
ART coverage was estimated using a mathematical model of HIV in the community, 
described in detail elsewhere [15]. Briefly, the growth of the community over time 
was projected using a cohort component projection model stratified by age and 
sex, with migration assumptions set to ensure model consistency with the change 
in population size and age distribution observed in regular community censuses. 
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Annual age-specific HIV incidence rates in males and females were estimated from 
a national model [16], and were scaled in order to ensure consistency between 
model estimates of HIV prevalence and levels of HIV prevalence measured in the 
community in 2005 and 2008 [5,17]. Untreated HIV infected adults were assumed 
to progress through a four-stage model of CD4 decline (CD4 >500,350-500,200- 
349 and <200), with AIDS death or ART initiation occurring in either of the last 
two stages. Rates of transition between untreated CD4 categories were estimated 
by fitting a separate model to data from South African surveys of CD4 distributions 
in HIV-positive adults [18,19,20], and these estimates were validated by 
comparing the modelled distribution of CD4 counts in untreated adults with the 
results of a CD4 survey conducted in the community in 2010. 
Rates of ART initiation, ART default, ART resumption, transfer in, transfer out and 
mortality after ART initiation were estimated from ART programme data routinely 
collected in the community. ART coverage in each year was calculated as the 
number of adults receiving ART at the middle of each year, divided by the sum of 
the number of treated adults, the number of ART-naive adults with CD4 counts 
below a defined threshold (200 or 350) and the number of untreated adults who 
had defaulted ART. 
14.2.7 ART coverage in the community in 2010 
A population-based HIV sero-prevalence survey was conducted between 
September and December 2010 which has been described in detail elsewhere [11]. 
In brief a house-to-house enumeration of the community in August 2010 provided 
a database of 12520 residents 15 years or older of whom 1300 residents were 
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randomly selected for inclusion in the study (10% of the community). Field 
workers invited the selected individuals to attend a mobile HIV testing service. 
Consent forms, questionnaires and HIV testing were all completed at the mobile 
HIV testing service. Individuals were asked if they were taking ART, they were 
tested for HIV and all HIV positive individuals had CD4 count measurement with a 
point of care test (Alere'Pima' CD4 Analyser, Waltham, MA, USA) using venous 
blood samples. Participation rate in the survey was 88%. 
14.2.8 Analysis 
All data were analysed using Stata 11.2 (StataCorp, College Station, USA). Analysis 
was restricted to adult (2: 15 years of age) residents receiving ART treatment. 
Descriptive statistics were used to characterize the demographic, clinical and 
laboratory variables of the ART cohort at baseline. 
The CD4 count distribution at the end of each calendar year was calculated on per 
patient bases. All CD4 count measurements between the 1st of May of the 
respective calendar year and the 28th of February of the next calendar year were 
included in the analysis to ensure that each patient in ART care in a given year 
contributed at least one CD4 count to the analysis. For most patients CD4 counts 
were measured 6 monthly, thus a period of 10 months starting on the 1St of May 
guaranteed the availability of at least one CD4 count per patient. If a patient had 
more than one CD4 count in that period the mean of all CD4 counts was calculated. 
Time from initiation of ART was used as the timeline for survival analysis. Cox 
proportional hazard analysis adjusted for age at initiation, sex and time-updated 
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CD4 count was used to assess the effect of ART coverage on TB risk. We assumed 
that the CD4 count remained constant until the midpoint between two 
measurements and then changed to the subsequent CD4+ count. The endpoint of 
the analysis was the time from ART initiation to incident TB. Follow-up of patients 
on continuous therapy was censored at the date of death, date of transfer, date of 
default or study end (31St December 2009). Patient-time of patients on TB 
treatment at time of ART initiation was excluded from denominator until they 
completed TB treatment. Patients developing incident TB during ART were again 
included in the analysis after they completed TB treatment. Patients' episodes 
were censored when they defaulted ART, but they were again included in the 
analysis when they restarted ART. The analysis was adjusted for multiple episodes 
of TB by using robust standard errors. Hazard proportionality was assessed by 
analysis of scaled Schoenfeld residuals. 
The exposure variable was ART coverage as estimated by the mathematical model. 
Yearly ART coverage estimates were used in the analysis and assumed to be 
constant within one calendar year. ART coverage was used in the model as a time- 
updated exposure variable. Thus patient time was split according to CD4 counts 
and ART coverage. ART coverage was measured as a proportion and included as a 
linear variable. The hazard ratio therefore describes the decrease in TB risk for an 
increase in ART coverage from 0% to 100%. 
14.3 Results 
14.3.1 Baseline characteristics and retention in care 
A total of 1444 adult residents received ART between 2004 and 2009 (Table 14.1). 
The majority of patients were women (66.7%) and median age was 31.7 years 
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(IQR) 27.2-37.0). Median CD4 count at initiation of ART was 132 cell/µL (IQR 60- 
201) and 70.6% were in WHO clinical stage 3 and 4. Median CD4 counts at 
initiation of ART were 80 (IQR 36-140), 146 (IQR 74-220), 153 (IQR 67-254), 122 
(IQR 50-187), 136 (IQR 62-196), 135 (IQR 76-191) in 2004,2005,2006,2007, 
2008 and 2009 respectively. By the end of 2009,841 patients were still receiving 
ART at the clinic or hospital, 239 had been transferred out, 299 had defaulted and 
65 had died (Figure 14.1) 
Table 14.1: Adult residents ever receiving ART (2004-2009) (N=1444) 
Variable N (%) Median (IQR) 
Women 962 (66.7) 
Age (years) 31.7 (27.2-37.0) 
Transfer-in 101(7.0) 
Year joining the cohort 
2004 119(8.2) 
2005 228 (15.8) 
2006 297 (20.6) 
2007 204 (14.1) 
2008 285 (19.7) 
2009 311(21.5) 
WHO clinical stage* 
1 167(12.7) 
2 220 (16.7) 
3 609 (46.2) 
4 321(24.4) 
CD4# (cells/ul) 132 (60-201) 
*26 missing values for WHO clinical stage, WHO clinical stage 
was not available for patients transferred into the service 
9 58 missing values for CD4 count 
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Figure 14.1: Cumulative number of adults in the ART cohort who were dead, 
lost to follow-up and transferred-out by calendar year 
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14.3.2 CD4 count distribution in the ART cohort by calendar year 
The CD4 count distribution shifted to the right in more recent calendar years 
(Figure 14.2). While almost 90% of the cohort had a CD4 count <_ 200 cells/µl in 
2004, the percentage of individuals with CD4 count <_ 200 cells/µl decreased to one 
third in 2005 (Table 14.2). The percentage of individuals with CD4 count s 200 
cells/µl remained constant between 2007 and 2009 (22.3-23.4%). The median 
CD4 count of the cohort increased from 119 cells/µl (IQR 60-161) in 2004 to 366 
cells/µI (IQR 213-546) in 2009. 
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Figure 14.2: CD4 count distribution in the ART cohort by calendar year 
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Table 14.2: CD4 count distribution in the ART cohort by calendar year 
CD 4 
2004 2005 2006 2007 2008 2009 
count(cells/µI) 
119 250 282 336 338 366 
Median (IQR) (60-161) (154-328) (185-389) (210-492) (212-511) (213-546) 
5200 89.4% 34.3% 29.4% 23.4% 22.3% 22.4% 
201-350 8.9% 45.2% 37.3% 28.5% 30.1% 24.7% 
>350 1.8% 20.5% 33.3% 48.1% 47.6% 53.0% 
14.3.3 ART coverage in the community 
Estimated adult ART coverage based on the CD4 threshold of 200 cells/µ1 
increased from 18% in 2004 to 84% in 2009 (Figure 14.3). After a rapid increase 
from 2004-2006, ART coverage slowed down after 2007. ART coverage estimates 
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were 7% in 2004 and 50% in 2009 using an ART eligibility threshold of 350 
cells/µL. In addition to deriving modeled estimates of ART coverage, we also 
directly measured coverage in 2010 via a community-based survey [11]. Using an 
eligibility threshold of 200 CD4 cells/µ1, adult ART coverage was 77.0% (95%CI 
68.1-84.4) in 2010. Using a CD4 threshold of 350 cells/µl, adult ART coverage was 
55.4% (95%CI 47.3-63.3). Overall coverage in 2010 was similar when comparing 
modeled and measured estimates with CD4 count thresholds of 200 cells/µl (83% 
versus 77.0%, respectively p=0.13) and 350 cells/µl (51% versus 55.4%, 
respectively p=0.27). 
14.3.4 TB incidence in the ART cohort 
A total of 67 patients did not contribute time to the analysis, as they entered the 
cohort on TB treatment and exited before TB treatment was completed: 17 
defaulted, 11 died and 8 were transferred out while on TB treatment. The 
remaining 31 patients did not complete TB treatment before the censoring date 
(31 December 2009) 
Mean follow-up time was 1.85 years per patient. Overall TB incidence was 5.4 per 
100 person-years (PYs) (95%CI 4.6-6.4). TB incidence was 21.3 (95%CI 15.5-29.1), 
8.4 (95%CI 6.0-11.8), 3.9 (95%CI 2.7-5.6), 3.4 (95%CI 2.2-5.2) and 2.6 (95%CI 1.6- 
4.3) per 100 PYs for time-updated CD4 counts s100,101-200,201-350,351-500 
and >500 cells/µl. 
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Figure 14.3: ART coverage estimates derived from a mathematical model 
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14.3.5 Association between TB risk in the ART cohort and ART coverage 
in the community 
Univariate analysis showed a 73% (95%CI 25%-90%) decreased risk of TB when 
increasing ART coverage from 0 to 100% using a CD4 threshold of 200 cells/µl. 
The risk was decreased 82% (95%CI 19%-96%) using a CD4 threshold of 350 
cells/µl. 
Multivariate analysis adjusted for current CD4 count revealed a hazard ratio (HR) 
of 0.36 (95%CI 0.13-0.98) for ART coverage at 200 cells/µ1 and 0.25 (95%CI 0.05- 
1.12) for ART coverage at 350 cells/µl (Table 14.3). Further adjustment for age and 
sex did not change the effect estimates (HR 0.37 for ART coverage at 200 cells/µl 
and 0.26 for ART coverage at 350 cells/µl). There was no association between TB 
risk and calendar year after adjusting for current CD4 count, age and sex (HR 0.92; 
95%CI 0.81-1.04, p=0.17). 
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Table 14.3: Effect of ART coverage on TB risk 
Coverage using 200 CD4 cells/µl as Coverage using 350 cells CD4 cells/µl 
threshold as threshold 
I Iniu2ri2to Mia *Iw riete I lni". ý. iýýe e\A. Iýi.. ý. iýrs 
Hazard 95% Cl Hazard 95% Cl 
Hazard 
95% Cl Hazard 
ratio ratio ratio ratio 
95% Cl 
Coverage 0.27 0.10-0.79 0.36 0.13-0.98 0.18 0.04-0.88 0.25 0.05-1.12 
CD4 count NA NA 0.98 0.96-0.99 NA NA 0.98 0.96-0.99 (per 10 cells/µl) 
14.4 Discussion 
To our knowledge this is the first study investigating the effect of community ART 
coverage on TB risk in an ART cohort. Increasing ART coverage from 0 to 100% 
decreased TB risk by 64% using CD4 eligibility criteria of : 5200 cells/µ1. TB risk 
was even further reduced (75%) when using the new WHO eligibility criteria of 
CD4 count <_350 cells/µl [21]. These results were adjusted for time-updated CD4 
count. Thus they represent the additional benefit of ART coverage beyond the 
positive effect of ART on the individual's CD4 count recovery. 
The additional benefit of ART might be explained by three mechanisms. First high 
ART coverage reduces the probability of contacts between individuals on ART and 
individuals with high risk for TB disease (HIV infected individuals with low CD4 
counts not yet on ART). Second active TB case finding conducted as part of the 
routine ART visit reduces the duration of infectiousness in HIV infected individuals 
with TB disease. Third ART effects nosocomial transmission in clinics due to active 
TB case finding and improved immune status of individuals attending the clinics. 
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Some studies indicate that access to ART care is facilitated if an individual knows 
somebody who is already on ART [9,10]. Therefore it is likely that both HIV and 
ART are clustered in households, partnerships and social networks [8,22,23]. Thus 
the improvement of the CD4 count distribution of the ART cohort in more recent 
calendar years might not only impact on nosocomial transmission in individuals on 
ART [241, but also on transmission in the community. 
Furthermore individuals on ART are regularly seen by health care professionals. 
Active TB case finding through symptoms screening was implemented at the start 
of the ART clinic in 2004. There was a significant reduction in untreated prevalent 
TB in the HIV infected population in this township between 2005 and 2008 as 
measured in two TB prevalence surveys [5]. The case detection rate among HIV 
infected individuals increased from 44% in 2005 to 64% in 2008, but remained 
stable in the HIV negative individuals over the same time period. This increase in 
case detection rate was entirely due to increased case detection among HIV 
infected individuals on ART. Increased TB case detection and timely diagnosis 
through active TB case finding followed by TB treatment will reduce the number of 
infectious individuals and the duration of infectiousness which potentially results 
in decreased transmission. 
In this study TB risk was assessed within an ART cohort. This allowed calculating 
TB rates and risks based on precise denominators and times at risk. TB incidence 
rates stratified by time-updated CD4 counts were comparable to rates reported 
from other South African ART cohorts [2,3]. 
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A major limitation of this study is the level of uncertainty regarding the variable 
"ART coverage". The study was conducted in a community where almost a third of 
the adult population (27%) had migrated into the community within the previous 
3 years [11]. Highly mobile populations are difficult to model, as there is 
substantial uncertainty regarding both the demographic profile and the HIV 
disease profile of individuals moving into and out of the community. Estimates of 
ART coverage are very sensitive to assumptions about rates of CD4 decline [25], 
which are difficult to quantify accurately and may differ between populations [26]. 
However, the fact that two different definitions of coverage were found to be 
similarly associated with TB incidence provides some assurance that inaccuracies 
in the estimated coverage levels did not substantially bias the results. In addition 
ART coverage estimates derived from a mathematical model correlated well with 
estimates from a population-based cross-sectional survey. 
Observational studies are prone to residual confounding both due to known and 
unknown confounders. CD4 counts were performed every 3-6 months. More 
frequent CD4 count measurement would have captured immune recovery more 
accurately. CD4 count is one of the strongest predictors for TB disease. It is 
therefore plausible that the effect of ART coverage on TB risk is entirely due to 
residual confounding by CD4 count. Misclassification of CD4 counts in 
observational cohorts with infrequent measurements is a well recognized problem. 
Misclassification of confounders introduces bias. In view of the high likelihood of 
residual confounding and bias due to confounder misclassification it is difficult to 
argue that there is true effect of ART coverage on TB risk. 
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ART coverage was associated with calendar year and therefore other factors such 
as migration and changes in the TB control program might have resulted in 
reduced burden of TB disease. The possibility that the time effect might be 
explained by factors other than ART coverage that were not measured cannot be 
excluded. 
Mathematical modelling suggests that the population CD4 count distribution in 
this community has not changed since rollout of ART (Dr Leigh Johnson personal 
communication). ART rollout prevented a further left shift of the population CD4 
count distribution, but did not lead to any improvement. Thus the effect of ART 
coverage on TB risk cannot be explained by improving overall immunity in the 
population. If indeed there is an effect of ART on TB transmission it might be 
confined to the ART cohort only. This is supported by unchanged TB notification 
rates in children in this community (Dr Keren Middelkoop personal 
communication) indicating stable TB transmission. 
In summary this study gives some evidence that increases in ART coverage were 
associated with reduced risk of TB in an ART cohort even when controlling for 
time-updated CD4 count, suggesting an additional effect of ART on TB incidence. 
Starting individuals even earlier might reduce TB incidence even further. Studies 
investigating antiretroviral treatment as an HIV prevention strategy should 
investigate potential impact on TB control. 
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15 Conclusions 
15.1 Main findings 
We reported a high uptake and diagnostic yield of community-based active TB case 
finding linked to a mobile HIV testing service. Treatment outcomes of actively 
found cases were as good as outcomes reported from primary health care clinics. A 
considerable proportion of TB cases did not start TB treatment ('early defaulters'), 
either because we were unable to contact them or they failed to start treatment. 
However the `early defaulter' rate was comparable to reported rates from primary 
health clinics in South Africa which used passive TB case finding. We found that the 
costs of the active TB case finding program were USD 1,177 per TB case diagnosed 
and USD 2,458 per successfully treated TB case. A recent report from South Africa 
estimated the cost of passive case finding with USD 766 per successfully treated TB 
case assuming a smear positivity rate of 10% [1]. Our active case finding program 
was only three times more expensive than passive case finding. This is somehow 
surprising, as the smear positivity rate in our program was much lower than the 
assumed 10% in the passive case finding program. In addition tracing patients and 
contacting clinics was time consuming and therefore expensive. Thus, overall cost- 
effectiveness of mobile active TB case finding compares favourably to passive case 
finding. These results provide evidence for the feasibility and cost-effectiveness of 
community-based active TB case finding as a TB control strategy. Feasibility 
assessment and cost-effectiveness data are important to inform wide-spread 
implementation of community-based active case finding programs. 
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Despite challenges regarding early diagnosis, linkage to HIV and ART care and 
retention in care ART coverage in a township in Cape Town was high. TB risk in the 
ART cohort decreased with increasing ART coverage even after controlling for 
time-updated CD4 count suggesting that as ART coverage increased, TB 
transmission was reduced. We hypothesise, that reduction in transmission was 
probably due to a combined effect of ART and routine active TB case finding in the 
ART program. ART improved CD4 counts resulting in an effect similar to herd 
immunity; and routine active TB case finding in the ART program decreased 
duration of infectiousness. TB risk reduction was even higher when using coverage 
estimates based on the new WHO eligibility threshold of 350 CD4 cells/µl [2]. This 
study is the first to show an association between risk of TB and ART coverage, and 
the potential impact of the new WHO eligibility threshold. 
The ultimate goal of HIV programmes is to achieve universal access as defined by 
current guidelines; however, the in depth analysis of test uptake, linkage, retention 
and coverage in this South African community highlights the challenges 
encountered in achieving this. Therefore although mathematical modelling has 
show that a `test and treat' strategy with high coverage of HIV testing and 
immediate initiation of ART regardless of the CD4 count would reduce HIV 
transmission and providing high impact on TB transmission [3,4), many obstacles 
are going to have to be overcome if this is to be achieved. 
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15.2 Limitations 
The community-based active TB case finding study and the ART coverage analysis 
did not investigate the impact on population TB incidence, as this was beyond the 
scope and time-frame of these studies. Direct measurement of TB incidence 
requires large sample sizes and are associated with major logistic and financial 
challenges [5]. As a result, there are few studies directly measuring TB incidence 
[6]. Tuberculin skin surveys have been used in the past to derive TB incidence 
estimates, but are deemed unreliable [7]. TB prevalence measured in repeated 
population-based surveys is at present the best indicator to assess impact of any 
TB control measures. 
A study from Zimbabwe showed that community-based active TB case finding 
using smear microscopy decreased population TB prevalence in a before-and-after 
design [8]. A similar design was used in a South African study showing a decrease 
in TB prevalence after ART roll-out [9]. While these studies provide some evidence 
for the effect of these TB control measures, they are limited by the lack of 
concurrent control groups due to coincidental time trends. Further evidence for 
the effectiveness of ART comes from mathematical modelling and studies 
reporting decreased TB notification rates after ART roll-out [4,10,11]. Overall, 
evidence on the impact of ART and active TB case finding on TB control is at best 
limited, with even less data available to inform operational and strategic questions. 
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15.3 Future research - community-based active TB case finding 
The best strategy and diagnostic algorithm for community-based active TB case 
finding is unknown. Diagnostic considerations include the number and sequence of 
tests, the choice of diagnostic tests such as chest X-ray, smear, culture or the new 
geneXpert MTB/RIF assay and symptom screens. Strategic questions relate to (i) 
timing and frequency of testing (ii) setting such as mobile services or work-places 
(iii) and additional services provided for example testing for other chronic or 
infectious diseases. 
The majority of studies report on one round of active TB case finding conducted 
over a relatively short time-span. Repeated rounds of case finding will be 
necessary for TB control and elimination to be achieved. Shorter intervals between 
rounds of case finding reduce the yield and cost-effectiveness of the programme, 
whereas longer intervals prolong duration of infectiousness resulting in less effect 
on transmission. The optimal interval to balance maximal yield and minimal 
duration of infectiousness is not known. A study in Czechoslovakia in the 1960s 
showed a decreasing yield of active TB case finding programmes conducting serial 
mass radiography [12]. However, in a study in Zimbabwe, the yield did not 
significantly decrease in six rounds of active TB case finding over a period of 3 
years [8]. Difference in follow-up and baseline TB incidence might explain the 
difference in results. In order to achieve acceptable yield, intervals will need to be 
adapted over the course of a screening programme and in line with the local 
setting. 
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Community-based active TB case finding studies comparing screening strategies 
such as temporary screening camps, mobile clinics utilizing existing community 
sites, fully mobile vans and home-based screening are rare. The Zimbabwean study 
compared mobile vans and home-based screening and found a higher overall yield 
when using mobile vans. However, the study was underpowered to show a 
difference in effect between the two screening strategies [8]. Unfortunately the 
study did not attempt to assess cost-effectiveness of the two screening strategies. 
Cost-effectiveness is an important parameter when considering widespread 
implementation of programs. 
TB care is often delivered by vertical programs [13]. Integration with other 
services such as HIV has only recently received attention [14,15,16]. It is therefore 
hardly surprising that most population-based active TB case finding studies offer 
TB screening as stand-alone service [6,8,17,18,19,20]. Feasibility, acceptability and 
costs of integrating TB screening with chronic disease and HIV screening in 
population-based programs are currently unknown. In the Zimbabwean active 
case finding study over two thirds of those diagnosed with TB who consented to 
diagnostic HIV testing were HIV positive. These data highlight the need to consider 
integration of TB and HIV services, not only within health centres [16], but also at 
the level of community-based interventions. Combining active HIV and TB case 
finding in high HIV-prevalence settings would have several benefits. First, testing 
for both diseases will support prioritization of resources according to need given 
that people infected with TB are at greater risk of death if they are HIV-positive. 
Second a combined approach will be less demanding for patients provided issues 
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of stigma and confidentiality are carefully addressed. Finally, providing integrated, 
dual testing may allow a more efficient use of scarce community-level resources. 
Number and sequence of diagnostic tests, the choice of test and symptom 
algorithms widely differ between studies [21]. Ultimately decisions need to be 
informed by yield, laboratory capacities, cost and diagnostic delays. One might 
argue that smear microscopy detects the most infectious patients and thus cuts the 
transmission chain. However, a more sensitive diagnostic test such as liquid 
culture detects TB cases earlier in the course of disease and increases the 
diagnostic yield of screening, which might allow for longer intervals between 
subsequent rounds of active TB case finding. 
Treatment initiation rates and treatment outcomes of actively detected TB cases 
are rarely reported [22,23,24,25,26]. Some studies suggested higher treatment 
refusal and default rates in actively compare to passively detected case [25,26]. 
These findings raise concerns regarding the emergence of drug resistance. 
Furthermore if actively detected TB cases do not start treatment the impact of 
active TB case finding on transmission will be limited and ultimately active TB case 
finding will be less cost-effective. Reporting of treatment initiation and outcome 
rates should therefore be encouraged in any active TB case finding study. 
15.4 Future research - antiretroviral therapy 
Cluster randomized trials designed to investigate the 'test and treat' strategy are 
an opportunity to assess the effect of ART not only on HIV, but also on TB 
219 
incidence provided TB prevalence and notification data are collected. The success 
of 'test and treat' both for HIV and TB control will rely on high and frequent test 
uptake and good linkage and retention in care. Resources, interventions, 
infrastructure and staffing will be plentiful in a trial setting. Widespread 
implementation of ART early in the course of HIV disease will probably be more 
challenging under operational conditions. If a positive effect of high ART coverage 
early in the course of disease is shown under trial conditions, impact evaluation 
needs to be performed in routine settings. 
While waiting for results of cluster randomized trials trends in TB notification 
rates might provide some insight of the effect of ART. Time-trends of TB 
notification rates in well described populations such as demographic surveillance 
sites with relatively precise ART coverage estimates should be analysed to provide 
more evidence for the effect of ART on TB control. 
15.5 Concluding remarks 
The studies presented in this thesis reported on feasibility, outcomes and costs of 
population-based active TB case finding and the losses along in the continuum of 
HIV care. The studies did not assess the impact of these control strategies on 
population TB incidence. The ideal study design to investigate the impact of 
community-based active TB case finding and ART would be a cluster randomized 
trial assessing TB prevalence using population-based surveys, MDR prevalence, 
treatment initiation and default rates and TB mortality preferably with long term 
(several years) follow-up [27,28,29]. 
220 
15.6 References: 
1. The cost of the Xpert diagnostic algorithm for TB. Results of the national TB 
cost model (NTCM) 2011/12 to 2016/17. (2011): University of the 
Witswatersrand and Centre for Global Health and Development, Boston 
University. 
2. Antiretroviral therapy for HIV infection in adults and adolescents: 
Recommendations for a public health approach (2010 version). (2010) 
Geneva: World Health Organization. 
http: //whglibdoc. who. int/publications/2010/9789241599764_eng. pdf last 
accessed 14/8/2010 
3. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal 
voluntary HIV testing with immediate antiretroviral therapy as a strategy for 
elimination of HIV transmission: a mathematical model. Lancet 373: 48-57. 
4. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, et al. (2010) 
Antiretroviral therapy for tuberculosis control in nine African countries. Proc 
Natl Acad Sci USA 107: 19485-19489. 
5. Global Tuberculosis Control (2010) Geneva, Switzerland: World Health 
Organization. http: //www. who. int/tb/publications/global_report/en/ last 
accessed 1/4/2011 
6. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Faussett P, et al. 
(2007) Epidemiology of tuberculosis in a high HIV prevalence population 
provided with enhanced diagnosis of symptomatic disease. PLoS Med 4: e22. 
7. TB Impact Measurement: Policy and recommendations for how to assess the 
epidemiological burden of TB and the impact of TB control (2009) Geneva, 
Switerland: World Health Organization. 
http: //www. who. int/tb/advisory_bodies/impact measurement taskforce/e 
n/index. html. last accessed 27/9/2011 
8. Corbett EL, Bandason T, Duong T, Dauya E, Makamure B, et al. (2010) 
Comparison of two active case-finding strategies for community-based 
diagnosis of symptomatic smear-positive tuberculosis and control of 
infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster- 
randomised trial. Lancet 376: 1244-1253. 
9. Middelkoop K, Bekker LG, Myer L, Whitelaw A, Grant A, et al. (2010) 
Antiretroviral program associated with reduction in untreated prevalent 
tuberculosis in a South African township. Am J Respir Crit Care Med 182: 
1080-1085. 
221 
10. Middelkoop K, Bekker LG, Myer L, Johnson LF, Kloos M, et al. (2011) 
Antiretroviral therapy and TB notification rates in a high HIV prevalence 
South African community. J Acquir Immune Defic Syndr 56: 263-269. 
11. Zachariah R, Bemelmans M, Akesson A, Gomani P, Phiri K, et al. (2011) 
Reduced tuberculosis case notification associated with scaling up 
antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis 15: 933-937. 
12. Krivinka R, Drapela J, Kubik A, Dankova D, Krivanek J, et al. (1974) 
Epidemiological and clinical study of tuberculosis in the district of Kolin, 
Czechoslovakia. Second report (1965-1972). Bull World Health Organ 51: 59- 
69. 
13. Raviglione MC, Pio A (2002) Evolution of WHO policies for tuberculosis 
control, 1948-2001. Lancet 359: 775-780. 
14. Harries AD, Zachariah R, Lawn SD (2009) Providing HIV care for co-infected 
tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc 
Lung Dis 13: 6-16. 
15. Harris JB, Hatwiinda SM, Randels KM, Chi BH, Kancheya NG, et al. (2008) 
Early lessons from the integration of tuberculosis and HIV services in 
primary care centers in Lusaka, Zambia. Int J Tuberc Lung Dis 12: 773-779. 
16. Howard AA, El-Sadr WM (2010) Integration of tuberculosis and HIV services 
in sub-Saharan Africa: lessons learned. Clin Infect Dis 50 Suppl 3: S238-244. 
17. Yimer S, Holm-Hansen C, Yimaldu T, Bjune G (2009) Evaluating an active 
case-finding strategy to identify smear-positive tuberculosis in rural Ethiopia. 
Int j Tuberc Lung Dis 13: 1399-1404. 
18. Shargie EB, Morkve 0, Lindtjorn B (2006) Tuberculosis case-finding through 
a village outreach programme in a rural setting in southern Ethiopia: 
community randomized trial. Bull World Health Organ 84: 112-119. 
19. Miller AC, Golub JE, Cavalcante SC, Durovni B, Moulton LH, et al. (2010) 
Controlled trial of active tuberculosis case finding in a Brazilian favela. Int J 
Tuberc Lung Dis 14: 720-726. 
20. Sekandi JN, Neuhauser D, Smyth K, Whalen CC (2009) Active case finding of 
undetected tuberculosis among chronic coughers in a slum setting in 
Kampala, Uganda. Int J Tuberc Lung Dis 13: 508-513. 
21. Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, et al. (2010) Yield of 
HIV-associated tuberculosis during intensified case finding in resource- 
limited settings: a systematic review and meta-analysis. Lancet Infect Dis 10: 
93-102. 
222 
22. den Boon S, Verver S, Lombard CJ, Bateman ED, Irusen EM, et al. (2008) 
Comparison of symptoms and treatment outcomes between actively and 
passively detected tuberculosis cases: the additional value of active case 
finding. Epidemiol Infect 136: 1342-1349. 
23. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, et al. (2007) Postpartum 
tuberculosis incidence and mortality among HIV-infected women and their 
infants in Pune, India, 2002-2005. Clin Infect Dis 45: 241-249. 
24. Koffi N, Ngom AK, Aka-Danguy E, Seka A, Akoto A, et al. (1997) Smear 
positive pulmonary tuberculosis in a prison setting: experience in the penal 
camp of Bouake, Ivory Coast. Int J Tuberc Lung Dis 1: 250-253. 
25. Santha T, Renu G, Frieden TR, Subramani R, Gopi PG, et al. (2003) Are 
community surveys to detect tuberculosis in high prevalence areas useful? 
Results of a comparative study from Tiruvallur District, South India. Int J 
Tuberc Lung Dis 7: 258-265. 
26. Cassels A, Heineman E, LeClerq S, Gurung PK, Rahut CB (1982) Tuberculosis 
case-finding in Eastern Nepal. Tubercle 63: 175-185. 
27. Fielding KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, et al. (2011) 
Thibela TB: design and methods of a cluster randomised trial of the effect of 
community-wide isoniazid preventive therapy on tuberculosis amongst gold 
miners in South Africa. Contemp Clin Trials 32: 382-392. 
28. Hayes RJ, Alexander ND, Bennett S, Cousens SN (2000) Design and analysis 
issues in cluster-randomized trials of interventions against infectious 
diseases. Stat Methods Med Res 9: 95-116. 
29. Sismanidis C, Moulton LH, Ayles H, Fielding K, Schaap A, et al. (2008) 
Restricted randomization of ZAMSTAR: a2x2 factorial cluster randomized 
trial. Clin Trials 5: 316-327. 
223 
